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ABSTRACT 
 
The aim of my research was to define the roles of local and hepatic-derived factor H, 
in particular the contribution of extra-hepatic factor H to plasma C3 regulation and 
spontaneous renal disease associated with factor H deficiency. Factor H is the major 
soluble regulator of the alternative pathway of complement activation, synthesised 
predominantly by the liver. To investigate the role of extra-hepatic factor H, I 
generated mice with hepatocyte-specific factor H deficiency (hepatocyte-Cfh-/-) by 
intercrossing conditional factor H-deficient animals with mice expressing Cre 
recombinase under the control of the murine albumin promoter. Plasma factor H 
levels in hepatocyte-Cfh-/- mice were 19% of wild-type levels and were associated 
with a secondary reduction in plasma C3 levels. Higher plasma C3 levels than in Cfh-
/- animals demonstrated that extra-hepatic factor H contributes to plasma C3 
regulation, confirmed by tubulointerstitial C3 staining in hepatocyte-Cfh-/- mice. Extra-
hepatic factor H prevented the GBM C3 deposition typical of complete factor H 
deficiency and was associated with spontaneous mesangial C3 deposition. To test 
the hypothesis that underlying dysregulation of the alternative pathway predisposes 
to exaggerated renal injury in the presence of additional complement activation, I 
assessed the response of hepatocyte-Cfh-/- mice to accelerated serum nephrotoxic 
nephritis. Injection of nephrotoxic serum led to the rapid onset of haemolytic uraemic 
syndrome. Subtotal deficiency of factor H in hepatocyte-Cfh-/- mice therefore 
provides a novel model of either C3 glomerulopathy or atypical haemolytic uraemic 
syndrome depending on the environmental milieu. This mouse model will enable the 
pathophysiological mechanisms involved to be further defined and new therapeutics 
investigated. I also examined the association between abnormalities in factor H-
related protein 5 and C3 glomerulopathy. Minimal expression of normal factor H-
related protein 5 within the kidney could not prevent CFHR5 nephropathy. Serum 
factor H-related protein 5 levels may be a marker of renal complement deposition. 
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AFU  arbitrary fluorescence unit 
bp  base pair 
BSA  bovine serum albumin 
C3GN  C3 glomerulonephritis 
C4BP  C4b-binding protein 
cDNA  complementary deoxyribonucleic acid 
CFA  complete Freund’s adjuvant 
Cfh-/-  homozygous factor H-deficient mice 
Cfh+/-  heterozygous factor H-deficient mice 
Cfi-/-  homozygous factor I-deficient mice 
DAF  decay-accelerating factor 
dNTP  deoxynucleotide triphosphate 
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ELISA  enzyme-linked immunosorbent assay 
FHL  factor H-like 
FHR  factor H-related 
FITC  fluorescein isothiocyanate 
GAPDH glyceraldehyde-3-phosphate dehydrogenase  
GBM  glomerular basement membrane 
GPI  glycosylphosphatidylinositol 
HRP  horseradish peroxidase 
6 
 
HUVEC human umbilical vein endothelial cell 
LHR  long homologous repeat 
MAC  membrane attack complex 
MASP  mannan-binding lectin-associated serine protease 
MBL  mannan-binding lectin 
MCP  membrane cofactor protein 
MgCl2  magnesium chloride 
MPGN membranoproliferative glomerulonephritis 
NTN  nephrotoxic nephritis 
NTS  nephrotoxic serum 
PAGE  polyacrylamide gel electrophoresis 
PAS  Periodic Acid-Schiff 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
qPCR  quantitative PCR 
RCA  regulators of complement activation 
RNA  ribonucleic acid 
RNase ribonuclease 
RT  reverse transcriptase 
SDS  sodium dodecyl sulphate 
TAE  tris-acetate buffer 
TMB  tetramethylbenzidine 
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1. CHAPTER ONE: INTRODUCTION 
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1.1. THE COMPLEMENT SYSTEM 
The complement system has long been recognised as a mediator in the 
development of renal disease. The identification of altered concentrations of 
complement components and complement-activating factors in serum along with the 
presence of complement deposits within glomeruli, have all led to the association of 
complement with renal injury. Whilst individual diseases may be associated with 
complement activation through particular pathways, downstream injury mediated by 
C5 activation may be a common mechanism in disease pathogenesis. Complement 
plays a role not only in acute glomerular injury, but also contributes to fibrosis, 
scarring and progressive kidney disease as a result of proteinuria and the 
subsequent generation of complement activation products in the tubular lumen. 
Complement was identified as a heat-labile component that augmented the anti-
bactericidal activity of plasma. Its diverse roles include host defence, clearance of 
apoptotic cells and immune complexes and modulation of the adaptive immune 
response. It consists of a large group of proteins, including pro-enzymes 
(zymogens), and activation pathways that are triggered in distinct ways: the classical 
(CP), lectin (LP), and alternative (AP) pathways (figure 1.1). These three pathways 
converge on complement C3, whose activation results in the production of C3 
effector functions and activation of the terminal (TP) pathway. Effector functions of 
complement include opsonisation, phagocyte recruitment and activation and cell 
surface damage through the generation of a pore-forming complex termed the 
membrane attack complex (MAC). Complement activation is controlled by proteins 
(complement regulators) that minimise damage to host tissues. I will now discuss in 
turn complement activation, function and regulation.  
1.2. COMPLEMENT ACTIVATION  
1.2.1. Classical Pathway 
The major trigger of the CP is the interaction of complement C1q with antibody 
complexed with antigen (immune complex). Complement activation resulting from 
recognition of apoptotic cell structures by C1q has also implicated the CP in the 
clearance of apoptotic cells and cellular debris in addition to immune complexes 
19 
 
(Botto, Dell'Agnola et al. 1998). C1q consists of six globular heads each assembled 
from three different polypeptide chains (A, B and C) and linked by a collagen-like tail 
(Reid and Porter 1976). These surround two molecules of each of the zymogens C1r 
and C1s which together with C1q form the C1 complex (Lepow, Naff et al. 1963). A 
conformational change occurs within the (C1r:C1s)2 complex when C1q binds to an 
immune complex. This results in enzymatic activation within C1r (autocatalysis) and 
subsequent cleavage of C1s by C1r (transactivation) to produce an active serine 
protease. C1 then cleaves C4 into C4a and C4b, exposing a thioester bond within 
C4b, which enables C4b to attach covalently to surfaces. C2 complexed with C4b 
(C4bC2) is cleaved by C1s releasing a small fragment (C2b) whilst the larger 
fragment (C2a) remains complexed with C4b and functions as an active protease 
(C4b2a). C4b2a is an enzyme complex termed a C3 convertase, since it cleaves C3 
into C3b (an opsonin) and C3a (an anaphylatoxin). 
1.2.2. Lectin Pathway 
Mannan-binding lectin (MBL) and ficolins (ficolin-1, -2 and -3) activate the LP 
following interaction with their ligands, which include mannose and acetylated 
groups. The LP is complex and incompletely understood. MBL and ficolins are 
present in complexes containing serine proteases termed MBL-associated serine 
proteases 1, 2 and 3 (MASP-1, -2, -3) and non-enzymatic proteins termed MAp44 
and MAp19. The MASP-1 gene encodes MASP-1, MASP-3 and MAp44 whilst the 
MASP-2 gene encodes MASP-2 and MAp19. Currently, it is thought that MBL/ficolins 
complexed with ligand trigger complement activation through MASP activation. 
These proteases have functional similarity to C1r and C1s. MASP-1 strongly 
activates MASP-2 under physiological conditions. MASP-2 can cleave both C4 and 
C2 whilst MASP-1 can cleave C2. The net result is the formation of a C3 convertase, 
C4b2a, identical in composition to that generated by classical pathway activation. 
Complete MASP-1 deficiency is associated with absence of the LP indicating its 
critical role in the activation sequence (Degn, Jensen et al. 2012). MBL can bind to 
aggregated IgA (Roos, Bouwman et al. 2001) which may be relevant to complement 
activation in IgA nephropathy.  
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1.2.3. Alternative pathway  
The AP is in a continuous state of low-level activation due to the spontaneous 
hydrolysis of the thioester bond within C3 that results in a C3 molecule (C3[H20]) 
with C3b-like activity in that it can bind the protease factor B (FB) to generate a pro-
convertase, C3[H20]B (Schreiber, Pangburn et al. 1978). When bound within the pro-
convertase, FB is cleaved by factor D (FD) releasing the FB fragment, Ba, and 
generating the AP C3 convertase: C3[H20]Bb. This C3 convertase, like C4b2a, 
cleaves C3 to generate C3b and C3a.  
 
C3b generated through the three activation pathways can trigger further C3b 
generation through a feed-back loop that utilises FB and FD (C3b amplification loop, 
figure 1.1). C3b interacts with FB generating pro-convertase, C3bB. Cleavage of 
bound FB by FD results in formation of the C3 convertase, C3bBb.  
 
Spontaneous activation of C3 through the AP is normally inefficient due to the 
presence of complement regulators in plasma and on cell surfaces. This prevents AP 
activation from causing either injury to host surfaces or C3 depletion. Complement 
regulators are discussed below. 
1.2.4. Terminal pathway 
TP activation is triggered by the formation of enzyme complexes that cleave 
complement C5. These complexes are termed C5 convertases and form when C3 
convertases bind an additional molecule of C3b: C4b2aC3b and C3bBbC3b. 
Cleavage of C5 results in the formation of the anaphylatoxin C5a and C5b. C5b 
initiates the formation of the MAC. C5b sequentially binds C6 and C7 to form a 
hydrophobic complex (C5b67) that inserts into lipid bilayers. Subsequent interaction 
with C8 allows binding and polymerisation of C9 to generate the pore-forming MAC. 
The MAC has a hydrophobic outer and hydrophilic inner surface, which allows the 
free passage of water and solutes across the cell membrane resulting in loss of 
membrane integrity and cell damage. MAC formation is particularly important for host 
defence against meningococcal infection, which is frequently seen in TP deficiency 
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states and may develop during therapeutic inhibition of C5 if preventative measures 
are not adopted (Lambris, Ricklin et al. 2008).  
1.2.5. Non-canonical activation 
In addition to the activation pathways depicted in figure 1.1, other activation 
pathways have been reported but their in vivo significance is unclear. Examples 
include antibody-mediated complement activation that proceeds in the absence of 
C2 or C4 (Deguchi, Gillin et al. 1987), direct activation of C3 by MASP-1 (Matsushita 
and Fujita 1995) and C3-independent activation of C5 by thrombin (Huber-Lang, 
Sarma et al. 2006). C3 and C5 can be cleaved by many enzymes including thrombin 
and plasmin (Amara, Flierl et al. 2010) and leucocyte elastase (Lachmann, Pangburn 
et al. 1982). The generation of activated C3 and C5 by enzymes derived from 
inflammatory cells is very likely to augment canonical complement activation at sites 
of tissue injury.  
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Figure 1.1 Complement activation and regulation. Complement activation generates C3 
convertases which comprise C4b2a (classical and lectin pathway) and C3bBb (alternative pathway) 
and C5 convertases which comprise: C4b2aC3b (classical and lectin pathway) and C3bBbC3b 
(alternative pathway). Activation of the terminal pathway triggers the assembly of the membrane 
attack complex (MAC). The MAC is formed by the sequential addition to C5b of C6, C7, C8 and 
multiple C9 molecules. Complement regulatory proteins, in plasma (red) and on cell membranes 
(blue) include C4b-binding protein (C4BP) for the classical pathway; factor H (FH) for the alternative 
pathway and CD59 for the terminal pathway. Properdin (P), a positive regulator, stabilises the C3 
convertase. MBL = mannose-binding lectin; MASP = MBL-associated serine protease; C1-INH = C1 
inhibitor; DAF = decay-accelerating factor (CD55); MCP = membrane cofactor protein (CD46); FI = 
complement factor I; CR1 = complement receptor 1 (CD35).  
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1.3. COMPLEMENT FUNCTION 
The established functions of complement include host defence against pathogens, 
the physiological removal of immune complexes and apoptotic cells (termed ‘waste 
disposal’) and a role as natural adjuvant. Effector mechanisms include opsonins 
(C3b, C4b), anaphylatoxins (C3a, C5a), MAC and interactions with complement 
receptors. More recently it has become evident that complement may contribute to 
tissue development and repair. For example, C3a and C5a were found to be 
necessary for liver cell survival during regeneration after liver resection (Markiewski, 
DeAngelis et al. 2009).  
 
Complement activation on pathogens results in opsonisation of the pathogen with 
C3b, which facilitates phagocytosis, the production of the anaphylatoxins C3a and 
C5a, which facilitate inflammatory cell recruitment and changes in vascular 
permeability and MAC-mediated membrane damage. Acting through their respective 
G-protein-coupled receptors, C3a and C5a promote phagocytosis by attracting 
neutrophils, monocytes and macrophages to sites of complement activation, thereby 
facilitating interaction of opsonins with complement receptors. The G-protein-
independent anaphylatoxin receptor, C5L2, may also act to modulate the 
inflammatory response. The interaction of C3b (or C4b) with complement receptor 1 
(CR1) contributes to neutrophil-mediated phagocytosis. CR1 also acts as cofactor for 
the factor I (FI)-mediated cleavage of iC3b to C3dg. iC3b interacts with CR3 
(CD11b/CD18) and CR4 (CD11c/CD18) on neutrophils and monocyte/macrophages 
and enhances phagocytosis. 
 
The complement receptor of the immunoglobulin family (CRIg) found on tissue-
resident macrophages also promotes phagocytosis by binding target-bound C3b and 
iC3b (Helmy, Katschke et al. 2006), and is also believed to regulate the C3b-
containing C3 and C5 convertases. Interaction of complement with the coagulation 
system also acts to prevent the spread of infection by promoting local coagulation 
and inhibiting fibrinolysis (Markiewski, Nilsson et al. 2007).  
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Complement also forms a link with adaptive immunity (Dunkelberger and Song 
2010). Both iC3b and C3dg acting as ligands for CR2 (CD21) promote B cell 
activation and differentiation (Carroll 2008). Anaphylatoxins exert regulatory effects 
on B cells (Fischer and Hugli 1997, Ottonello, Corcione et al. 1999). The threshold 
for Fcγ receptor activation may also be lowered by C5a receptor signalling as a 
result of upregulation of the activating Fcγ receptors FcγR I and III and 
downregulation of the inhibitory FcγRIIB, whilst C5 synthesis itself may also be 
promoted by FcγR activation (Kumar, Ali et al. 2006). The effects of complement 
deficiency also suggest that complement is involved in the T cell response (Kopf, 
Abel et al. 2002), and may influence the polarisation of T cells to Th1 or Th17 cells 
(reviewed in (Ricklin, Hajishengallis et al. 2010)). 
 
The complement system also plays a critical role in removing immune complexes 
and apoptotic cells, not only contributing to the resolution of inflammation but also 
promoting tissue repair (Botto and Walport 2002, Flierman and Daha 2007, 
Markiewski, DeAngelis et al. 2009). The failure to successfully remove cellular debris 
has been implicated in the development of systemic lupus erythematosus (reviewed 
in (Manderson, Botto et al. 2004)). C3b- and/or C4b-opsonised immune complexes 
interact with CR1 on red cells, which enable immune complexes to be transferred to 
the phagocytic cells within the liver and spleen. Cells undergoing apoptosis are able 
to bind complement and become opsonised as a result of changes to cell surface 
molecules. The loss of CD46 and CD59 permits complement activation, deposition of 
C3b and C4b and removal by phagocytosis (Cole, Hughes et al. 2006, Flierman and 
Daha 2007). The prevention of excessive complement activation and inflammation 
by remaining surface regulators and those in plasma together with changes such as 
the down-regulation of interleukin 12, ensure a more measured response than that 
elicited following foreign invasion (Kim, Elkon et al. 2004). The recruitment of C-
reactive protein (CRP) to the apoptotic cell surface facilitates the binding of C1q and 
CP activation, whilst binding of the AP regulator, complement factor H (FH), inhibits 
AP amplification and downstream inflammation and lysis (Gershov, Kim et al. 2000). 
The importance of the CP is demonstrated by the reduction in apoptotic cell uptake 
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by macrophages from individuals deficient in components C1q, C4 and C2 (Botto, 
Dell'Agnola et al. 1998, Gullstrand, Martensson et al. 2009).  
 
1.4. COMPLEMENT REGULATION 
Complement activation is regulated by a series of soluble and membrane-bound 
proteins termed complement regulators. Control of targeted complement attack is 
required to prevent consumption of components and unwanted injury to host tissues. 
The need for such regulation is clear from the effects of excessive complement 
activation seen in deficiency states. Regulation occurs at multiple steps within the 
activation pathways and both within plasma and on host surfaces. Regulation 
mechanisms include the prevention of convertase formation, promotion of 
convertase decay and proteolytic degradation of activated components. Six of the 
regulators (FH, C4b-binding protein [C4BP], membrane cofactor protein [MCP], 
decay-accelerating factor [DAF], CR1 and CR2) are encoded by genes within the 
regulators of complement activation (RCA) gene cluster on chromosome 1. Each of 
these proteins consists of a number of repeating cysteine-rich modules of 
approximately 60 amino acids, termed short consensus repeat (SCR) domains. I will 
first summarise the key regulatory proteins and then discuss the major proteins in 
two groups: the membrane-bound and soluble complement regulators. FH, a major 
plasma complement regulator, is discussed in detail, as the biology of this protein 
was central to my thesis. 
 
C1 inhibitor (C1-Inh) blocks the active site of C1r and C1s dissociating them from 
C1q and preventing CP activation. C4BP interacts with C4b to prevent the formation 
of the CP and LP C3 pro-convertase (C4bC2). C4BP also accelerates the 
spontaneous decay of the convertase (C4b2a) and will act as a cofactor for the FI-
mediated cleavage of C4b. The AP and C3b amplification loop are regulated by FH, 
which will interact with C3b to prevent pro-convertase formation (C3bB) and 
accelerate convertase decay (C3bBb). It is also a soluble cofactor for the FI-
mediated cleavage of C3b to iC3b. On host surfaces, DAF facilitates dissociation of 
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the convertases whilst MCP has cofactor activity for the FI-mediated cleavage of 
C3b and C4b. Membrane-bound CD59 prevents MAC assembly through its 
interaction with C8 and C9. The soluble C5b-7 complex may be prevented from 
inserting into membranes by interaction with vitronectin, clusterin and C8 in plasma. 
The anaphylatoxins C3a, C4a and C5a are inactivated by plasma carboxypeptidase-
N through its cleavage of the C-terminal arginine residue exposed during their 
generation.  
 
1.4.1. Membrane-bound regulatory proteins 
1.4.1.1. Membrane cofactor protein (MCP, CD46, measles virus receptor) 
MCP is a type 1 membrane glycoprotein expressed as four common isoforms (MCP-
BC1, MCP-BC2, MCP-C1, and MCP-C2) derived from alternative splicing, and 
appearing as ‘upper’ (59-68kDa) and ‘lower’ (51-58kDa) bands on sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). All isoforms share the 
same amino-terminal consisting of four contiguous SCR domains containing the 
binding sites for C3b and C4b. The alternatively spliced STP domain rich in serines, 
threonines and prolines follows this, and is O-glycosylated to generate the BC and C 
isoforms. Twelve amino acids with unknown function then precede the 
transmembrane domain and intracytoplasmic anchor. Two distinct cytoplasmic tails 
of 16 or 23 amino acids, Cyt-1 or Cyt-2, also result from alternative splicing. MCP is 
a cofactor for the FI-mediated cleavage of C3b and C4b, and as a membrane-bound 
regulator, only inactivates C3b and C4b deposited on the cell on which it is 
expressed.  
1.4.1.2. Decay-accelerating factor (DAF, CD55) 
DAF is a widely-distributed single-chain glycosylphosphatidylinositol (GPI)-anchored 
membrane glycoprotein. The four SCR domains making up the amino terminus are 
followed by a serine and threonine-rich region heavily modified by post-translational 
O-linked glycosylation. DAF accelerates the decay of the classical and alternative 
pathway C3 and C5 convertases by causing the rapid release of C2a and Bb from 
their binding sites on C4b and C3b respectively (Fujita, Inoue et al. 1987). 
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Interestingly the binding of DAF to the C3 convertase appears stronger than to C3b 
or C4b alone (Pangburn 1986). It is expressed on all haematopoietic cells and most 
other cell types including endothelial and epithelial cells. Deficiency of DAF on 
erythrocytes in paroxysmal nocturnal haemoglobinuria renders the affected cells 
susceptible to lysis by complement. This commonly results from a mutation in the 
phosphatidylinositol glycan A gene leading to defective GPI assembly and 
impairment of expression of GPI-linked proteins such as DAF. 
1.4.1.3. CD59  
CD59 is an 18-20-kDa GPI-anchored membrane single-chain glycoprotein encoded 
by a gene on chromosome 11 in humans (and chromosome 2 in mice), which inhibits 
MAC formation. Synthesised as a precursor including an N-terminal signal peptide, 
the carboxyl terminus has a hydrophobic sequence, which like DAF, is replaced 
post-translationally by a GPI anchor. It is widely distributed in humans including on 
all circulating cells, endothelial cells and epithelial cells but weakly expressed in the 
central nervous system. CD59 binds to C5b-7 complex in membranes preventing the 
interaction of C8 with the C5b-7 complex. With binding sites for both the α-chain of 
C8 and the b-domain of C9 (Ninomiya and Sims 1992), CD59 may also bind C9 in 
partially assembled MAC. Loss of CD59 from the erythrocyte cell membrane in 
paroxysmal nocturnal haemoglobinuria also contributes to increased susceptibility to 
complement-mediated lysis.  
1.4.1.4. Complement receptor type 1 and type 2  
CR1 (C3b/C4b receptor, CD35, immune adherence receptor) is a type 1 integral 
membrane glycoprotein of between 190-280kDa depending on variable N-linked 
glycosylation. Present on all peripheral blood cells (except natural killer cells and 
platelets) and also glomerular podocytes, CR1 contains a signal peptide and 
extracellular, transmembrane and cytoplasmic domains. The duplication or deletion 
of a large segment of genomic DNA has generated four major structural allotypes in 
humans, of which the most common is CR1*1 which has 30 extracellular SCR 
domains. The N-terminal 28 SCRs are arranged into larger long homologous repeats 
(LHRs) containing 7 contiguous SCRs each, with ligand binding sites residing in 
each of the first three LHRs. CR1*1 possesses two binding sites for C3b and three 
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for C4b demonstrating that each CR1 molecule can interact with complexes 
containing multiple C3b and C4b molecules. Aside from its role in immune complex 
processing, CR1 functions as a complement regulator. It has both cofactor and 
decay-accelerating activities. It is a cofactor for the FI-mediated cleavage of C3b to 
iC3b, iC3b to C3dg and of C4b to C4d. It accelerates the spontaneous decay of the 
CP/LP and AP C3 and C5 convertases.  
  
CR2 (CD21) plays a major role in the immune response but has also been shown to 
have weak FI cofactor activity although the physiological significance of this is 
unclear. 
 
1.4.1.5. The rodent-specific complement regulator: Crry 
Whilst rodents possess MCP and DAF homologues, they express an additional 
complement regulator, Crry (Holers, Kinoshita et al. 1992). The presence of this 
rodent-specific regulator is important in interpreting murine phenotypes of 
complement dysregulation. It is a 65-kDa transmembrane glycoprotein expressed in 
most tissues, although the level of expression varies amongst different tissues along 
with tissue-specific isoforms. Crry regulates C3 activation in the same way as human 
MCP and DAF, acting as a cofactor for the FI-mediated inactivation of mouse C3b 
and C4b and possessing decay-accelerating activity for the CP and AP C3 
convertases (Kim, Kinoshita et al. 1995). Crry deficiency is embryonically lethal as a 
result of the failure to regulate maternal complement activation at the feto-placental 
interface. Viable Crry-deficient animals can be generated if the mother is rendered 
C3 deficient (Xu, Mao et al. 2000). Crry is critical in the mouse as it is the only 
ubiquitously-expressed membrane-bound regulatory molecule. Crry-expressing cells 
in vitro are protected from C3b deposition whilst antibody-mediated blockade of rat 
Crry led to increased C3b deposition on glomerular endothelial and mesangial cells 
(Molina, Wong et al. 1992, Quigg, Morgan et al. 1995). Antibody-induced blockade of 
Crry in vivo in rat kidney resulted in C3 activation in the vicinity of glomeruli, tubules 
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and perivascular capillaries associated with inflammation and tissue injury (Nomura, 
Nishikawa et al. 1995). 
 
1.4.2. Fluid-phase regulatory proteins 
1.4.2.1. C1 Inhibitor 
Control of the cleavage of C4 to C4b by C1s following activation of the classical 
pathway is mediated by the plasma serine protease inhibitor, C1-Inh. Heavily 
glycosylated, C1-Inh is a 105-kDa single-chain member of the serpin family of serine 
protease inhibitors, present in plasma at a concentration of 120-200µg/ml. By 
covalently binding to the catalytic site on the β-chains of activated C1r and C1s, C1-
Inh causes their disassembly from C1q, which remains bound to antibody. Whilst 
preventing excessive complement activation on a target and activation of C1 in the 
fluid-phase, C1-Inh does not inhibit appropriate complement activation of C1 by IgM 
or IgG on a microbial surface. 
1.4.2.2. C4b-binding protein (C4BP) 
C4BP is an oligomeric plasma protein that exists in three isoforms in humans. The 
predominant isoform (α7β1) consists of seven identical 75-kDa α-chains (C4BPα) 
and one 45-kDa β-chain (C4BPβ), linked by disulphide bonds in their carboxyl 
terminal regions and which may be more compact in the soluble form. Minor 
populations exist of the other isoforms, α7/β0 and α6/β1. Mouse C4BP has no β 
chain and no inter-chain disulphide bonds. 
Both α- and β-chains contain SCR domains similar to other complement regulatory 
proteins, and whilst SCRs 1-3 of the α-chain are critical for C4b binding (Ogata, 
Mathias et al. 1993), the β-chain is responsible for binding protein S. The C4BPA 
and C4BPB genes are closely linked in tandem within the RCA cluster on 
chromosome 1 with C4BPA lying downstream of C4BPB. Primarily synthesised by 
the liver, C4BP is present in plasma at a concentration of 150-300µg/ml. 
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C4BP has both decay-accelerating and cofactor activity. Accelerating the decay of 
the classical pathway C3 and C5 convertases, multivalent binding of C4b can 
prevent C2 binding and act as a cofactor for the FI-mediated cleavage of C4b. The 
classical pathway C3 convertase is inherently unstable without the properdin-
stabilisation of the AP C3 convertase, and once dissociated, C2a cannot rebind. In 
contrast to the FI-mediated cleavage of C3b at two sites generating iC3b and C3f, 
iC4b is generated transiently from cleavage at a single site before being cleaved to 
C4c and C4d. The second cleavage of iC4b is required for its inactivation due to its 
ability to form an active C3 convertase with C2 (Yamazaki, Ichihara et al. 1986). 
C4BP may also bind C4i and weakly to C4c, but not C4d. It also shows weak affinity 
and cofactor activity for C3b.  
1.4.2.3. Factor I 
Following activation of native C3 or C4 by hydrolysis or proteolysis, FI mediates the 
subsequent proteolytic degradation of the products. C3i (or C4i) generated by the 
spontaneous or induced hydrolysis of the parent molecule and possessing an 
inactivated thioester group, is degraded in the same way as C3b (or C4b) but still 
retains the C3a (or C4a) domain. FI is constitutively active but in humans requires a 
cofactor for all cleavage reactions it mediates. FH and C4BP provide cofactor activity 
in plasma whilst MCP and CR1 act as cofactors on host surfaces. The degradation 
of surface-bound C3 and C4 derivatives by FI also determines their specificity for 
cellular complement receptors such as CR1, CR2 and CR3. The human FI gene lies 
on chromosome 4 and FI is synthesized primarily by the liver but also by monocytes, 
fibroblasts and endothelial cells amongst others (Dauchel, Julen et al. 1990). FI is 
found in plasma at a concentration of 35 µg/ml but as an acute-phase protein is 
upregulated by interferon-γ (IFN-γ) in hepatocytes, fibroblasts and endothelial cells 
(Dauchel, Julen et al. 1990, Vyse, Morley et al. 1996). Derived from a single-chain 
precursor, FI consists of two chains linked by a disulphide bond. The 50-kDa heavy 
chain originates from the amino-terminal of the precursor and includes a number of 
structural modules, whilst the serine protease domain resides within the 38-kDa light 
chain and is very similar to β-trypsin. By cleaving the α’-chains of C3b and C4b in the 
presence of appropriate cofactors (FH, MCP or CR1 for C3b, and C4BP, MCP or 
CR1 for C4b), FI prevents the formation of both the C3 and C5 convertases. FI-
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mediated cleavage of C3b at two positions in the α’-chain generates iC3b and C3f, a 
17-amino acid peptide. Further degradation of iC3b with CR1 as a cofactor, leads to 
the release of C3c and the production of C3dg, which remains bound to the target. 
Possessing the surface-binding site, C3dg is a ligand for CR2. Cleavage of C4b 
meanwhile on either side of the thioester releases C4c and yields C4d that remains 
attached to the surface. 
1.4.2.4. Vitronectin and Clusterin 
Vitronectin is a 75-80-kDa glycoprotein encoded by chromosome 17. Derived mainly 
from the liver and present in human plasma at 250-450µg/ml, it is also synthesized 
by platelets, megakaryocytes, macrophages and human umbilical vein endothelial 
cells (HUVEC), and is found in urine. The mature protein is generated from a single-
chain polypeptide but allelic variation results in processing to either a single-chain or 
two-chain form. A heparin-binding domain at the carboxyl terminus facilitates 
vitronectin binding to sulphated polysaccharides contributing to its MAC regulatory 
activity. By binding to the metastable binding site of nascent C5b-7 complex, 
vitronectin prevents its insertion into the cell membrane (Podack, Kolb et al. 1977). 
Vitronectin contributes to the protection of ‘self’ cells from ‘bystander’ MAC attack 
since nascent MACs are not restricted to the surface on which complement is 
activated and can insert into any cell membrane. Any vitronectin-C5b-7 complexes 
that subsequently bind C8 and C9 are lytically inactive (Bhakdi and Tranum-Jensen 
1983). 
 
Clusterin (previously termed complement lysis inhibitor, apolipoprotein J) is an 80-
kDa heterodimeric glycoprotein composed of two non-identical subunits (α and β) of 
approximately equal size, and is derived from the CLI gene on human chromosome 
8. Widely distributed in a variety of human tissues and cells (except T lymphocytes), 
clusterin is present in plasma associated with lipoproteins at a concentration of 100-
300 µg/ml (Hogasen, Mollnes et al. 1993) and is also found in urine, cerebrospinal 
fluid and semen. Similar to vitronectin, clusterin incorporates into nascent C5b-7 
preventing its insertion into the cell membrane and producing complexes that are 
soluble and lytically inactive. This inhibitory function is dependent on a 
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thrombospondin-like region at the amino terminus enabling clusterin to bind to C7, 
the β-chain of C8 and the b domain of C9 (Tschopp, Chonn et al. 1993). Clusterin 
also prevents C9 polymerisation. 
 
1.5. The Complement factor H (FH) protein family 
1.5.1. Overview 
FH is a 155-kDa single polypeptide chain glycoprotein found in plasma, first 
identified as β1H by Nilsson and Müller-Eberhard (Nilsson and Mueller-Eberhard 
1965). It is composed of 20 SCR domains and its plasma concentration is 
approximately 500µg/ml although this is highly variable between individuals (figure 
1.2). Each SCR domain contains 60 amino acid residues that follow a typical 
arrangement of highly conserved amino acids including four cysteines (forming intra-
domain disulphide bridges), two prolines and one tryptophan (Barlow, Norman et al. 
1992) and are characterised by a compact hydrophobic core wrapped in β-sheet, 
with multiple stranded anti-parallel β-sheets linked by loops and turns (Perkins, Haris 
et al. 1988, Norman, Barlow et al. 1991, Barlow, Norman et al. 1992, Barlow, 
Steinkasserer et al. 1993). FH is encoded by the CFH gene within the regulation of 
complement activation (RCA) gene cluster on chromosome 1q32 (Rodriguez de 
Cordoba and Rubinstein 1986). The CFH gene spans 94kb of genomic DNA and 
consists of 23 exons, each of which encodes a single SCR except exons 3 and 4 
that encode SCR2 (Male, Ormsby et al. 2000, Perez-Caballero, Gonzalez-Rubio et 
al. 2001). Exon 10 contributes to the terminal amino acids of an alternative splice 
product of the CFH gene termed FH-like protein 1 (FHL-1; figure 1.2) (Estaller, 
Schwaeble et al. 1991). Removal of exon 10 from the FH mRNA by splicing enables 
exons 9 and 11, coding for SCRs 7 and 8, to be joined. Post-translational 
modifications include disulphide bond formation and glycosylation, with seven 
consensus sites for N-linked glycosylation. Adjacent and downstream of the CFH 
gene are five genes that encode FH-related proteins. The genomic order of these 
genes is CFHR3, CFHR1, CFHR4, CFHR2 and CFHR5 that encode for complement 
FH-related proteins 3, 1, 4, 2 and 5 respectively (FHR3, -1, -4, -2, -5; figure 1.2). The 
FH protein family therefore consists of FH, FHL-1 and the five FHR proteins: FHR1, 
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FHR2, FHR3, FHR4 and FHR5. FH is an established major inhibitor of AP activation 
and the C3b amplification loop. The biological role of the FHR proteins has been 
elusive. Currently, they are thought to act as competitive antagonists (deregulators) 
of FH. In this section I discuss FH, FHL-1 and the FHR proteins. I also include 
sections on extra-hepatic synthesis and our present understanding of its biological 
relevance. 
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Figure 1.2 The human FH protein family. (A) FH consists of 20 SCR domains. Regulatory and 
surface binding region domains are indicated. FHL-1 is a splice variant comprised of the initial 7 FH 
domains. (B) and (C) FHR1, FHR2 and FHR5. These FHR proteins have high amino acid sequence 
similarity with the two carboxyl terminal domains of FH (indicated by percentages) and contain highly 
similar amino terminal domains which mediate obligate ‘head to tail’ dimerization (C) enabling the 
formation of homodimers and heterodimers. (D) FHR3 and FHR4. FHR4 has two splice variants 
termed FHR4A and FHR4B.   
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1.5.2. Complement factor H (FH) 
FH regulates complement activation in three ways; by inhibiting formation of the AP 
C3 convertase through competition with FB for binding to C3b, by accelerating the 
decay of the AP C3 convertase (Whaley and Ruddy 1976) and by acting as a 
cofactor for the FI-mediated proteolytic inactivation of C3b to iC3b (Whaley and 
Ruddy 1976, Pangburn, Schreiber et al. 1977). These complement regulatory 
activities of FH all reside within SCRs 1-4. Rapidly able to inactivate C3b in plasma, 
the ability of FH to inactivate surface-bound C3b is influenced by the surface 
involved. The affinity of FH for surface-bound C3b may be less than fluid-phase C3b 
(Pangburn and Muller-Eberhard 1983) but may be enhanced in the presence of sialic 
acids and other polyanions such as heparin and glycosaminoglycans (Fearon 1978), 
likely due to concurrent recognition of C3b and sialic acids by the same FH 
molecule. Multiple binding sites for C3b and polyanions have been identified in FH, 
and the deposition of increasing amounts of C3b and iC3b on surfaces lacking 
polyanions also promotes FH-mediated inactivation of newly deposited C3b on these 
surfaces (Pangburn and Muller-Eberhard 1983). Surfaces on which bound C3b is 
relatively well protected from FH are susceptible to AP activation, as are antigen-IgG 
complexes with bound C3b (Pangburn and Muller-Eberhard 1978, Fries, Gaither et 
al. 1984). 
The affinity with which FH binds the C3 convertase C3bBb, is similar to that with C3b 
alone (Pangburn 1986). Binding of FH to C3bBb results in irreversible displacement 
of the Bb fragment and loss of the active convertase, as occurs with DAF and CR1 
binding on the cell surface. A specific interaction between Bb and the regulator or an 
allosteric effect on the conformation of C3b may be responsible (Pangburn 1986). 
The affinity of FI for C3b is greatly increased by FH thereby facilitating effective 
inactivation of C3b generated by tick over (Pangburn and Muller-Eberhard 1978). In 
addition to preventing the formation of further C3 convertase, the cleavage of C3b to 
iC3b on surfaces also provides a ligand for CR3 whilst further cleavage by FI in the 
presence of CR1 provides a ligand for CR2 in the form of C3dg. 
FH possesses three distinct binding sites for both C3b and polyanions such as sialic 
acid and heparin. C3b binding occurs at SCR1-4, SCR12-14 and SCR19-20 whilst 
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heparin binding sites exist in SCR7, SCR13 and SCR19-20. FH also interacts with 
other plasma proteins such as CRP through SCR7, and with proteins derived from a 
variety of microorganisms at a number of different sites. Critical for its role as a 
cofactor in the FI-mediated inactivation of C3b is the C3b-binding site located in 
SCR1-4 (Sharma and Pangburn 1996), whilst the C3b- and polyanion binding sites 
in SCR19-20 are essential for regulating complement activation on host cells (Meri 
and Pangburn 1990, Pangburn 2000). The different roles mediated by the various 
functional domains of FH initially elucidated by techniques including site-directed 
mutagenesis and the use of monoclonal antibodies, have also become evident from 
the different phenotypes observed in the setting of FH dysfunction.  
Many pathogenic organisms including Neisseria meningitidis, Neisseria gonorrhoeae 
and Streptococcus pneumoniae have evolved mechanisms to bind both FH and/or 
FHL-1 to make use of their AP inhibitory activities to prevent complement activation 
on their surface and thereby promote their survival (Ram, McQuillen et al. 1998, 
Hellwage, Meri et al. 2001, Jarva, Janulczyk et al. 2002, Meri, Hartmann et al. 2002, 
Huang, Qiao et al. 2008). The classic example of this is the binding of FH by the M6 
protein and other M serotypes of Streptococcus pyogenes, leading to reduced 
surface deposition of C3b and macrophage and PMN-mediated phagocytosis 
(Horstmann, Sievertsen et al. 1988). The M protein binding site was found to be 
situated in SCR7 of FH close to the heparin and CRP binding sites (Sharma and 
Pangburn 1997), although FHL-1 has been subsequently shown to bind M proteins 
at this site with greater affinity than FH (Kotarsky, Hellwage et al. 1998) involving the 
hydrophobic tail specific to FHL-1 (Perez-Caballero, Alberti et al. 2000). 
Furthermore, the binding of FHL-1 to Fba proteins on the streptococcal surface may 
promote invasion via entry into epithelial cells (Pandiripally, Wei et al. 2003). 
Meningococcal strains possess a high affinity receptor, termed FH-binding protein, 
which has nanomolar affinity for human FH. This fhbp-FH interaction protects the 
pathogen from complement-mediated damage (Huang, Qiao et al. 2008). 
Tumour cells may also exploit FH on their surface to prevent complement-mediated 
lysis and glioblastoma cells have been shown to inactivate surface-bound C3b to 
iC3b more effectively than other cell types (Junnikkala, Jokiranta et al. 2000, 
Fedarko, Jain et al. 2001). The apparent production of FH or a FH-like protein by 
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bladder tumour cells has also been utilised in immunoassays using patient urine 
(BTAstat and BTA TRAK) as an adjunct for diagnosing and monitoring bladder 
cancer alongside cystoscopy and urine cytology (Kinders, Jones et al. 1998, 
Thomas, Leyh et al. 1999). The urinary antigen identified as FH or a FH-like protein 
not only contains eight amino terminal residues identical to the corresponding amino 
acids in FH, but also binds C3b and accelerates cleavage of C3b in the presence of 
FI (Kinders, Jones et al. 1998). 
1.5.3. Complement FH-like protein 1 (FHL-1) 
FHL-1 is a 43-kDa human plasma protein encoded by an mRNA from the CFH gene, 
and contains the first 7 SCR domains present in FH along with four unique amino 
acid residues (Ser-Phe-Tyr-Leu) at its C-terminus (figure 1.2) (Schwaeble, Zwirner et 
al. 1987). The FHL-1 cDNA is 1644bp long representing 449 amino acids, the first 
445 of which are identical to the N-terminal of FH. An additional exon (exon 10) 
present in the CFH gene is specific for the C-terminal region of this alternatively 
spliced 1.8kb FHL-1 transcript, and is located between the exons encoding for SCRs 
7 and 8 (Sim, Kolble et al. 1993). Differing expression of FHL-1 and FH transcripts 
despite an identical promoter and transcription start site suggests regulation at the 
transcriptional and post-transcriptional level. Post-translational modifications include 
glycosylation with one consensus site for N-linked glycosylation in FHL-1. 
Like FH, FHL-1 is constitutively synthesised by the liver (Schwaeble, Zwirner et al. 
1987, Misasi, Huemer et al. 1989) but also by a variety of other cell types including 
peripheral blood monocytes, fibroblasts, human umbilical vein endothelial cells, 
oligodendrocytes and myoblasts (Friese, Hellwage et al. 1999). Expression may 
similarly be induced by a number of inflammatory mediators such as IFN-γ and anti-
inflammatory agents such as dexamethasone reflected by the IFN-γ and 
glucocorticoid response elements identified in the gene promoter. Present in plasma 
at a concentration of 10-50µg/ml, FHL-1 also possesses cofactor and decay 
accelerating activity, promoting cleavage of C3b by FI and the dissociation of the C3 
convertase respectively (Misasi, Huemer et al. 1989, Kuhn, Skerka et al. 1995, Kuhn 
and Zipfel 1996). Whilst displaying complement regulatory activity similar to FH, 
FHL-1 also has unique biological functions. Whilst SCR4 in both FH and FHL-1 
38 
 
contain the RGD (Arg-Gly-Asp) motif involved in the adhesive properties of matrix 
proteins such as fibronectin (Pierschbacher and Ruoslahti 1984), only FHL-1 acts as 
a matrix for cell attachment and spreading (Hellwage, Kuhn et al. 1997). The RGD 
domain of FHL-1 may be bound by an integrin receptor, a heterodimeric membrane 
glycoprotein, leading to loss of its complement regulatory activity mediated by SCRs 
1-4. However by simultaneously binding C3b on target cells and integrin receptors 
on effector cells, FHL-1 (and FH) may promote the binding of phagocytic cells to 
their target surfaces. FHL-1 interacts with Streptococcus pyogenes where FHL-1 
preferentially binds to streptococcal M protein compared to FH (Kotarsky, Hellwage 
et al. 1998). FHL-1 levels are altered in some disease states. For example, in 
rheumatoid arthritis it is expressed by synovial lining cells (Friese, Manuelian et al. 
2003) and levels in synovial fluid are higher than those of FH (Friese, Hellwage et al. 
1999). 
1.5.4. Complement FH-related proteins 
FHR1, FHR2, FHR3, FHR4 and FHR5 (Jozsi and Zipfel 2008) are a group of highly 
related proteins encoded by separate genes within the RCA gene cluster which, like 
FH, are composed of SCR domains exhibiting varying degrees of amino acid 
sequence identity to each other and to FH. FHR1 is composed of 5 SCRs and has 
two consensus sequences for N-linked glycosylation leading to two glycosylated (37- 
and 42-kDa) forms in human plasma. FHR1α and FHR1β have one and two 
carbohydrate side chains respectively (Skerka, Horstmann et al. 1991). FHR1 
associates with high density lipoproteins (HDL) in the circulation and is reported to 
have a plasma concentration of 70-100µg/ml (Park and Wright 1996) (Skerka and 
Zipfel 2008). Comprised of 4 SCRs, FHR2 exists in two glycosylated forms in plasma 
at unknown concentration. At 24kDa and 28kDa respectively, the single and double 
glycosylated forms exist as part of HDL molecules like FHR1 (Skerka, Timmann et 
al. 1992, Park and Wright 1996). A number of glycosylated forms of FHR3 also exist, 
although the plasma concentration of this 35-56-kDa protein has not been 
determined. FHR4 is present in plasma in two isoforms derived from the CFHR4 
gene by alternative splicing. The nine SCR-containing FHR4A forms an internal 
doublet, with SCRs1-4 demonstrating a high level of sequence identity to SCRs 5-8, 
whilst FHR4B contains only 5 SCRs representing SCR1 and SCR6-9 of FHR4A. The 
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plasma concentrations of the 86-kDa FHR4A and 42-kDa FHR4B are not known 
although FHR4A is the major isoform in plasma. FHR4 also circulates in association 
with HDL and very low density lipoprotein particles (Skerka, Hellwage et al. 1997, 
Jozsi, Richter et al. 2005). At 65kDa, FHR5 is the largest of the FHRs with 9 SCR 
domains (McRae, Cowan et al. 2001). It is also glycosylated and associated with low 
and high density lipoproteins (Park and Wright 1996, McRae, Duthy et al. 2005), 
circulating in the plasma at a concentration of approximately 5µg/ml.  
All five FHRs lack SCRs that are similar to the four N-terminal complement inhibitory 
domains of FH. However, there is high sequence similarity between the terminal 
carboxyl two domains within the FH and FHR proteins (Skerka and Zipfel 2008). The 
C-terminus of FH is the main site of surface recognition and binding to cell surface 
glycosaminoglycans, heparin, C3b and C3d (Manuelian, Hellwage et al. 2003, 
Oppermann, Manuelian et al. 2006). The C-termini of FH (SCR19-20) and FHR1 
(SCR4-5) are the most alike in that FHR1 (SCR4-5) differs by only two amino acids, 
both located within SCR5. FH and FHR2 share 75% sequence identity compared to 
50% for the C-termini of FHR3, FHR4 and FHR5 (Skerka and Zipfel 2008). The initial 
two SCR domains of FHR3 and FHR4 have amino acid sequence identity with FH 
SCR domains 6-7 of 79% and 66% respectively. In contrast, the initial two domains 
of FHR1, FHR2 and FHR5 are nearly identical and have recently been shown to 
mediate obligate dimerization (Goicoechea de Jorge, Caesar et al. 2013). This has 
revealed the existence of both homodimers and heterodimers within FHR1, FHR2 
and FHR5.  
FHR1, FHR3, FHR4 and FHR5 have all been reported to bind to C3b and may also 
bind C3d (Hellwage, Jokiranta et al. 1999, McRae, Duthy et al. 2005, Heinen, 
Hartmann et al. 2009).  
FHR1 binds C3b, a number of microorganisms such as Borrelia burgdorferi and 
Group A Streptococci (Kotarsky, Gustafsson et al. 2001, Haupt, Kraiczy et al. 2007), 
and has been reported to possess C5 convertase inhibitory activity (Heinen, 
Hartmann et al. 2009). FHR1 inhibited C5 cleavage leading to a reduction in C5a 
generation and C5b deposition on sheep erythrocytes, and on binding C5, inhibited 
MAC formation (Heinen, Hartmann et al. 2009). FHR3 has been shown to bind to 
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C3b, C3d and heparin, and a complement modulatory role has also been proposed 
(Hellwage, Jokiranta et al. 1999). SCRs 4 and 5 of FHR4B bind the C3d region of 
C3b (Hellwage, Jokiranta et al. 1999), and in fact both isoforms have been shown to 
bind soluble C3b, iC3b and C3d (Hebecker and Jozsi 2012). FHR4A and FHR4B 
have also been reported to enhance FH cofactor activity (Hebecker and Jozsi 2012) 
(Hellwage, Jokiranta et al. 1999), although no cofactor activity was identified for 
FHR4A (Hebecker and Jozsi 2012) in contrast to reports of weak cofactor activity for 
FHR4B (Hellwage, Jokiranta et al. 1999). Native pentameric C-reactive protein has 
been identified as a ligand for FHR4, binding via an exposed site in SCR1 and 
resulting in enhanced opsonisation of necrotic cells through FHR4-mediated 
activation of C2/C4-dependent pathways (Hebecker, Okemefuna et al. 2010). FHR4 
has also been reported to be able to activate the AP on surfaces where it can bind, 
via formation of C3 convertases from FHR4-bound C3b (Hebecker and Jozsi 2012). 
FHR4 has therefore been proposed as a promoter of complement activation and 
opsonisation, and such alternative forms of the C3 convertase may exhibit resistance 
against FH-mediated decay (Hebecker and Jozsi 2012). FHR5 has been reported to 
bind C3b and heparin and possess weak cofactor activity for the FI-mediated 
cleavage of C3b, along with fluid-phase C3 convertase inhibitory activity (McRae, 
Duthy et al. 2005). Notably, it was first identified as a component of glomerular 
immune deposits in a variety of renal pathologies where it was located in a similar 
distribution to C3 and C5b-9 (Murphy, Georgiou et al. 2002). The biological functions 
of the FHR family remain unclear although it appears from in vitro studies with FHR1, 
FHR2 and FHR5 that they do not possess any complement regulatory activities at 
physiological concentrations and may function as competitive antagonists of FH 
(Goicoechea de Jorge, Caesar et al. 2013, Tortajada, Yebenes et al. 2013). 
The large genomic repeat regions along the CFH-CFHR gene locus predispose to de 
novo chromosomal recombination and duplication events in which whole genes or 
exons may be altered (figure 1.3) (Zipfel, Edey et al. 2007) (Heinen, Sanchez-Corral 
et al. 2006). The most frequent event has resulted in a CFH-CFHR allele in which 
recombination led to complete loss of the CFHR3 and CFHR1 genes (ΔCFHR3-1, 
figure 1.3) (Feifel, Prodinger et al. 1992). Disease-associated rearrangements have 
also been described and include a CFH-CFHR1 hybrid gene in atypical haemolytic 
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uraemic syndrome (aHUS) (Venables, Strain et al. 2006) and an internal duplication 
in the CFHR5 gene in familial C3 glomerulonephritis (termed CFHR5 nephropathy) 
endemic in Cyprus (Gale, de Jorge et al. 2010).  
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Figure 1.3 Schematic depiction of the human CFH-CFHR gene locus. This locus is situated on 
chromosome one and spans approximately 358 kb (A). It contains areas of long homologous repeats 
(depicted in colour), which predispose to non-allelic recombination events that can result in gene 
deletion or the formation of hybrid genes. Black arrows indicate position of the CFH and CFHR genes. 
Note the genomic order of the CFHR genes does not follow the numerical sequence i.e. the order is 
CFHR3, CFHR1, CFHR4, CFHR2 and CFHR5.  (B) Recombination between the inter-genic regions 
flanking the CFHR1-CFHR3 region results in complete loss of these genes. This is a common 
polymorphism and denoted:  ΔCFHR3-1. kb – kilobases. 
A 
B 
CFH$CFHR&gene$locus$on$chromosome$1$$
358kb$$
CFH CFHR3 CFHR1 CFHR4 CFHR5 CFHR2 
1:196621008$ 1:196978804$
CFH CFHR4 CFHR5 CFHR2 
CFH$CFHR&gene$locus$with$deleted$CFHR3$and$CFHR1$genes$
ΔCFHR3$1&&
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1.5.5. Murine complement factor H (mFH) and mFH-related (mFHR) proteins 
The sequence of mFH is reported to have 61% homology to human FH (Kristensen 
and Tack 1986) and is encoded by a ~100-kb gene (cfh) located on chromosome 1 
(Munoz-Canoves, Tack et al. 1989). The total length of the cfh gene is approximately 
24 times the length of its mRNA, although one quarter of this comprises the leader 
sequence exon and first intron (Vik, Keeney et al. 1988). mFH is encoded by 22 
exons with the first exon encoding the 5’-untranslated region and the 18-amino acid 
leader peptide. Nineteen of the twenty SCRs in mFH are each encoded by a single 
exon whilst the coding sequence of SCR2 is split between two exons (Vik, Keeney et 
al. 1988). The exons vary in size from 77 to 210bp with an average of 178bp, and 
are grouped either in pairs (exons 2-11) or in a cluster (exons 12-20). Analysis of the 
exons at the nucleotide level revealed clustering into two major homology groups 
and one minor one. Exons 5 and 13-21 made up the first group, 6-11 and 22 the 
second group, and 2 and 12 the minor group, whilst exons 3 and 4 encoding SCR2, 
show no homology with any of the other exons. mFH also has a high cysteine and 
proline content, conserved amino acid residues, and eight potential sites for 
asparagine-linked glycosylation with a carbohydrate content of 4-18% by weight 
(Kristensen and Tack 1986). The RGD motif in FH is conserved in evolution and 
found in a corresponding position in murine and human FH (Kristensen and Tack 
1986). 
 
mFH-related proteins are present but poorly characterised in mice. Initial studies in 
the mouse identified three liver RNA species of 3.5kb, 2.8kb and 1.8kb using cDNA 
cloning and a full-length mFH cDNA probe (Vik, Munoz-Canoves et al. 1990). Three 
mFH-encoding transcripts from two distinct cfhr genes were subsequently found 
associated with two mFHR proteins in mouse plasma (Hellwage, Eberle et al. 2006). 
The cDNA sequences of these ~100- and 38-kDa proteins reported to represent 
murine FHR-C and FHR-B respectively, are similar to those clones reported 
previously (Vik, Munoz-Canoves et al. 1990). The cfhr-c gene encodes full-length 
mFHR-C and two splice variants. mFHR-C comprises 856 amino acids in 14 SCR 
domains and contains four consensus sites for N-linked glycosylation. SCRs 1-12 
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are homologous to SCRs 6-17 of mFH whilst SCRs 13 and 14 have sequence 
identity to SCRs 19-20 of mFH. The splice variant contains 13 SCRs lacking the 
mouse FH SCR 17-related domain. The cfhr-b gene encodes mFHR-B and another 
likely splice variant. Mature mFHR-B contains 309 residues arranged in 5 SCRs 
homologous to SCRs 5-7, 19 and 20 of murine FH, and contains four N-linked 
glycosylation sites. Recombinant mFHR-B was found to bind heparin and C3b. 
However whilst both native proteins bound heparin, mFHR-C bound C3b with greater 
affinity than mFHR-B. mFHR-C was also shown to bind to endothelial cells, a 
process mediated by polyanionic surface structures (Hellwage, Eberle et al. 2006). A 
rat FH-related protein containing 11 SCRs has previously been identified, the mRNA 
of which was upregulated in glomeruli exposed to complement activation (Ren, 
Doshi et al. 2002). The recombinant form of the protein was also found to bind rat 
C3b and inhibit AP activation.  
1.5.6. The synthesis of FH and the FHR proteins 
Understanding the contribution of complement synthesised locally to that 
synthesised at a distant site is important and relevant for the soluble proteins. The 
contribution of the major synthesis site (e.g. the liver) versus local synthesis within 
tissues (e.g. by organ-specific cell populations like synoviocytes or podocytes) has 
been addressed using animal models or by comparing allotypic differences in 
humans who have undergone organ transplantation. For example, significant extra-
hepatic synthesis has been demonstrated for the complement proteins C3 and C6. In 
a study of patients who had undergone bone marrow or liver transplantation in whom 
there was a mismatch for C3 allotypes, marrow-derived C3 was shown to contribute 
0.2-5.2% of the total circulating C3 immediately following transplantation when 
inflammatory stimuli were likely to be present (Naughton, Botto et al. 1996). 
Monocytes and their precursors were deemed to be the source of the C3, but the 
drop in C3 levels after haematological recovery suggested that the contribution of 
myeloid-derived C3 in the resting state is negligible. Total extra-hepatic C3 synthesis 
meanwhile provided 5.6-11.4% of total circulating C3 in the liver transplant recipients 
and remained at this level for up to 1 year post transplant. Transplantation of livers 
from C6-deficient rats into C6-sufficient rats demonstrated that 30-40% of systemic 
C6 was extra-hepatic in origin for up to 100 days post-transplant (Brauer, Baldwin et 
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al. 1994). Bone marrow-derived C6 was shown to contribute 5% of circulating rat C6 
levels for a similar period post-BMT, with monocytes and granulocytes responsible 
for the C6 synthesis observed. 
The predominant site of synthesis of FH is the liver, which accounts for the vast 
majority of the plasma FH pool. In a single report of an individual who underwent 
hepatic transplantation, differences in recipient and donor FH allotypes enabled 
selective measurement of FH derived from the liver transplant and that derived from 
extra-hepatic FH synthesis in the host. This showed that almost all of the plasma FH 
was derived from the donor transplant (Brown, Tellez et al. 2012). Nevertheless, a 
diverse range of cell types including endothelial cells, fibroblasts, monocytes and 
oligodendrocytes have also been shown to synthesize FH (Schwaeble, Schwaiger et 
al. 1991) (Katz and Strunk 1988, Ripoche, Mitchell et al. 1988, Gasque and Morgan 
1996).  
Northern blot analysis and subsequent hybridisation with cDNA probes 
demonstrated expression of two different FH mRNA species (4.3kb and 1.8kb; 
produced by alternative splicing) in primary cell cultures of monocytes, fibroblasts 
and HUVEC, whilst a third 1.4kb FH mRNA was found only in liver tissue 
(Schwaeble, Schwaiger et al. 1991).  The 4.3kb mRNA encodes FH whilst the 1.8kb 
mRNA encodes FHL-1. Not only did FH expression appear tissue-specific in terms of 
the nature and relative quantity of these different mRNA species, but also with 
regards to the response to cytokines.  The addition of IFN-γ led to a six-fold increase 
in the abundance of the FH transcript in fibroblasts and a two-fold increase in 
HUVEC but had no effect on monocytes. Tumour necrosis factor-α (TNF-α) was able 
to induce expression of FH in the U937 pre-monocyte cell line. Identified previously 
in cultured HUVEC under standard conditions, stimulation with IFN-γ was also 
associated with a six- to seven-fold increase in both FH and FHL-1 transcript along 
with a rise in the secretion of FH itself (Ripoche, Mitchell et al. 1988). Expression of 
the FHL-1 transcript in HUVEC was only 20% that of the FH transcript, whilst in the 
liver expression was more comparable, with levels of FHL-1 up to 70% that of FH 
(Ripoche, Mitchell et al. 1988, Schwaeble, Schwaiger et al. 1991).  Both FH and 
FHL-1 transcripts were identified in fibroblasts along with the corresponding proteins, 
all of which were increased by stimulation with IFN-γ (Katz and Strunk 1988).  
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Constitutive secretion of FH was also demonstrated at very low levels in a human 
oligodendrocyte cell line (HOG), and this was enhanced by stimulation with IFN-γ 
and TNF-α in a time- and dose-dependent manner (Gasque and Morgan 1996).      
Renal synthesis of FH has been demonstrated in human mesangial cells and 
proximal tubular epithelial cells, and rodent podocytes (van den Dobbelsteen, 
Verhasselt et al. 1994, Gerritsma, Gerritsen et al. 1997, Ren, Doshi et al. 2003).  FH 
was shown to be constitutively expressed by human mesangial cells in culture, and 
this was upregulated by IFN-γ in a dose- and time-dependent manner (van den 
Dobbelsteen, Verhasselt et al. 1994).  Basal production of FH by human proximal 
tubular epithelial cell (PTEC) lines in vitro was also enhanced by incubation with IFN-
γ, a finding not reproduced by incubation with other cytokines including TNF-α 
(Gerritsma, Gerritsen et al. 1997). In rats, mRNA of both glomerular epithelial cell FH 
and a rat FH-related protein with a similar structure to human FHR5 were found to be 
upregulated following exposure to complement activation both in vitro and in vivo 
(Ren, Doshi et al. 2002, Ren, Doshi et al. 2003). FH was found to be present on the 
plasma membrane of cultured glomerular epithelial cells (GEC), and FH mRNA 
expression increased over time in cultured GEC exposed to complement activation 
(Ren, Doshi et al. 2003). Passive Heymann’s nephritis was used as the in vivo model 
of membranous nephropathy in which complement is activated in the proximity of the 
GEC, and the increased FH mRNA was also associated with a rise in FH expression 
at the protein level. Expression of FH has also been demonstrated in the retinal 
pigment epithelium/choroid in the eye (Hageman, Hancox et al. 2006). 
The major site of synthesis of the FHRs is also presumed to be hepatic, but 
expression has been reported in other tissues.  FHR1 is expressed in the retina 
(although at levels >250,000 fold lower than in liver (Hageman, Hancox et al. 2006)), 
and in the lining of blood vessels in the kidney, particularly larger arteries and in the 
afferent and efferent arterioles of glomeruli (Heinen, Hartmann et al. 2009). FHR1-5 
were also detected in middle ear effusion fluid in children with otitis media (Narkio-
Makela, Hellwage et al. 2001). FHR5 was identified in complement deposits within 
the kidney in a wide range of diseases although whether this was hepatic or renal-
derived was not deduced (Murphy, Georgiou et al. 2002). Recurrence of CFHR5 
nephropathy in an unrelated renal transplant demonstrates that normal renal-derived 
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FHR5 cannot prevent disease and I discuss this study further in my third results 
chapter (Vernon, Gale et al. 2011).  Notably recurrence rates of FH-related aHUS in 
renal transplants are known to be high, again indicating that any renal-derived FH is 
insufficient to prevent disease (Kavanagh and Goodship 2011).   
1.5.7. The function of extra-hepatic FH and the FHR proteins  
In this section I discuss efforts to understand the biological roles of extra-hepatic FH 
and FHR production. In certain situations, the local production of complement 
proteins may play a more critical role than the circulating component.  This has been 
postulated for C3 in the settings of allogeneic renal transplantation, cold ischaemia-
induced renal injury and internalisation of uropathogenic bacteria into urinary 
epithelium (Springall, Sheerin et al. 2001, Pratt, Basheer et al. 2002, Farrar, Zhou et 
al. 2006). In mice, the transplantation of C3-deficient MHC-mismatched kidneys was 
associated with long-term graft function when compared to the transplantation of 
wild-type kidneys which were rapidly rejected (Pratt, Basheer et al. 2002).  Graft 
survival was also much greater than that observed in C3-deficient recipients 
receiving wild-type grafts. In another renal isograft model, ischaemic C3-deficient 
kidneys transplanted into wild-type individuals exhibited only mild degrees of 
structural and functional disturbance, in comparison to widespread tissue damage 
and severe acute renal failure when C3-sufficient kidneys were transplanted into 
either C3-sufficient or C3-deficient recipients (Farrar, Zhou et al. 2006). These 
findings suggest that in this context at least, locally synthesized C3 appears to have 
a greater influence than the circulating component.  
To date, the physiological importance of extra-hepatic FH and FHR synthesis is 
unknown. Reconstitution of irradiated FH-deficient mice with wild-type bone marrow 
was neither able to prevent the development of the spontaneous C3 glomerulopathy 
seen in FH-deficient mice or restore circulating plasma FH levels (Alexander, 
Aneziokoro et al. 2006).  Plasma FH remained undetectable in FH-deficient mice that 
had received a single wild-type renal transplant kidney although some FH was 
detected within the kidney (Alexander, Wang et al. 2007). These data show that 
neither bone marrow-derived cells nor the kidney contribute to the circulating plasma 
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FH pool in mice, a finding consistent with the informative liver transplantation study 
discussed above (Brown, Tellez et al. 2012).  
FH on the surface of platelets and podocytes in rodents appears to be involved in the 
processing of immune complexes through binding C3b in the complexes, in an 
analogous manner to CR1 on erythrocytes and podocytes in primates (Alexander, 
Hack et al. 2001, Alexander, Wang et al. 2007). The glomeruli of irradiated wild-type 
mice reconstituted with FH-deficient bone marrow and subjected to a model of 
immune complex injury (chronic serum sickness induced by apoferritin immunization) 
contain immune complexes. These are thought to accumulate due to failure of 
removal in plasma by platelet FH (Alexander, Hack et al. 2001, Alexander, Wang et 
al. 2007). In this chronic serum sickness model, greater renal injury was seen in wild-
type hosts that received FH-deficient kidneys compared to those receiving wild-type 
kidneys. This may reflect pre-existing glomerular disease in the FH-deficient kidney 
but could also indicate that renal-derived FH was important in this model. Further 
data in this study argued that podocyte-derived FH acted to protect the kidney in this 
setting. 
  
1.6. Complement and renal disease 
Complement plays an important role in renal injury both within the glomerular and 
tubulointerstitial compartments. In the majority of cases, complement-mediated 
damage is one of several injurious mechanisms operating in a given renal pathology. 
However, in some distinct situations complement activation is the key driver of the 
renal pathology. Examples of these pathologies are aHUS and C3 glomerulopathy.  
In this section, I will start with a general overview of the contribution of complement 
to glomerular disorders where additional non-complement mediated mechanisms are 
present. These include lupus nephritis, anti-neutrophil cytoplasmic antibody-
associated vasculitis (AAV), membranous nephropathy, IgA nephropathy and 
diabetic nephropathy and tubulointerstitial injury. I will then focus on aHUS and C3 
glomerulopathy. Both these pathologies are characterised by an inability to regulate 
complement and can be described as renal disorders associated with complement 
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dysregulation. This dysregulation may be inherited or acquired and in both 
pathologies defective function of FH is common. 
1.6.1. Complement activation in glomerular disease 
1.6.1.1. Lupus nephritis  
Complement plays an important physiological role in the removal of immune 
complexes and apoptotic cells and defects in this function predispose to systemic 
autoimmunity. This is termed the ‘waste disposal’ hypothesis and apoptotic cells are 
considered to be the source of lupus autoantigens (reviewed in (Manderson, Botto et 
al. 2004)). C1q deficiency is associated with an SLE-like illness in humans and in an 
experimental model of murine C1q deficiency (Botto, Dell'Agnola et al. 1998).  
 
Excessive complement activation within the glomerulus due to immune complex 
deposition contributes to renal injury in lupus nephritis.  Anti-C1q antibodies are 
strongly correlated with renal disease in SLE, and can exacerbate antibody-mediated 
glomerular damage by augmenting the ability of immune complexes to activate 
complement (Trouw, Groeneveld et al. 2004). In experimental models, AP activation 
and C5 activation contribute to renal injury in SLE. Prevention of AP activation by 
introducing either FB (Watanabe, Garnier et al. 2000) or FD (Elliott, Jarmi et al. 
2004) deficiency resulted in amelioration of renal injury in the spontaneous lupus 
mouse model (MRL/lpr (now termed MRL/MpJ-Tnfrsf6lpr) mice). Consistent with 
these observations, targeted inhibition of complement using an artificial inhibitor 
(CR2-Crry) improved survival and renal function and histology (Atkinson, Qiao et al. 
2008). Antibody-mediated C5 inhibition ameliorated renal injury in the NZB/NZW F1 
lupus murine model (Wang, Hu et al. 1996) and a murine model of lupus nephritis 
induced by hybridoma-derived human IgG anti-DNA antibodies (Ravirajan, Wang et 
al. 2004).  
 
Notably, deficiency of C3 in MRL/lpr mice was associated with enhanced albuminuria 
and glomerular IgG deposition (Sekine, Reilly et al. 2001). This illustrates that 
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complement plays a beneficial (immune complex removal) and deleterious (tissue 
injury through the AP and C5 activation) role in SLE.  
1.6.1.2. Anti-neutrophil cytoplasmic antibody (ANCA)-associated 
glomerulonephritis (AAV) 
AAV is characterised by a pauci-immune necrotizing crescentic glomerulonephritis. 
However, there is immunoglobulin and complement deposition in some biopsies and 
the presence of electron dense deposits in these individuals was associated with 
greater proteinuria (Neumann, Regele et al. 2003). ANCA IgG plays a critical role in 
the development of AAV (Xiao, Heeringa et al. 2002, Schlieben, Korbet et al. 2005). 
Induction of glomerulonephritis in mice by the intravenous injection of anti-
myeloperoxidase IgG has also been shown to require neutrophils (Xiao, Heeringa et 
al. 2005) and factors released from activated neutrophils may activate complement 
(Vogt 1996, Wirthmueller, Dewald et al. 1997). In both the anti-MPO IgG and anti-
MPO splenocyte transfer mouse AAV model, depletion of C3 by cobra venom factor 
completely prevented the induction of glomerulonephritis (Xiao, Schreiber et al. 
2007). C5-deficient and FB-deficient mice were also protected from the induction of 
crescentic glomerulonephritis by anti-MPO IgG. The influx of neutrophils and 
monocytes was attenuated, likely secondary to the lack of C5 activation and 
generation of C5a. The demonstration of C3a production following complement 
activation by MPO-ANCA or PR3-ANCA IgG-stimulated human neutrophils, led the 
authors to hypothesize that necrotizing inflammation is mediated by activation of the 
AP by factors released from ANCA IgG-stimulated neutrophils. Pre-treatment with a 
monoclonal anti-C5 antibody again prevented disease, whilst treatment following 
disease induction led to more than 80% reduction in glomerular crescent formation 
(Huugen, van Esch et al. 2007).  Mice with C4 deficiency were not protected 
excluding a role for the CP and LP in this model. Lack of involvement of the CP and 
LP in humans is supported by the absence of C1q, C4d and MBL in renal biopsy 
specimens from patients with MPO-ANCA positive glomerulonephritis (Xing, Chen et 
al. 2009).  
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1.6.1.3. Membranous nephropathy 
Membranous nephropathy (MN) is an autoimmune disease characterised by 
deposition of immune complexes along the outer aspect of the glomerular basement 
membrane (GBM). Podocyte M-type phospholipase A2 receptor is the antigen in the 
majority of cases of idiopathic MN. Heymann nephritis (HN) is a rat model of MN 
where the podocyte antigen is megalin.  Proteinuria in HN has been reported to 
result from podocyte injury secondary to antibody-mediated complement activation 
and MAC formation (Cybulsky, Rennke et al. 1986). Complement-mediated changes 
to the slit diaphragm involving alterations in the distribution of nephrin and its 
association with actin also appear to play a role in the proteinuria observed (Saran, 
Yuan et al. 2003). Despite similar amounts of deposited sheep antibody and 
subepithelial deposits, complement-depleted rats maintained their slit diaphragm 
integrity and did not suffer the dissociation of nephrin from actin observed in 
complement-sufficient HN rats. In human MN the IgG deposited in the kidney is 
predominantly IgG4 which does not activate complement via the CP, with recent 
data suggesting that activation may be via the LP (Ma H 2011). 
1.6.1.4. IgA nephropathy 
Mesangial deposition of IgA1 characterises IgA nephropathy (IgAN), the commonest 
form of primary glomerulonephritis worldwide. Aberrant IgA1 glycosylation has been 
implicated in pathogenesis with variable amounts of these molecules detected in 
immune deposits (Giannakakis, Feriozzi et al. 2007) In some biopsies deposition of 
C3, C5b-9 and properdin in association with IgA may be seen (Bene and Faure 
1987) implicating AP activation. Polymeric or chemically aggregated IgA can activate 
the LP through an interaction with MBL (Roos, Bouwman et al. 2001). Complement 
activation by the LP is only seen in a subpopulation of patients with IgAN (Roos, 
Rastaldi et al. 2006), although LP activation appears to be associated with more 
severe renal injury (Roos, Rastaldi et al. 2006). The presence of mesangial C4d also 
seems to predict a worse renal prognosis, with 10-year renal survival in C4d-positive 
patients reported as 43.9% compared to 90.9% in C4d-negative patients (Espinosa, 
Ortega et al. 2009). Recently, an unexpected association with the allele carrying 
deletion of both CFHR1 and CFHR3 (ΔCFHR3-1) has been described (Gharavi, 
Kiryluk et al. 2011). The presence of ΔCFHR3-1 was associated with protection 
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against IgAN. How this works mechanistically is unclear but an attractive hypothesis 
is that lack of these FHR proteins reduces FH antagonism thereby enhancing the 
ability of FH to limit complement-mediated injury in IgAN (Malik, Lavin et al. 2012).   
1.6.1.5. Diabetes mellitus 
MAC deposition within the kidneys and blood vessels of diabetic patients (Falk, 
Sisson et al. 1987) led to the suggestion that complement activation may be involved 
in the development of proliferative diabetic complications. Through the release of 
growth factors from targeted endothelium, the MAC has been associated with 
stimulating smooth muscle cell, fibroblast and mesangial cell proliferation (Halperin, 
Taratuska et al. 1993). MAC triggered the production of extracellular matrix (ECM) 
proteins by mesangial cells. The glomerulosclerosis characteristic of diabetic 
nephropathy may thus be partially dependent on MAC-induced ECM expansion and 
vascular proliferation (Ziyadeh 1993). 
 
The identification of a lysine residue that is not only susceptible to glycation but is 
also adjacent to a conserved amino acid essential for CD59 function, supported a 
hypothesis that glycation of CD59 in diabetes leads to its inactivation and the 
subsequent increased MAC deposition (Acosta, Hettinga et al. 2000). CD59 
underwent glycation in vivo adversely affecting its function and site-directed 
mutagenesis of the lysine residue prevented sensitivity of human CD59 to glycation-
inactivation (Acosta, Hettinga et al. 2000). Glycated human CD59 has also been 
shown to co-localise with MAC in diabetic, but not non-diabetic, kidney tissue (Qin, 
Goldfine et al. 2004). Glycation inactivation of CD59 and increased MAC deposition 
may also be exacerbated by antibodies directed against neo-antigens in glycated 
proteins (Orchard, Virella et al. 1999). 
1.6.2. Tubulointerstitial (TI) disease 
Although the glomerulus may be the site of initial injury, associated TI damage plays 
a major role in predicting renal prognosis (Nath 1998). Proteinuria is a strong 
predictor of progression in CKD with greater levels predicting a poorer outcome 
(Remuzzi, Benigni et al. 2006). Proteinuria is believed to be a significant cause of TI 
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injury as observed in animal models (Eddy 1989), and reducing proteinuria is 
associated with a more favourable prognosis. Whilst albumin and growth factors in 
urine of proteinuric patients have been suggested as possible mediators of renal 
damage (Olson, de Urdaneta et al. 1985, Honkanen, Teppo et al. 1997), 
complement proteins are also present and on activation within the tubular lumen 
generate complement activation products and the MAC (Morita, Ikeguchi et al. 
2000). Evidence suggests that the AP is responsible for complement activation on 
the brush border of the proximal tubules (Camussi, Tetta et al. 1983). Furthermore, 
the lack of complement regulators on the apical surface of tubular cells (Ichida, 
Yuzawa et al. 1994) along with the additional formation of the AP convertase by 
amidated C3, may contribute to intraluminal complement activation. The MAC has 
been implicated in TI injury in proteinuric animal models, with C6-deficient rats 
exhibiting less severe TI injury than wild type rats with equivalent proteinuria 
(Nangaku, Pippin et al. 1999).  Tubular C5b-9 deposition has also been associated 
with interstitial monocyte infiltration and volume expansion (Mosolits, Magyarlaki et 
al. 1997), and may promote peritubular myofibroblast accumulation in focal 
segmental glomerulosclerosis (FSGS) (Rangan, Pippin et al. 2004). Myofibroblast 
accumulation is reported to be a predictor of progression in a number of human 
glomerular diseases (Abbate, Zoja et al. 2002). 
 
Patients with FSGS, characterised by nephrotic-range and non-selective proteinuria, 
have one of the highest rates of urinary C5b-9 excretion (Morita, Ikeguchi et al. 
2000) and increased TI deposition of C5b-9 (Mosolits, Magyarlaki et al. 1997). 
Adriamycin-induced nephropathy in rodents is considered an analogue of human 
minimal change disease and FSGS, with long-term features typical of chronic 
progressive renal disease in humans (Okuda, Oh et al. 1986). The involvement of 
the AP in mediating injury in this model has been demonstrated using complement-
deficient mice (Turnberg, Lewis et al. 2006, Lenderink, Liegel et al. 2007). Mice 
deficient in C3 and FD were protected from renal disease (Turnberg, Lewis et al. 
2006) whilst complement activation in the glomeruli and TI was also reduced in FB-
deficient mice (Lenderink, Liegel et al. 2007). FB inhibition using a monoclonal 
antibody in wild-type mice also led to the delayed onset of renal failure (Lenderink, 
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Liegel et al. 2007). Similarities in disease seen in C1q-deficient and wild-type mice 
demonstrated that complement activation in this model is not mediated by the CP. In 
contrast, mice lacking CD59 developed significantly greater glomerular and TI injury 
than controls (Turnberg, Lewis et al. 2006).  
 
The generation of the anaphylatoxin C5a has also been implicated in TI damage and 
the production of profibrotic mediators (Boor, Konieczny et al. 2007), with inhibition 
of C5 (and C5a) in experimental models leading to a reduction in TI injury (Boor, 
Konieczny et al. 2007). 
1.6.3. Renal disorders associated with complement dysregulation 
The prototypic renal disease associated with complement dysregulation is dense 
deposit disease (DDD) (Fakhouri, Fremeaux-Bacchi et al. 2010). Subsequently, 
aHUS was recognised as a condition in which many cases were associated with 
defective AP regulation. In both conditions there are frequently either inherited or 
acquired defects of AP regulation (reviewed in (Smith, Alexander et al. 2007)). Since 
these conditions are pathologically distinct (DDD is characterised by 
glomerulonephritis and aHUS by renal thrombotic microangiopathy), a key question 
was: how does AP dysregulation give rise to these distinct phenotypes? Lessons 
from animal models and the characterisation of informative mutations have 
demonstrated that, although AP dysregulation is common to both DDD and aHUS, in 
DDD the dysregulation is within plasma (fluid-phase) whilst in aHUS it occurs along 
the renal endothelium. In DDD, such is the enormity of fluid-phase C3 activation and 
consumption of complement components, that systemic complement activity is 
frequently absent. The lesion is thought to occur because of the accumulation of C3 
fragments along the GBM (Smith, Harris et al. 2011). In contrast in aHUS, impaired 
surface regulation along the renal endothelium occurs in the presence of functional 
complement regulation in the plasma (Pickering, de Jorge et al. 2007). The lesion is 
thought to occur because of an inability to control complement activation along the 
renal endothelium.  
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More recently, it is clear that DDD is part of a spectrum of glomerular pathologies in 
which there is predominant C3 accumulation. The term C3 glomerulopathy was 
coined to describe this group of glomerular pathologies (Fakhouri, Fremeaux-Bacchi 
et al. 2010). I will first discuss C3 glomerulopathy and then aHUS. I will particularly 
emphasise the role of models of FH deficiency since these have been particularly 
informative mechanistically and understanding their phenotypes is relevant to the 
interpretation of my thesis data.   
1.6.4. C3 glomerulopathy 
C3 glomerulopathy refers to glomerular pathology in which there is predominant C3 
deposition over immunoglobulin (Fakhouri, Fremeaux-Bacchi et al. 2010).  In the 
most extreme case, immunoglobulin is absent but this definition is too restrictive as 
in many cases of DDD scanty or 1+ immunoglobulin staining may be seen in the 
presence of predominant C3 staining. The most characterised entities within this 
pathological classification are DDD and C3 glomerulonephritis (C3GN).  
 
The defining feature of DDD is the presence of intramembranous electron dense 
transformation of the GBM (Berger and Galle 1969). Historically DDD was re-named 
as a subtype of membranoproliferative glomerulonephritis (MPGN), termed MPGN 
type 2 (Habib, Gubler et al. 1975).  However, when the original defining feature is 
used only approximately one third of biopsies have evidence of MPGN (Walker, 
Ferrario et al. 2007). Therefore viewing DDD as a category of MPGN is misleading 
and the term DDD should be used. The light microscopic appearances of DDD are 
highly variable and include: mesangial proliferative, crescentic and exudative in 
addition to MPGN (Walker, Ferrario et al. 2007).  
 
DDD is commonly associated with the presence of hypocomplementaemia most 
often due to the presence of C3 nephritic factor (reviewed in (Smith, Alexander et al. 
2007), an auto-antibody that stabilises the AP C3 convertase, C3bBb (Spitzer, 
Vallota et al. 1969, Daha, Fearon et al. 1976). The result is uncontrolled C3 
activation through the AP. Rarer causes of uncontrolled C3 activation through the AP 
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and DDD include complete FH deficiency (Levy, Halbwachs-Mecarelli et al. 1986, 
Pickering and Cook 2008), autoantibodies to FH that result in functional FH 
deficiency (Meri, Koistinen et al. 1992, Jokiranta, Solomon et al. 1999), gain of 
function mutation in FB (Jokiranta, Solomon et al. 1999, Strobel, Zimmering et al. 
2010) and gain of function mutation in C3 (Martinez-Barricarte, Heurich et al. 2010). 
These are summarised in figure 1.4.  
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Figure 1.4 Mechanisms of C3 dysregulation associated with DDD. (A) In plasma the conversion of 
C3 to C3b by the AP convertase (C3bBb) is inhibited by FH.  In addition, any C3b generated is 
proteolytically cleaved by FI to iC3b. The iC3b, unlike C3b, cannot contribute to further C3b activation 
via the C3b amplication loop. (B) Mechanisms that impair the FH-mediated inhibition of plasma C3 
activation are associated with DDD. These include (i) C3 nephritic factor, an autoantibody that 
stabilises C3bBb preventing its inhibition by FH; (ii) FH autoantibodies that interfere with the binding 
of FH to the convertase; (iii) gain of function mutations in C3 that are resistant to inhibition by FH and 
(iv) genetic deficiency of FH (figures adapted from (Smith, Harris et al. 2011) ).  
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C3GN is characterised by subendothelial electron dense deposits and the absence 
of the highly electron dense intramembranous change characteristic of DDD 
(Servais, Fremeaux-Bacchi et al. 2007). Like DDD, light microscopic appearances 
are heterogeneous (Fakhouri, Fremeaux-Bacchi et al. 2010). The importance of 
C3GN is that it tells us that there is a spectrum of C3 dominant glomerular 
pathologies and consequently it is likely that additional mechanisms beyond fluid-
phase C3 dysregulation are present. This is most obvious from the observation that 
many patients with C3GN do not have systemic hypocomplementaemia (Fakhouri, 
Fremeaux-Bacchi et al. 2010). The most well characterised cause of C3GN derived 
from studies of familial C3GN in Cyprus (Gale, de Jorge et al. 2010). Affected 
individuals had an autosomal dominant C3GN characterised by normal plasma 
complement profile, absence of causative factors described for DDD (e.g. C3 
nephritic factor), synpharyngitic macroscopic haematuria (leading in some cases to 
an erroneous diagnosis of IgAN) and more severe renal disease in males (Gale, de 
Jorge et al. 2010, Athanasiou, Voskarides et al. 2011). Genetic studies revealed that 
this disease was due to a heterozygous internal duplication in the CFHR5 gene and 
led to it being termed CFHR5 nephropathy (Gale, de Jorge et al. 2010). This 
mutation does not alter the genetic architecture of the CFH gene so that FH function 
is ostensibly normal. As discussed earlier, the current biological role for FHR 
proteins including FHR5 is that they compete with FH for binding to ligand 
(Goicoechea de Jorge, Caesar et al. 2013, Tortajada, Yebenes et al. 2013). 
However, unlike FH they are not able to prevent C3b amplification, as they have no 
intrinsic complement regulatory activity at physiological concentrations (Goicoechea 
de Jorge, Caesar et al. 2013, Tortajada, Yebenes et al. 2013). The result is that they 
function as FH deregulators. In CFHR5 nephropathy, the current hypothesis is that 
the mutant FHR5 protein acts as a ‘gain of function’ FH deregulator and impairs the 
ability of FH to prevent accumulation of C3 along the GBM. I discuss this and further 
associations between familial C3GN and FHR mutations in Chapter 5.  
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1.6.4.1. Spontaneous porcine FH deficiency 
Hereditary porcine membranoproliferative glomerulonephritis type II was described in 
piglets of the Norwegian Yorkshire breed that had developed spontaneous FH 
deficiency (Jansen, Hogasen et al. 1993, Hogasen, Jansen et al. 1995). Although 
healthy at birth, the piglets failed to thrive and died within 72 days from renal failure 
associated with rapidly progressive glomerulonephritis. Histological examination 
revealed thickening of the glomerular capillary wall, glomerular proliferation, and 
extensive dense deposits within a thickened GBM, all associated with capillary wall 
deposition of complement but not immunoglobulin. This lesion was therefore 
analogous to DDD and has been referred to as porcine DDD. Low plasma C3 levels 
and elevated terminal complement complex (TCC) were felt to reflect excessive fluid-
phase complement activation. The increased C3 and reduced TCC levels witnessed 
in piglets transfused with plasma led to the subsequent fractionation of normal 
porcine plasma and the identification of a single protein responsible for the 
complement inhibitory activity. With a molecular weight of 150kDa, in vitro FI cofactor 
activity, immunologic cross-reactivity with human FH and an amino-terminal amino 
acid sequence similar to human, murine and rabbit FH, the single chain protein was 
confirmed as porcine FH.  
 
The disease was found to follow an autosomal recessive pattern of inheritance and 
showed complete penetrance in homozygosity. Heterozygous carriers were healthy. 
FH levels in affected piglets were found to be ~3% compared to healthy littermates, 
whilst half normal levels were observed in their parents. Two non-synonymous single 
nucleotide changes were identified in the porcine factor H gene, one in SCR9 and 
one in SCR20 (Hegasy, Manuelian et al. 2002). FH expression at the mRNA and 
protein levels was found to be intact but the mutant protein was not secreted and 
accumulated within hepatocytes.  
1.6.4.2. Gene-targeted FH-deficient mice  
Mice rendered completely FH-deficient through gene targeting were also found to 
develop spontaneous renal disease (originally described as MPGN type 2 but now 
would be described as a C3 glomerulopathy) associated with increased mortality and 
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albuminuria (Pickering, Cook et al. 2002). Mice had severely reduced plasma C3 and 
C5 levels (Pickering, Cook et al. 2002, Pickering, Warren et al. 2006, de Jorge, 
Macor et al. 2011). Glomerular lesions consisted of mesangial matrix expansion, 
mesangial hypercellularity, capillary loop thickening and double contouring of the 
GBM. Mesangial cell interposition, new basement membrane formation and 
subendothelial electron dense deposits on electron microscopy were accompanied 
by capillary wall and mesangial C3 and C9 deposition. Subendothelial deposits 
contained C3 and C9 on immunoelectron microscopy, but no IgG. Glomerular 
deposition of C3 and C9 was found to precede the appearance of subendothelial 
deposits, and these were both followed by development of the light microscopic 
features. Notably, heterozygous FH deficiency did not result in the development of 
MPGN.  
 
The absolute requirement for uncontrolled C3 activation in the development of the 
renal lesion was demonstrated by the lack of renal disease in FH-deficient mice that 
were unable to activate the AP due to the introduction of FB deficiency.  Mice with 
combined deficiency of both FH and FB had normal plasma C3 levels and normal 
renal histology (Pickering, Cook et al. 2002). 
 
The deleterious effect of glomerular C3 deposition alone was evident by comparing 
the spontaneous renal phenotype of mice with combined deficiency of both FH and 
C5 with mice that were deficient in FH alone (Pickering, Warren et al. 2006). Despite 
having significantly lower mortality and creatinine levels, 12-month old combined FH- 
and C5-deficient mice had comparable albuminuria to FH-deficient mice indicating 
that chronic C3 deposition along the GBM was sufficient to disrupt GBM 
permeability. Capillary wall double contours, GBM thickening and subendothelial 
electron dense deposits were still present in the FH- and C5-deficient mice, 
indicating that these develop in the absence of C5.   However, the absence of C5 
was associated with reduced glomerular cellularity, neutrophils and crescent 
formation (Pickering, Warren et al. 2006). 
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Mice with complete FH deficiency were also found to be more susceptible to renal 
injury induced by accelerated (Pickering, Cook et al. 2002) and heterologous 
(Pickering, Warren et al. 2006) serum nephrotoxic nephritis (NTN).   The 
administration of nephrotoxic serum (NTS) to pre-immunised animals (accelerated 
NTN) led to haemoglobinuria and significantly greater albuminuria and mortality 
compared to wild-type animals. The importance of C3 activation through the AP in 
this phenotype was demonstrated by the prevention of the phenotype in mice with 
combined deficiency of FH and FB (Pickering, Cook et al. 2002). In heterologous 
NTN, FH-deficient mice exhibited an excess of glomerular neutrophils, additional C3 
deposition and proteinuria in comparison to wild-type animals (Pickering, Warren et 
al. 2006). The increase in neutrophil numbers and proteinuria was shown to be 
dependent on C5 activation, in particular the formation of C5a rather than the MAC. 
Concomitant C6 deficiency failed to prevent the increased neutrophil numbers and 
proteinuria seen in FH-deficient mice, whilst these were abrogated by either genetic 
or antibody-mediated C5 deficiency (Pickering, Warren et al. 2006). 
 
Whilst uncontrolled AP activation and isolated glomerular C3 deposition are common 
in human DDD there were differences between the lesions seen in the FH-deficient 
mice and what is typically seen in human DDD. The mice developed subendothelial 
electron dense deposits and not intramembranous deposits typical of DDD. So in 
current terms, the murine lesion would be better described as C3GN. The deposits 
stained directly for C3 and C9 in the mice whereas deposits in DDD characteristically 
stain for C3 at the margins only. On C3 staining this marginal staining results in 
mesangial deposits appearing as ‘rings’ and GBM C3 deposition as ‘rail-road tracks’ 
(Sibley and Kim 1984). Deposits are also common within Bowman’s capsule and the 
tubular basement membranes in DDD whereas deposits were not identified at this 
location in the FH-deficient mice. Interestingly, during periods of 
hypocomplementaemia, paramesangial C3 deposits have been described in DDD 
(West and McAdams 1995), which again are not seen in the FH-deficient mice. 
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1.6.5. Atypical haemolytic uraemic syndrome (aHUS) 
aHUS is characterised by microangiopathic haemolytic anaemia, thrombocytopaenia 
and renal failure in the absence of infection with shigatoxin-producing bacteria like 
strains of Escherichia coli. The renal lesion is thrombotic microangiopathy. Unlike 
DDD, hypocomplementaemia is not typically seen in aHUS. Triggers include 
infection, pregnancy, malignancy, transplantation and drugs such as 
immunosuppressive and cancer therapies, and the oral contraceptive pill (Caprioli, 
Noris et al. 2006). 
 
The role of uncontrolled AP activation in aHUS is now well recognised with 60% of 
patients possessing inherited or acquired abnormalities that result in AP 
dysregulation (reviewed in (Kavanagh and Goodship 2011)). Mutations are either 
loss of function changes in complement regulators: FH (Warwicker, Goodship et al. 
1998, Caprioli, Bettinaglio et al. 2001, Perez-Caballero, Gonzalez-Rubio et al. 2001, 
Richards, Buddles et al. 2001, Sanchez-Corral, Perez-Caballero et al. 2002, 
Manuelian, Hellwage et al. 2003), FI (Fremeaux-Bacchi, Dragon-Durey et al. 2004, 
Kavanagh, Kemp et al. 2005) and MCP (Noris, Brioschi et al. 2003, Richards, Kemp 
et al. 2003), or gain of function changes in the AP activation proteins, FB 
(Goicoechea de Jorge, Harris et al. 2007)  and C3 (Fremeaux-Bacchi, Miller et al. 
2008). They are typically heterozygous and mutations in FH are most frequent. 
Acquired FH dysfunction due to anti-FH autoantibodies has been reported (Skerka, 
Zipfel et al. 2010).  Interestingly, anti-FH autoantibodies are most frequently seen in 
patients with the ΔCFHR3-1 deletion allele (Zipfel, Edey et al. 2007, Jozsi, Licht et al. 
2008). aHUS in this setting has been termed ‘deficiency of FHR proteins and auto-
antibody positive-HUS’ (DEAP-HUS), and it most commonly affects children (Skerka, 
Zipfel et al. 2010). 
 
The molecular pathogenesis of aHUS is most clearly understood for FH mutations. 
The majority of FH mutations occur within the terminal SCR domains (SCR 19 and 
SCR 20). These mutations selectively impair the surface recognition domains of FH 
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since the complement regulatory domains reside within SCR domains 1-4. Mutations 
may be sequence variants within the exons encoding for these domains or a 
consequence of copy number variation. Examples of the latter are FH hybrid genes 
in which there are non-allelic recombination events that result in the terminal FH 
domains being replaced by exons from the downstream FHR proteins. This 
generates hybrid FH-FHR proteins that lack either both or one of the FH SCR 19 and 
20 surface domains (Venables, Strain et al. 2006, Francis, McNicholas et al. 2012). 
Hybrid proteins described to date include FH-FHR1 (consists of FH SCR 1-18 linked 
to FHR1 SCR domains 4 and 5) (Venables, Strain et al. 2006) and FH-FHR3 
(consists of FH SCR 1-19 linked to FHR3 SCR domains 1 to 5) (Francis, McNicholas 
et al. 2012).  
 
Consistent with the selective targeting of aHUS-associated FH mutations to its 
surface recognition domains, functional analyses of many FH aHUS-associated 
mutations have demonstrated normal complement regulatory activity in fluid-phase 
(typically using FI cofactor assays) but impaired surface recognition activity (typically 
impaired binding to surface-bound C3b and polyanions with consequent limited 
ability to prevent complement-mediated cell lysis) (Pangburn 2002, Sanchez-Corral, 
Perez-Caballero et al. 2002, Manuelian, Hellwage et al. 2003). Similarly, FH 
autoantibodies in aHUS are directed against the surface recognition domains and 
result in an acquired defect of surface recognition without disrupting complement 
regulatory activity in plasma (Jozsi, Strobel et al. 2007). 
 
Presently, aHUS is thought to require a combination of a complement mutation, an 
environmental trigger (e.g. pregnancy) and the presence of predisposing 
polymorphisms (Esparza-Gordillo, Goicoechea de Jorge et al. 2005, Esparza-
Gordillo, Jorge et al. 2006). The latter include variants within MCP (Esparza-Gordillo, 
Goicoechea de Jorge et al. 2005) and certain haplotypes across the CFH gene 
locus. A FH haplotype (termed H3 and defined by five SNPs across the gene: -332T, 
c.184G, c.1204T, c2016G, and c.2808T) was significantly increased in patients with 
aHUS versus controls (Kavanagh and Goodship 2011). Interestingly, a distinct FH 
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haplotype (termed H1, -332C, c.184G, c.1204C, c.2016A and c.2808G) was 
associated with DDD. Furthermore, plasma FH levels vary widely within the general 
population but show consistency amongst individuals. In a Spanish population of 358 
individuals from 21 pedigrees, plasma FH levels were found to vary over a five-fold 
range (116-562µg/ml). Of the phenotypic variability, 62% was found to be genetically 
determined and three quantitative trait loci, including one within the RCA gene 
cluster at 1q32 were detected (Esparza-Gordillo, Soria et al. 2004). Polymorphisms 
exist in FH for which the functional implications are not clear as they are neutral at 
the protein level and do not appear to be associated with altered FH levels. Three 
SNPs lacking any apparent effect on the protein or its circulating level have also 
been detected in aHUS patients more frequently than in controls (Caprioli, Castelletti 
et al. 2003). FH levels may influence the penetration of aHUS since inactivation of 
surface-bound C3b has long been known to be more sensitive to FH levels than 
inactivation of fluid-phase C3b (Schreiber, Pangburn et al. 1978). 
 
The outcome for aHUS patients has been transformed by the availability of a 
therapeutic monoclonal antibody, termed Eculizumab that inhibits C5. This has 
recently been shown to be effective in both plasma-sensitive and plasma-resistant 
aHUS and its efficacy is independent of the presence or type of complement 
mutation (Legendre, Licht et al. 2013). The application of Eculizumab in this 
condition derived from mechanistic studies and these include the development of a 
mouse model of FH-associated aHUS in which the renal pathology was shown to be 
C5-dependent (de Jorge, Macor et al. 2011). I now discuss this model in detail.  
 
1.6.5.1. A murine model of FH-associated aHUS  
To develop a model of FH-associated aHUS, mice expressing mFH lacking the 
surface recognition domains were generated (Pickering, de Jorge et al. 2007). Like 
FH, complement regulatory domains of mFH reside within the amino SCR domains 
and surface recognition domains reside within the carboxyl termini (Cheng, Hellwage 
et al. 2006). The transgenic mice expressed a mutant mFH protein lacking the five 
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C-terminal SCR domains (FHΔ16-20) thereby creating a mutant protein that would 
lack surface recognition but maintain complement regulation in plasma. Wild-type 
mice transgenic for the mutant mouse protein were inter-crossed with FH-deficient 
mice (Cfh-/-) to generate either homozygous (Cfh-/-.FHΔ16-20) or heterozygous 
(Cfh+/-.FHΔ16-20) FH-deficient mice transgenic for FHΔ16-20 (Pickering, de Jorge et 
al. 2007). Significantly higher C3 levels were observed in Cfh-/-.FHΔ16-20 mice 
compared to Cfh-/- mice, and similarly in Cfh+/-.FHΔ16-20 mice compared with Cfh+/- 
animals. This demonstrated that the mutant FHΔ16-20 protein could regulate plasma 
C3 activation in vivo. Furthermore, this was sufficient to prevent the accumulation of 
C3 along the GBM that is characteristic of FH-deficient mice. As Cfh-/-.FHΔ16-20 
mice aged many developed haematuria and premature mortality. In mice that were 
unwell there was uraemia and red cell fragmentation on peripheral blood smears. 
Critically, the renal pathology showed thrombotic microangiopathy and no evidence 
of the C3GN-like lesions typical of the FH-deficient mouse. When these mice were 
rendered C5-deficient (by inter-crossing with the spontaneous C5-deficient DBA2 
strain that had been previously back-crossed on to the C57BL/6 genetic background) 
renal thrombotic microangiopathy was prevented although abnormal glomerular 
mesangial C3 deposition persisted (de Jorge, Macor et al. 2011). This indicated a 
critical role for C5 in the development of thrombotic microangiopathy in these 
animals and this has been recapitulated by the success of Eculizumab in aHUS. The 
relative contribution of C5a and MAC to renal injury is still to be ascertained. 
 
Notably, a second transgenic line was reported that expressed FHΔ16-20 at levels of 
only 2% of normal wild-type FH levels. These animals did not develop thrombotic 
microangiopathy but did develop mild mesangial expansion in association with 
mesangial C3 and infrequent subendothelial electron dense deposits (Pickering, de 
Jorge et al. 2007). The interpretation was that for thrombotic microangiopathy to 
develop some degree of intact complement is required in plasma in addition to 
defective regulation along the renal endothelium. FH-deficient mice have no FH 
protein in circulation so have both defective plasma and surface regulation. 
However, the defective surface regulation does not result in thrombotic 
microangiopathy since there is no intact complement in plasma to mediate the injury. 
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In this respect FH-associated aHUS mutations can be thought of as deleterious 
because they provide inadequate surface protection whilst maintaining intact 
complement in plasma to mediate the endothelial injury. 
 
1.7. Generation of a conditional FH-deficient mouse 
In my thesis I wanted to explore the contribution of local FH to renal injury. To test 
this experimentally I wanted to be able to generate tissue-specific FH deficiency in 
mice. In my supervisor’s laboratory, they had generated a conditional FH-deficient 
mouse, depicted schematically in figure 1.5. The strategy was to flank exons 2 and 3 
of the mouse cfh gene with loxP sites so that this would enable excision of these 
exons by Cre recombinase. The Cre recombinase of the P1 bacteriophage is a site-
specific recombinase that recognises a specific 34-bp consensus recognition site 
(termed ‘locus of X-over P1’ and denoted loxP) and recombination between the loxP 
sites results in excision of the intervening DNA sequence. Deletion of exons 2 and 3 
was predicted to result in a reading frameshift leading to the generation of a stop 
codon in exon 4 and therefore a null allele (figure 1.6). In the original gene-targeted 
FH-deficient animal, deletion of exon 3 was performed. This also resulted in a 
reading frameshift and a predicted null allele which was subsequently demonstrated 
in vivo (Pickering, Cook et al. 2002). The targeted locus also contained a neomycin-
resistant (Neo) positive selectable marker flanked by flippase (Flp) recombinase 
recognition target (FRT) sites. The positive selectable marker enabled selection of 
the desired recombination events in embryonic stem cells. The flanking FRT sites 
enabled excision of the FRT-flanked Neo cassette using Flp recombinase at a later 
stage if needed. The conditional FH-deficient mouse was successfully generated and 
was back-crossed onto the C57BL/6 genetic background prior to inter-crossing with 
Cre recombinase-expressing strains.  
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Figure 1.5 Generation of conditional FH-deficient mouse.  (A) The targeting vector contained loxP 
sites located either side of exons 2 and 3 of the cfh gene and a positive selectable marker (neomycin 
cassette, Neo) flanked by FRT sequences (see text). (B) Following homologous recombination the 
targeted gene contains the construct elements without altering the exon structure of the cfh gene. The 
recombination event was detected by Southern blotting using a probe (as indicated) that differentiated 
between a 16-kb and 10-kb Nco1 genomic DNA fragment. (C) Predicted gene structure following Cre 
recombinase excision of the loxP-flanked DNA. 
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Figure 1.6 Deletion of exons 2 and 3 of the mouse cfh gene. Exon junction sequences show that 
exon 1 is in intron phase 1 whilst exon 3 is in intron phase 2. After excision of exons 2 and 3 there is a 
frameshift in the reading sequence with the generation of a stop codon (TAG) at the fourth codon 
within exon 4. 
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1.8. Aims of my project 
The overarching aim of my thesis was to experimentally dissect the contributions of 
local and hepatic-derived FH.  
 
My specific aims were: 
1.8.1. To define the contribution of extra-hepatic FH production to plasma C3 
regulation and spontaneous renal disease associated with FH deficiency.  
I approached this experimentally by generating and analysing a novel hepatocyte-
specific FH-deficient mouse strain. This was achieved by inter-crossing the 
conditional FH-deficient strain with mice expressing Cre recombinase under the 
control of a hepatocyte-specific promoter. I discuss these experiments in Chapter 3.  
1.8.2. To define the contribution of extra-hepatic FH production to experimentally 
triggered renal injury.  
FH-deficient mice were previously demonstrated to be hypersensitive to 
experimentally triggered renal injury using either the heterologous or accelerated 
NTN models. Based on these observations and my data from the analysis of the 
spontaneous phenotype of the hepatocyte-specific FH-deficient mouse, I assessed 
the response of this strain to accelerated NTN. I discuss these experiments in 
Chapter 4. 
1.8.3. To understand the mechanism underlying the association between 
abnormalities in FHR proteins and C3 glomerulopathy.  
During my thesis I characterised the recurrence of CFHR5 nephropathy in the 
transplant kidney and characterised an individual with C3 glomerulopathy associated 
with infection and heterozygous deficiency of FHR5. I discuss these experiments in 
Chapter 5. 
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2. CHAPTER TWO: MATERIALS AND 
METHODS 
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2.1. Molecular biology techniques 
2.1.1. Ribonucleic acid (RNA) extraction  
Mouse liver, whole mouse kidney, and human liver and kidney tissue were 
homogenized in liquid nitrogen and RNA extracted using RNA-Bee isolation reagent 
(Amsbio, Abingdon, UK).  The RNAqueous®-4PCR kit (Ambion, Huntingdon, UK) 
and RNeasy mini kit (Qiagen, Manchester, UK) were subsequently used to extract 
RNA. The methodology chosen was determined by the starting material and 
remained the same within experiments. Human liver and kidney tissue were obtained 
from the tissue bank at our institution after appropriate ethical approval was given. 
 
2.1.2. Deoxyribonucleic acid (DNA) extraction from mouse tissue 
Mouse tissue was digested overnight in 400µl of lysis buffer (0.2M NaOH, 1% 
sodium dodecyl sulphate [SDS]) containing proteinase K at 55°C in a rotating 
hybridisation oven. Proteinase K was heat inactivated (75°C for 10 minutes) prior to 
use in polymerase chain reactions. 
 
2.1.3. Complementary DNA (cDNA) synthesis 
Whilst cDNA was initially synthesized using oligo(dT)12-18 primers and Superscript™ 
II Reverse Transcriptase (RT) (Invitrogen, Paisley, UK), this was superceded by the 
use of random primers to ensure transcription of 5’ sequence. Following denaturation 
at 68°C for 10 minutes, 2µg RNA was typically transcribed in the presence of buffer, 
deoxynucleotide triphosphate (dNTP), RT random primers, ribonuclease (RNase) 
inhibitor and reverse transcriptase using the Applied Biosystems High Capacity 
cDNA reverse transcription kit (Applied Biosystems, Warrington, UK). Thermocycling 
conditions were: 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 seconds and 
4°C to infinity.  
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2.1.4. Polymerase chain reaction (PCR) and quantitative PCR (qPCR) 
PCR conditions were optimised for each reaction as required. Amplification of both 
cDNA and genomic DNA involved the use of 50-100ng DNA in each PCR reaction, 
accompanied by 100ng of sequence-specific oligonucleotide primers and 0.2mM of 
each dNTP in the presence of NH4 buffer, MgCl2 and BioTaq DNA polymerase. 
Thermal cycling programmes typically consisted of incubation at 94°C for 2 minutes, 
followed by 30 cycles of: 94°C for 30 seconds (denaturation), 50-65°C for 1 minute 
(annealing; variable temperature depending on individual primers), 72°C for 1 minute 
(extension), and 72°C for a further 10 minutes.  
 
Relative expression of FH and the FHR proteins in liver and kidney tissue was 
investigated using qPCR. Beta-actin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used as housekeeping genes. Primers were 
designed to yield an amplicon of between 150-200 base pairs (bp) in size, and 
optimal annealing temperatures determined using gradient PCR.  Reactions were 
performed with the Stratagene Brilliant II SYBR green qPCR kit (Agilent, Stockport, 
UK) using 100ng of cDNA for the qPCR reaction. The ABI 7900H thermal cycler 
(Applied Biosystems, Warrington, UK) was used to perform the reaction, and a 
dissociation step was added to determine the melting temperatures of the PCR 
products and identify the presence of any primer-dimers or non-specific products.  
 
The primers used are listed in table 2.1. 
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Table 2.1.List of primers 
Target Primer pairs 
(forward + reverse primer in 5 prime to 3 prime orientation) 
size 
(bp) 
mFH 
 
TAATAGTCGGTGGATTGGAC + CTCGGCACTTTGGTTTTT  
TAATAGTCGGTGGATTGGAC + CTGTCCATATCCCATTTTCAC 
CTGTCAGCAAGAATTATTTGGC + ACACATCGTGGCTTTTCATTGC 
AGGGGGAAAGAGAGAGATG + CAGCAGCTGGCCTTCTCTGCTTGTGTAAG 
212 
193 
** 
*** 
FHR-A CAGTGCCAGAACTATTATGTAC + CTGTAGCAGTAATATTCATGTGC 
ATATCAGTGCCAGAACTATTATG + AACTCAATATCCTCTCCTGAC 
539 
191 
FHR-B GTACAGAGAATGGCTGGTC + AGTGATCCTCTTGCTTTCTG 
CAACCTGTTTACATGCATGTG + CAGTGATCCTCTTGCTTTCTG 
370 
154 
FHR-C CTGTGACATGTATTAATGGCC + CACTGATAGTCAACTGATGAG 
 
150 
 
Beta actin 
Mouse 
Human 
 
 
CCTCTATGCCAACACAGTG + TGATCCACATCTGCTGGAAG  
CACCATGTACCCTGGCATTG + TGCTTGCTGATCCACATCTG 
 
197 
170 
GAPDH 
Mouse 
Human 
 
TGTCTCCTGCGACTTCAAC + CCAGGGTTTCTTACTCCTTG  
GTCTCCTCTGACTTCAACAG + CTTACTCCTTGGAGGCCATG 
 
 
 
176 
165 
FH TGCACATGGGACTAAATTGAG + CGGATTCACACAGGAGGTG 
TAGGAGAAAAATGGTCTCACC + CGGATTCACACAGGAGGTG 
481 
172 
FHR1 CATTTTCCCAGGTTCCTACAG + CTGTCTCGACAGTATATGAGC 365 
 
FHR2 ATCTGGAAGGTGATACTGTAC + TCTGACACATTGCTCGAAATG 465 
FHR3 CACACAAAATGGGTGGTCAC + CTGTCACTTCTTCCTTTTAAC 647 
FHR4 GAGCCAAGAGTAATGGCATG + GTGAGAAGTGGAAGTTGGAC 569 
FHR5 
 
 
FP(2) + RP(3): 
GCCACCTCAGATACCTAATG + TTCTTCAGATACCACACATGG 
FP(3) + RP(3): 
CTCAGAATATGACAACCACAG + TTCTTCAGATACCACACATGG 
gFP(2) + gRP(2): 
TCCTCAACTCTCCAATGGTG + TCATTTCTGCAATTCACCTCG 
 
TAACAATGGAGATACCACCTC + TTCTTCAGATACCACACATGG 
 
363 
 
343 
 
266 
 
171 
mFH loxP(FP) + loxP(RP): 
AGGGGGAAAGAGAGAGATG + TCCTAGTAGCAAAGCTAAACAG 
 
* 
 ALB-CRE CRE-1(FP) + CRE-2(RP): 
GCGGTCTGGCAGTAAAAACTATC + GTGAAACAGCATTGCTGTCACTT 
 
100 
 IL-2 IL-2(FP) + IL-2(RP): 
CTAGGCCACAGAATTGAAAGATCT + GTAGGTGGAAATTCTAGCATCATCC 
 
324 
 *450-bp amplicon in wild-type cfh gene and 527-bp amplicon in floxed cfh gene 
**610-bp amplicon in wild-type cfh gene and 318-bp amplicon in cfh gene after Cre recombinase-
mediated excision of exons 2 and 3 
***546-bp amplicon in cfh gene after Cre recombinase-mediated excision of exons 2 and 3 
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2.1.5. Agarose gel electrophoresis 
Agarose was dissolved in Tris-acetate buffer (TAE) to a concentration of between 1-
3% depending on the size of the DNA fragments to be visualised. TAE was prepared 
as a 50x stock comprised of: 2M Tris-acetate and 50mM ethylene diamine tetra-
acetic acid (EDTA). Ethidium bromide was then added to a final concentration of 0.2-
0.25 µg/ml, after which the mixture was poured into horizontal gel trays to set. For 
visualisation of PCR products, 10µl of DNA was added to 5µl of loading buffer (30% 
glycerol, 0.25% xylene cyanol, 0.25% bromophenol blue) and loaded into the gel 
alongside an appropriate size marker e.g. Hyperladder I (Bioline, London, UK). 
Electrophoresis was performed in 0.5x TAE buffer at a constant voltage of 120 Volts. 
Nucleic acids were subsequently visualised and photographed using the gel imaging 
system: G Box (Syngene, Cambridge, UK).  
 
2.1.6. DNA purification from PCR mixtures and agarose gels and sequencing  
Following amplification by PCR, DNA fragments were purified using the 
ChargeSwitch PCR clean-up kit (Life Technologies, Paisley, UK). Utilising magnetic 
beads with a changeable surface charge depending on the pH of the surrounding 
buffer, low pH conditions were used to bind DNA (from a 25µl aliquot of PCR 
product) to positively charged beads. Wash buffer was used to remove unbound 
proteins and other contaminants, and neutralisation of the surface charge by raising 
the pH to 8.5 resulted in elution of the purified DNA into a low salt elution buffer 
(elution volume 25µl). 
 
Following electrophoresis on a 1% agarose gel and visualisation using ultraviolet 
light, DNA excised in an agarose band was purified using the Illustra GFX PCR DNA 
and gel band purification kit according to the manufacturer’s instructions (GE 
Healthcare UK Ltd, Little Chalfont, UK).  
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Sequencing reactions were typically prepared using 90ng of purified DNA (at least 
10ng DNA per 100bp) in a 10µl reaction containing 0.32 pmol per primer. 
Sequencing reactions were performed using BigDye Terminator 3.1 Cycle 
Sequencing Kit (Life Technologies, Paisley, UK). Both PCR and sequencing reaction 
products were purified using Edge Biosystems Gel Filtration plates (Life 
Technologies, Paisley, UK). The sequence was run on a 3730 DNA Analyzer (Life 
Technologies, Paisley, UK) and analyzed using the Sequencer DNA sequencing 
analysis software. 
 
2.2. Mice 
Mice were housed in specific pathogen-free conditions and all animal procedures 
were performed in accordance with institutional guidelines and under licence by the 
UK. Mice used in models of experimental renal disease were matched for age and 
sex, and aged between 10 to 12 weeks at the time of the experiment. Animals were 
sacrificed by terminal anaesthesia using hypnorm (fentanyl citrate and fluanisone) 
mixed with midazolam and distilled H2O in a ratio of 1:1:2. Mice expressing Cre 
recombinase under the control of the murine albumin promoter (Alb-Cre) were 
purchased from the Jackson laboratories (B6.Cg-Tg[Alb-cre]21Mgn/J, strain number 
003574, http://jaxmice.jax.org/strain/003574.html). Genotyping was performed by PCR 
on digested tissue using primers (table 2.1 and chapter 3). 
  
2.3. Mouse phenotypic analyses 
2.3.1. Preparation of mouse plasma 
Mouse blood samples were collected directly into EDTA-containing Eppendorf tubes 
and kept on ice until centrifugation and aliquots stored at -80°C. Repeated 
freeze/thaw cycles were avoided. 
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2.3.2. Measurement of mouse plasma FH levels 
Plasma FH levels were measured by enzyme-linked immunosorbent assay (ELISA) 
using a set of cross-reactive anti-human FH polyclonal antibodies. The capture 
antibody was: polyclonal sheep anti-human FH antibody (antibodies-online.com) and 
detection antibody was: biotinylated goat anti-human FH antibody (Quidel, San 
Diego, USA). FH levels in the samples were quantified relative to normal wild-type 
mouse plasma used in the standard curve. 
 
The ELISA procedure was as follows: NUNC Maxisorp ELISA plates 
(Thermoscientific, Waltham, USA) were coated with sheep anti-human FH antibody 
diluted 1:1000 in 50 mM carbonate buffer (0.795g Na2CO3 and 1.565g NaHCO3 in 
500ml distilled H2O, pH 9.6) overnight at 4°C. Following one wash with phosphate-
buffered saline (PBS)-Tween, wells were blocked with 2% bovine serum albumin 
(BSA)/PBS (1g BSA in 50mls 1x PBS) for 2 hours at room temperature, after which 
two further washes with PBS-Tween were performed. Plasma samples were diluted 
1:25 in 2% BSA/PBS (ascertained by prior optimisation) and incubated in duplicate 
at room temperature for 1 hour. A standard curve was generated on each plate using 
normal wild-type mouse plasma diluted in 2% BSA/PBS from a dilution of 1:12.5 to 
1:256,000 using double dilutions. Biotinylated goat anti-human FH antibody was then 
added at a concentration of 5µg/ml for 1 hour at room temperature following four 
washes. Streptavidin-alkaline phosphatase (BD Biosciences, Oxford, UK) diluted 
1:2000 with 2% BSA/PBS was then added for 1 hour at room temperature after 
repeated washing as before. Further washes were followed by the addition of p-
nitrophenyl phosphate (tablets dissolved in double-distilled H2O as per 
manufacturer’s instructions; Sigma, Dorset, UK) and the optical densities were read 
at 405nm using an ELISA reader. 
  
2.3.3. Measurement of mouse plasma C3 levels 
Plasma C3 levels were measured by ELISA. The capture antibody was: polyclonal 
goat anti-mouse C3 antibody (MP Biomedical, Cambridge, UK) and the detection 
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antibody was the same antibody but conjugated to horseradish peroxidase (HRP) 
(MP Biomedical, Cambridge, UK). The standard curve was generated using acute 
phase serum containing a known quantity of C3 (Calbiochem, Hertfordshire, UK) and 
used as a reference to quantify samples.  
 
The ELISA procedure was as follows: NUNC Maxisorp ELISA plates were coated 
with 50µl of polyclonal goat anti-mouse C3 antibody diluted 1:8000 in coating buffer 
(0.1M sodium bicarbonate, pH 9.5), and left at 4°C overnight. The plates were then 
washed once for 5 minutes with 100 µl/well of wash buffer comprising 50mM Tris 
base, 150mM NaCl and 0.2% Tween 20, adjusted to a pH of 7.4 using hydrochloric 
acid. 100µl blocking buffer (2% BSA in wash buffer) was then added to each well for 
1 hour at room temperature. This was followed by two further 100µl washes with 
wash buffer after which samples were added to the plates.  Acute phase serum was 
used to generate a standard curve through the use of double dilutions starting from a 
dilution of 1:500 down to 1:2,048,000 using blocking buffer. Plasma samples were 
diluted 1:12000 using blocking buffer, and as for the standard curve, were tested in 
duplicate and incubated for 1 hour at room temperature. Following five consecutive 
five-minute washes with wash buffer, 50µl of HRP-conjugated goat anti-mouse C3 
antibody diluted 1:25,000 in blocking buffer, was added to each well for 1 hour at 
room temperature. After five further washes, 50µl of tetramethylbenzidine (TMB) 
substrate (prepared by mixing equal volumes of solutions A and B) was then added 
to each well, and the reaction was stopped thereafter by adding 20µl of stop solution. 
The plates were then read at 450 and 540nm. 
 
2.3.4. Western blotting of mouse FH and C3 
Mouse FH was detected using a polyclonal sheep anti-human FH antibody 
(antibodies-online.com) at a dilution of 1:2,000 in blocking buffer. Mouse C3 was 
detected using a polyclonal goat anti-mouse C3 antibody (MP Biomedical, 
Cambridge, UK). Detection of both antibodies was performed using HRP-conjugated 
monoclonal anti-goat/sheep IgG (diluted 1:20,000 in blocking buffer; Sigma-Aldrich, 
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Dorset, UK). Reduced samples were prepared by the addition of 2-mercaptoethanol 
to the sample mix and heating to 96°C for 10 minutes prior to loading into the gel. 
Rainbow protein marker (GE Healthcare, Amersham, UK) was used to determine 
protein size.  
 
The western blotting procedure was as follows: 8% resolving and 4% stacking 
acrylamide gels were prepared using acrylamide:bisacrylamide solution and the 
respective resolving/stacking buffer dissolved in double-distilled water. 10% 
ammonium persulphate was added as a source of free radicals to initiate 
polymerisation and was stabilised by the addition of N, N, N’, N’-
tetramethylethylenediamine to optimise polymerisation. Gels were polymerised 
between two glass plates in a gel caster. The stacking gel solution was added on top 
of the resolving gel once it had polymerised and wells were created by the insertion 
of a comb prior to polymerization. Following loading onto the gel, proteins were 
separated by SDS-PAGE in the presence of running buffer (0.192M glycine, 0.025M 
Tris base, 0.1% SDS (w/v), pH 8.3) using a constant voltage of 200V across the gel 
for approximately 1 hour in the Bio-Rad mini protean II system (Bio-Rad, Hemel 
Hempstead, UK). Gels were then removed and placed in transfer buffer  (0.039M 
glycine, 0.048M Tris base, 0.0375% SDS (w/v), pH 8.3) following removal of the 
stacking gel. After activation with methanol for 15 seconds, polyvinylidine fluoride 
(PVDF) membrane (Sigma-Aldrich, Dorset, UK) was also placed in transfer buffer. 
The gel and PVDF membrane remained in their respective transfer buffer at room 
temperature for 5 minutes, following which they were prepared for protein transfer. 
The gel was carefully laid onto a clean glass plate on top of which was laid a piece of 
PVDF membrane, with care taken to remove any air bubbles between the gel and 
membrane. Two pieces of 3MM paper soaked in transfer buffer were then placed on 
top of the membrane, followed by the outer sponge. After removal from the glass 
plate, two pieces of 3MM paper soaked in transfer buffer were placed on the 
exposed surface of the gel, on top of which was placed the remaining outer sponge. 
This “sandwich” was then placed into the transfer tank filled with transfer buffer, and 
proteins were transferred at 300mA for an hour. After transfer, the membrane was 
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removed and placed into blocking buffer (PBS, 0.05% Tween 20, 3% BSA) for 30 
minutes at room temperature. 
After incubation with the relevant antibodies for one hour, the membrane was 
washed three times with PBS-Tween (PBS, 0.05% Tween 20) and the appropriate 
HRP-conjugated secondary antibody added for 30 minutes at room temperature. 
Four further washes with wash buffer were followed by visualisation of the proteins 
using Pierce electrochemiluminescent (ECL) substrate (Thermo Scientific, IL, USA). 
Equal volumes of solutions 1 and 2 were mixed and then pipetted uniformly onto the 
membrane for 1 minute at room temperature. Excess solution was allowed to drain 
off and the membrane was inserted between two layers of plastic film and then 
exposed to Kodak BioMax MS Film (Sigma-Aldrich, Dorset, UK). 
 
2.3.5. Plasma urea levels 
Plasma urea was measured using an ultraviolet method according to the 
manufacturer’s instructions (R-Biopharm, Glasgow, UK). Plasma samples were 
diluted 1:40 using 1x PBS and a standard preparation of urea of known 
concentration was included as an internal control. 
 
2.3.6. Albuminuria 
Mice were placed in metabolic cages for 24 hours to facilitate urine collection for 
quantification of albuminuria. Radial immunodiffusion using a rabbit anti-mouse 
albumin antibody (AbD Serotec, Oxford, UK) was used to quantify albuminuria, with 
purified mouse albumin (Sigma-Aldrich, Dorset, UK) used as a standard. 10ml 
aliquots of 1.2% agarose were prepared by dissolving 1.2g agarose in 100ml 1x 
PBS, and were equilibrated at 55°C prior to the addition of 150µl of rabbit anti-mouse 
albumin antibody. Following mixing, the gel was poured onto a 3-inch glass plate and 
allowed to set at 4°C for 30 minutes. Wells of a known volume were then formed in 
the gel and arranged in a 7x4 matrix. A standard curve was generated using double 
dilutions of purified mouse albumin in 1x PBS, starting from a concentration of 
10mg/ml down to 0.078mg/ml. Analysis of proteinuria using urine reagent sticks 
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determined whether urine samples were added neat to the wells or at a dilution of 
1:10. Urine samples with 3+ or 4+ proteinuria by urine dipstick were diluted 1:10 in 
1x PBS, whilst those with ≤ 2+ proteinuria were added neat. 5µl of urine or standard 
was added to each well, and the gel was then left in a wet box overnight at 4°C. 1x 
PBS was then used to wash the gel three times after which the gel was dried on gel 
bond. Pre-wetted 3MM paper was then placed on top of the gel followed by a stack 
of towels and a weight for an hour at room temperature. The gel bond (with the 
transferred gel) was dried and placed in Coomassie blue for approximately 30 
minutes until stained. Gels were destained using destain solution: 1500mls 
methanol, 500mls glacial acetic acid and 3000mls distilled water. The diameter of 
each ring was measured using a graduated magnifying lens and the concentration of 
albumin in each sample calculated by reference to the standard curve. 
 
2.3.7. Urinalysis 
Proteinuria and haematuria were assessed by adding urine to Hema-Combistix urine 
reagent strips (Siemens, Frimley, UK). For haematuria the strips detected: negative, 
trace, 1+, 2+ and 3+. For proteinuria the strips detected: negative, trace, 1+ (0.3 g/l), 
2+ (1 g/l), 3+ (3 g/l) and 4+ (≥20 g/l). 
 
2.3.8. Haematocrit 
Haematocrit was measured by centrifuging EDTA-treated blood in ammonium-
heparin capillary tubes (VWR International Ltd, Lutterworth, UK) at 13,000rpm for 5 
minutes after which haematocrit was calculated by measuring the packed cell height 
to total height ratio. 
 
2.3.9. Red cell fragments 
4ml of EDTA-treated blood was used to make a peripheral blood smear on glass 
slides. Once dry, the smear was stained using the Diff Quick staining kit 
(Polysciences, Warrington, USA) and mounted with DePex mounting medium (VWR 
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International Ltd, Lutterworth, UK). Red cell fragments were quantified as the 
number per 200 red blood cells counted at high power (x40). 
 
2.4. Histological studies 
2.4.1. Light microscopy 
Kidneys were fixed in Bouin’s solution (Sigma-Aldrich, Dorset, UK) for 2-4 hours and 
then transferred to 70% ethanol. Sections were embedded in paraffin and stained 
with periodic acid-Schiff (PAS) reagent and examined by light microscopy. Sections 
were scored for glomerular thrombosis and glomerular neutrophil infiltration. 
Analyses were all done blinded to the sample identity with 20 glomeruli scored per 
section. Glomerular thrombosis was scored according to the amount of PAS-positive 
material per glomerular cross-section as follows: grade 0, no PAS-positive material; 
grade 1, 0-25%; grade 2, 25-50%; grade 3, 50-75%; grade 4, 75-100%. Glomerular 
neutrophils were scored according to the number of neutrophils per glomerular 
cross-section. Glomerular histology was graded as follows: grade 0, normal; grade 1, 
segmental hypercellularity in 10–25% of the glomeruli; grade 2, hypercellularity 
involving >50% of the glomerular tuft in 25–50% of glomeruli; grade 3, 
hypercellularity involving >50% of the glomerular tuft in 50–75% of glomeruli; grade 
4, glomerular hypercellularity in >75% or crescents in >25% of glomeruli. 
 
2.4.2. Immunostaining for mouse C3, mouse IgG and sheep IgG 
Kidneys were placed in 1x PBS on collection and then transferred into 15 x 15 x 
5mm plastic moulds (Dispomould, CellPath Ltd, Newtown, UK) containing OCT 
embedding matrix (CellPath Ltd, Powys, UK).  They were then snap frozen in 
isopentane pre-cooled over liquid nitrogen and stored at -80°C until cut on a cryostat 
(Bright Instruments, Huntingdon, UK).  Frozen sections were cut at a thickness of 
5µm, dried in acetone (immersed for 15 minutes and allowed to air dry) and stored at 
-80°C until use. Kidney sections were stained for murine C3, murine IgG and sheep 
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IgG by direct immunofluorescence. Slides were defrosted for 10 minutes and the 
section then encircled using a PAP pen (Invitrogen, Paisley, UK).  
 
For mouse C3 and mouse IgG staining, sections were blocked using 60µl of 20% 
normal goat serum (diluted in 1x PBS) for 30 minutes at room temperature. For C3 
staining: 60µl of fluorescein-isothiocyanate (FITC)-labelled polyclonal goat anti-
mouse C3 (MP Biomedical, Cambridge, UK) diluted 1:100 in 1x PBS was applied for 
1 hour at room temperature. For mouse IgG staining: a FITC-conjugated polyclonal 
goat anti-mouse IgG Fc γ-chain specific antibody (Sigma-Aldrich, Dorset, UK) diluted 
1:200 in 1x PBS was used. For sheep IgG, sections were incubated with 60µl of 
FITC-conjugated monoclonal mouse anti-goat/sheep IgG (Sigma-Aldrich, Dorset, 
UK) diluted 1:100 in 1x PBS for 1 hour at room temperature without a preceding 
blocking step. Sections were then washed three times in 1x PBS and mounted using 
Vectashield Hard Set mounting medium (Vector Laboratories, Peterborough, UK). 
Sections were kept covered in the dark at 4°C and left overnight for the mounting 
medium to set. 
 
2.4.2.1. Immunostaining for mouse C3d  
Sections were blocked using 60µl of 20% normal goat serum (diluted in 1x PBS) for 
30 minutes at room temperature. After a brief wash in 1x PBS they underwent the 
first step of biotin blocking using 1 drop of avidin for 10 minutes at room temperature 
(Dako, Ely, UK). A 5-minute wash with 1x PBS was then followed by a second 
blocking step at room temperature using 1 drop of biotin for 10 minutes. Following a 
further 5-minute wash, a biotinylated goat anti-mouse C3d antibody (R&D, 
Minneapolis, USA) was added (diluted 1:10 in 1x PBS) for 1 hour at room 
temperature. The sections were then incubated with 1:100 streptavidin-phycoerythrin 
(BD Biosciences, Oxford, UK) for 30 minutes at room temperature after three 
washes had been performed. The sections were mounted using Vectashield Hard 
Set mounting medium (Vector Laboratories, Peterborough, UK) after three final 5-
minute washes with 1x PBS. For dual staining (mouse C3d and mouse C3) the 
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procedure was followed by addition of FITC-labelled polyclonal goat anti-mouse C3 
(MP Biomedical, Cambridge, UK). 
 
2.4.2.2. Immunostaining for mouse FH 
Sections were blocked using 60µl of 20% normal goat serum (diluted in 1x PBS) for 
30 minutes at room temperature. For mouse FH a cross reactive anti-human FH 
antibody was used: goat anti-human FH antibody (Quidel, San Diego, USA) diluted 
1:100 in 1x PBS was applied to the section for 1 hour at room temperature. Three 
washes in 1x PBS were followed by incubation with FITC-conjugated mouse anti-
goat/sheep IgG (Sigma-Aldrich, Dorset, UK) diluted 1:100 in 1x PBS for an hour at 
room temperature. Sections were mounted as described above. For dual staining 
(mouse FH and mouse C3): goat anti-human FH antibody (Quidel, San Diego, USA) 
diluted 1:100 in 1x PBS was applied to the section for one hour at room temperature. 
Three washes in 1x PBS were followed by application of a Texas Red-conjugated 
rabbit anti-goat IgG (Abcam, Cambridge, USA) diluted 1:200 in 1x PBS for an hour at 
room temperature. Following three washes with 1x PBS, FITC-labelled polyclonal 
goat anti-mouse C3 (MP Biomedical, Cambridge, UK) diluted 1:100 in 1x PBS was 
applied for 1 hour at room temperature as described above. Sections were mounted 
as described above. 
 
2.4.2.3. Quantitative immunofluorescence analysis 
Quantitative immunofluorescence analyses were performed on sections stained at 
the same time to prevent variability due to fluorochrome decay and without 
knowledge of the sample identity as previously described (Robson, Cook et al. 
2001). Sections were visualised using an Olympus fluorescent microscope with 
digital camera (Olympus, Southend, UK) and images analysed using Image-Pro Plus 
software (Media Cybernetics, Silver Spring, USA). Ten glomeruli were examined per 
section with the mean fluorescence intensity expressed in arbitrary fluorescence 
units (AFU). 
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2.4.2.4. Electron microscopy 
1mm3 samples of renal cortex were fixed in 3% glutaraldehyde overnight and post-
fixed in 2% aqueous osmium tetroxide prior to embedding in Spurr’s resin. Ultra-thin 
sections were stained with 1% aqueous uranyl acetate and Reynold’s lead citrate. 
  
2.5. Serum nephrotoxic nephritis 
Nephrotoxic nephritis (NTN) was induced by the intravenous injection of 200µl of 
sheep nephrotoxic serum (NTS), a sheep IgG serum fraction containing anti-mouse 
GBM antibodies. The NTS had been previously prepared in my supervisor’s 
laboratory. Five days prior to administration of the NTS, mice were pre-immunised 
with an intra-peritoneal injection of 200µg of sheep IgG (Sigma-Aldrich, Dorset, UK) 
in complete Freund’s adjuvant (CFA) (Sigma-Aldrich, Dorset, UK). The sheep IgG in 
CFA was prepared as an emulsion containing 4mls of 1x PBS, 5mls of CFA and 
10mg of sheep IgG. The final concentration of sheep IgG in the emulsion was 200 
micrograms per 200 microlitres (the injection volume). Prior to immunisation and the 
administration of NTS, all mice were weighed and urinalysis recorded. Thereafter, 
urinalysis was recorded daily and on the penultimate day of the experimental period, 
when all mice were placed in metabolic cages overnight in order that urine could be 
collected for formal quantification of albuminuria. The duration of the experimental 
period was variable depending on the strain of mice used (see chapter 4). 
 
2.6. Analysis of FHR5 
2.6.1. Quantification of FHR5 by ELISA  
An ELISA was used to measure serum FHR5 levels. The capture antibody was: 
rabbit anti-human FHR5 (Abnova, Taipei, Taiwan). The detection antibody was: 
mouse anti-human FHR5 (Abnova, Taipei, Taiwan). A standard curve generated 
using recombinant FHR5 (R&D, Minneapolis, USA) was used to calculate serum 
FHR5 concentrations. NUNC maxisorp ELISA plates were coated with 50µl of rabbit 
anti-human FHR5 antibody diluted 1:500 in capture buffer (0.1M NaHCO3, pH 9.5) 
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overnight at 4°C. Following washing with PBS-Tween (0.2%), 1% BSA (diluted in 
wash buffer) was used as blocking buffer with 100µl added to all wells for 1 hour at 
room temperature. After washing twice with PBS-Tween, samples as prepared below 
were added to the plate. Recombinant FHR5 diluted in blocking buffer was used to 
generate a standard curve through the use of double dilutions. As for the standard 
curve, serum samples diluted in blocking buffer were added in duplicate (50µl/well) 
and incubated at room temperature for 1 hour. Following four washes, 50µl of mouse 
anti-human FHR5 antibody (diluted 1:1000 in blocking buffer) was added to each 
well for 1 hour at room temperature. This was followed by incubation with HRP-
conjugated polyclonal rabbit anti-mouse immunoglobulin antibody (Dako, Ely, UK) 
diluted 1:1000 in blocking buffer for 30 minutes at room temperature after four 
washes had been completed. TMB substrate (comprising equal volumes of solutions 
A and B) was then added to each well for 5-10 minutes. The reaction was 
subsequently stopped with stop solution and the plate read at 450 and 540nm. 
 
2.6.2. Western blotting of FHR5  
FHR5 was detected using a rabbit anti-human FHR5 (Abnova, Taipei, Taiwan) and 
HRP-conjugated polyclonal swine anti-rabbit immunoglobulin antibody (Dako, Ely, 
UK). Following separation of non-reduced serum samples by SDS-PAGE, western 
blotting and detection were performed as described above using Pierce 
electrochemiluminescent (ECL) substrate and Kodak BioMax MS Film. 
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2.7. List of antibodies 
The following table provides the details of the antibodies used in the thesis: 
Table 2.2 List of antibodies  
Antibody description Supplier: Cat. No. 
FITC-conjugated polyclonal goat anti-mouse 
C3        
(IgG fraction) 
 
MP Biomedical, 
Cambridge, UK 
55500 
Polyclonal goat anti-mouse C3d                               
(antigen affinity purified) 
 
R&D, Minneapolis, 
USA 
AF2655 
FITC-conjugated polyclonal goat anti-mouse 
IgG 
(Fc specific, affinity isolated antibody, 
buffered aqueous solution) 
 
Sigma-Aldrich, Dorset, 
UK 
F5387 
FITC-conjugated monoclonal mouse anti-
goat/sheep IgG 
(purified immunoglobulin, buffered aqueous 
solution) 
Sigma-Aldrich, Dorset, 
UK 
F4891 
Texas Red-conjugated polyclonal rabbit 
anti-goat IgG 
(IgG fraction) 
Abcam, Cambridge, 
USA 
A6739 
Polyclonal goat anti-human FH 
(whole anti-serum) 
Quidel, San Diego, 
USA 
A312 
Polyclonal mouse anti-human FHR5 
(MaxPab® antibody*, buffered aqueous 
solution) 
Abnova, Taipei, 
Taiwan 
H00081494-
B01P 
Polyclonal rabbit anti-human FHR5 
(MaxPab® antibody*, buffered aqueous 
solution) 
Abnova, Taipei, 
Taiwan 
H00081494-
D01P 
Horseradish peroxidase-conjugated 
polyclonal rabbit anti-mouse 
immunoglobulins 
Dako, Ely, UK P0260 
Horseradish peroxidase-conjugated 
polyclonal swine anti-rabbit 
immunoglobulins 
Dako, Ely, UK P0217 
Cat. No. = Supplier’s catalogue number, *polyclonal antibodies generated from 
annotated sequence-verified full-length proteins expressed in mammalian cell 
lysates 
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2.8. Statistical analysis 
Non-parametric data was represented as the median with the range of values given 
in parentheses. Two groups were analysed using the Mann-Whitney test whilst one-
way analysis of variance with Bonferroni’s multiple comparison test was used to 
analyse three or more groups. Data were analyzed using GraphPad Prism version 
3.0 for Windows (GraphPad Software, San Diego, USA). P value of <0.05 was 
considered significant. 
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3. CHAPTER THREE: GENERATION OF 
HEPATOCYTE-SPECIFIC FACTOR 
H-DEFICIENT MICE 
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3.1. Introduction 
Mice with complete FH deficiency (Cfh-/-) have marked depletion of plasma C3 
secondary to uncontrolled activation of the AP and develop spontaneous 
membranoproliferative glomerulonephritis (MPGN)(Pickering, Cook et al. 2002). 
Light microscopy in these animals showed mesangial matrix expansion and 
hypercellularity with capillary wall thickening and a double contour appearance to the 
GBM. Immunofluorescence revealed linear capillary wall C3 and C9 deposition. The 
absence of disease in mice with concurrent FB deficiency demonstrated that the 
renal disease was dependent on C3 activation. Capillary wall C3 deposition in Cfh-/- 
mice appears deleterious even in the absence of TP activation. One-year old mice 
with combined FH and C5 deficiency (Cfh-/-.C5-/-) had comparable albuminuria to 
Cfh-/- mice, indicating that chronic C3 deposition along the GBM could disrupt the 
glomerular permeability barrier in the absence of C5 activation. Furthermore, 
capillary wall double contours and subendothelial electron dense deposits were 
present in Cfh-/-.C5-/- mice demonstrating that MPGN can develop in this setting in 
the absence of C5 (Pickering, Warren et al. 2006). The appearance of marked 
capillary wall C3 deposition in Cfh-/-C3-/- kidneys transplanted into Cfh-/- hosts also 
indicates that the GBM C3 seen in Cfh-/- mice is derived from the circulation (Rose, 
Paixao-Cavalcante et al. 2008). 
Despite the presence of uncontrolled C3 activation, mice with FI deficiency (Cfi-/-) do 
not develop either spontaneous C3 deposition along the GBM or MPGN (Rose, 
Paixao-Cavalcante et al. 2008). These animals develop spontaneous mesangial 
expansion, often with hyalinosis, and have abnormal C3 staining within the 
mesangium. In contrast to Cfh-/- mice, the Cfi-/- animals do not develop GBM C3 
accumulation. Furthermore, the absence of MPGN in mice with combined FH and FI 
deficiency (Cfh-/-Cfi-/-) and the finding of similar glomerular C3 staining to FI-deficient 
animals alone, illustrates the absolute requirement for FI for the GBM C3 deposition 
and MPGN observed in FH deficiency (Rose, Paixao-Cavalcante et al. 2008). C3 
predominantly circulates as C3b in Cfh-/-Cfi-/- and Cfi-/- mice since the proteolytic 
cleavage of C3b is FI dependent. When serum containing FI is administered to Cfh-/-
Cfi-/- animals, cleavage of C3b is seen. Unexpectedly, this is accompanied by the 
loss of mesangial C3 staining and the appearance of C3 along the GBM. One 
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interpretation of this data is that in the setting of uncontrolled C3 activation, 
metabolites of C3b (iC3b and/or C3d) target the GBM, whilst C3b localises to the 
mesangial areas. 
Mice with heterozygous FH deficiency have modestly reduced plasma C3 levels 
compared to wild-type mice. However, they do not develop capillary wall C3 
deposition or MPGN (Pickering, Cook et al. 2002). Consistent with this, pigs with 
heterozygous FH deficiency also do not develop spontaneous MPGN (Hogasen, 
Jansen et al. 1995). 
The liver is the major source of FH, but extra-hepatic synthesis has been reported in 
human umbilical vein endothelial cells, fibroblasts, mesangial cells and podocytes. 
The significance of this extra-hepatic FH production is unknown. Studies in human 
liver transplantation suggest that extra-hepatic C3 production accounts for between 
5.6-11.4% of the circulating plasma C3 pool (Naughton, Botto et al. 1996). C6-
sufficient rats receiving C6-deficient liver transplants demonstrated that 30-40% of 
systemic C6 in rats is extra-hepatic in origin (Brauer, Baldwin et al. 1994). 
To investigate the biological significance of extra-hepatic FH production, I generated 
mice with hepatocyte-specific FH deficiency (hepatocyte-Cfh-/-). My aim was to firstly 
measure circulating FH levels and determine if these were sufficient to maintain 
plasma C3 regulation and prevent the development of GBM C3 deposition. 
In mice with functioning loxP-flanked target loci, hepatocyte-specific gene disruption 
has been achieved in vivo by selectively expressing Cre recombinase in hepatocytes 
using the albumin promoter/enhancer sequence (Postic, Shiota et al. 1999). In my 
supervisor’s laboratory, a mutant animal containing loxP sites flanking exons 2 and 3 
of the Cfh gene (CfhloxP/loxP) was generated. Following Cre recombinase-mediated 
excision of exons 2 and 3, generation of a null Cfh allele was predicted as a similar 
strategy had been used in the original Cfh-/- strain (Pickering, Cook et al. 2002). To 
generate hepatocyte-Cfh-/- mice, my plan was to inter-cross CfhloxP/loxP mice with a 
strain expressing Cre recombinase under the control of the albumin promoter (Alb-
Cre). In this chapter, I present the data showing the successful generation of a 
hepatocyte-Cfh-/- strain. 
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3.2. Inter-crossing conditional FH-deficient animals with mice 
expressing Cre recombinase under the control of the mouse albumin 
promoter 
 
Hepatocyte-Cfh-/- mice were generated by inter-crossing CfhloxP/loxP animals with mice 
expressing Cre recombinase under the control of the murine albumin promoter (Alb-
Cre). Offspring were screened for the presence of the floxed cfh allele (figure 3.1A) 
and the Cre recombinase transgene (Alb-Cre, figure 3.1B). Hepatocyte-Cfh-/- animals 
were viable and fertile under specific pathogen-free conditions. Hepatocyte deletion 
of exons 2 and 3 of the cfh gene was confirmed by amplifying the floxed cfh locus 
from cDNA synthesised from hepatic RNA isolated from hepatocyte-Cfh-/- animals. 
Cre recombinase-mediated excision of exons 2 and 3 in these animals resulted in a 
smaller 318-bp amplicon not present in the Alb-Cre animals (figure 3.2). Data 
demonstrating that this Cre-mediated recombination was hepatocyte-specific is 
shown in the appendix. I next expanded the hepatocyte-Cfh-/- strain for phenotypic 
analysis.  
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Figure 3.1 Genotyping PCR in hepatocyte-Cfh-/- mice. (A) The presence of the floxed cfh allele 
results in a 527-bp amplicon, whereas these primers amplify a 450-bp amplicon in the wild-type cfh 
locus. (B) The presence of the Alb-Cre transgene was also determined by PCR and these primers 
amplify a 100-bp amplicon when the transgene is present. In this gel, DNA from mice 1-14 generates 
this amplicon together with a single 527-bp amplicon using the primers in (A). These mice are 
therefore all hepatocyte-Cfh-/- mice. 
  
recombinant allele  = 527bp 
wild-type allele  = 450bp 
Lane 1 – Size marker 
Lane 2 – FLOX / FLOX 
Lane 3 – FLOX / WT 
Lane 4 – WT / WT 
Lane 5 – H2O  
1        2        3       4        5  
600bp 
400bp 
200bp 
A 
B 1  2 ……                  …… 14  15  16  
400bp 
200bp 
600bp 
400bp 
Lane 1 – Size marker 
Lane 2-14 = hepatocyte-Cfh-/- mice 
Lane 15 – positive control  
Lane 16 – H2O  
recombinant allele  = 527bp 
Alb-Cre transgene = 100bp 
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Figure 3.2 PCR on cDNA generated from RNA from livers of hepatocyte-Cfh-/- (lanes 2-4) and 
Alb-Cre mice (lanes 5-7). The PCR used primers that flanked exons 2 and 3 and resulted in a 610-
bp amplicon using cDNA from wild-type mice. After Cre recombinase-mediated excision of exons 2 
and 3 the amplicon is reduced to 318bp. The smaller amplicon is seen in all hepatocyte-Cfh-/- mice 
(lanes 2-4). 
  
wild-type allele  = 610bp 
Recombinant allele post Cre 
recombinase-mediated excision 
of exons 2 and 3 = 318bp 
Lane 1 – Size marker 
Lane 2-4  = hepatocyte-Cfh-/- mice 
Lane 5-7 = Alb-Cre mice 
Lane 8 – H2O  
1   2   3   4    5   6   7    8 
600bp 
400bp 
200bp 
800bp 
94 
 
3.3. Spontaneous complement profile in hepatocyte-specific FH-
deficient mice 
3.3.1. Plasma FH 
The critical role played by FH in regulating complement activation within plasma is 
evident from the phenotype seen in complete FH deficiency, where uncontrolled 
activation leads to secondary depletion of complement components such as C3 
(Pickering, Cook et al. 2002). To date, the contribution made by extra-hepatic FH to 
the total FH pool has not been described. I therefore sought to answer this by 
measuring plasma FH levels in 8-12 week old hepatocyte-Cfh-/- mice by ELISA 
(figure 3.3) and western blotting (figure 3.4). 
Using an ELISA, plasma FH levels were significantly reduced in hepatocyte-Cfh-/- 
mice (median 19% of wild-type levels, range 14-29%, n=7) compared to CfhloxP/loxP 
animals (median 59.5% of wild-type levels, range 37-103%, n=8, p<0.001, 
Bonferroni multiple comparison test). This was evident from a semi-quantitative 
assessment by western blotting for plasma FH using samples from these animals 
(figure 3.4). 
To conclude that extra-hepatic FH was responsible for approximately 19% of the 
plasma FH pool (derived from the FH levels in the hepatocyte-Cfh-/- mice), I would 
need to be certain that not only was there (i) no hepatocyte-specific FH production 
remaining in the hepatocyte-Cfh-/- mice (i.e. no ‘leakiness’), but also (ii) that 
production of FH from the floxed cfh allele was equivalent to that from wild-type cfh 
allele.  Unexpectedly, CfhloxP/loxP animals had significantly lower plasma FH levels 
(median 59.5% of wild-type, range 37-103%, n=8) than Alb-Cre mice (median 93% of 
wild-type, range 71-137%, n=6, p<0.01, Bonferroni multiple comparison test). This 
suggested to me that the production of FH from the floxed cfh allele was not normal.  
To investigate this further I assessed plasma C3 levels in all groups of mice to 
determine if, as expected plasma C3 levels would be reduced in the hepatocyte-Cfh-
/- mice in proportion to the reduction in plasma FH. I also compared C3 levels 
between Alb-Cre and CfhloxP/loxP animals to determine if the lower plasma FH levels 
in the latter group were correlated with a fall in plasma C3.   
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Figure 3.3 Plasma FH levels in 12-week old Alb-Cre (n=6), CfhloxP/loxP (n=8) and hepatocyte-Cfh-/- 
(n=7) mice. Horizontal bars denote median values.  
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Figure 3.4 Plasma FH western blot. In (A) plasma FH in hepatocyte-Cfh-/- plasma is compared with 
wild-type (WT), heterozygous (Cfh+/-) and homozygous (Cfh-/-) FH-deficient mice and CfhloxP/loxP 
samples. FH is indicated by arrow. Lower bands represent factor H-related proteins (FHR). In (B) 
serial plasma dilutions from WT and hepatocyte-Cfh-/- plasma confirm that plasma FH is significantly 
reduced in the hepatocyte-Cfh-/- strain. 
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3.3.2. Plasma C3 
The contribution of extra-hepatic FH to fluid-phase C3 regulation is also unknown. I 
therefore measured plasma C3 levels in hepatocyte-Cfh-/- mice by ELISA and 
compared these with the levels in Cfh-/-, CfhloxP/loxP and Alb-Cre animals. Consistent 
with the low plasma FH levels, hepatocyte-Cfh-/- mice had a secondary reduction in 
circulating C3 levels (median 44.3µg/ml, range 26.0-81.2, n=7). These were 
significantly lower than in CfhloxP/loxP animals (median 188.2µg/ml, range 97.6-247.0, 
n=8, p<0.001, Bonferroni multiple comparison test) and higher than that seen in Cfh-/- 
mice (median 26.1µg/ml, range 21.2-64.7, n=13, figure 3.5).  
Importantly, the plasma C3 concentration in the CfhloxP/loxP animals was significantly 
lower (median 188.2µg/ml, range 97.6-247.0, n=8) than in Alb-Cre mice (median 
277.4µg/ml, range 176.4-396.8, n=6, p<0.001, Bonferroni multiple comparison test). 
This confirmed my suspicion that the floxed cfh allele had impaired production of FH 
and that this resulted in sub-optimal plasma C3 regulation. These data meant that I 
could not draw firm conclusions on the contribution of hepatic and extra-hepatic FH 
synthesis in the hepatocyte-Cfh-/- mice. 
I next determined if the reduced FH levels were associated with spontaneous renal 
disease in not only the hepatocyte-Cfh-/- mice but also the CfhloxP/loxP strain. 
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Figure 3.5 Plasma C3 levels in 12-week old Alb-Cre (n=6), CfhloxP/loxP (n=8), hepatocyte-Cfh-/- (n=7) 
and Cfh-/- (n=13) mice. Horizontal bars denote median values.  
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3.4. Spontaneous renal phenotype in hepatocyte-specific FH-deficient 
mice 
The uncontrolled complement activation in Cfh-/- mice is associated with increased 
albuminuria compared to wild-type controls and results in spontaneous MPGN. I 
wanted to investigate whether extra-hepatic FH production influenced this 
phenotype. Specifically, I hypothesised that extra-hepatic FH would ameliorate the 
spontaneous renal phenotype seen in Cfh-/- mice. 
To investigate this experimentally I generated cohorts of mice, which were monitored 
for a period of 9 months. The cohorts comprised: 
Strain Male Female Total 
hepatocyte-Cfh-/- 12 13 25 
Cfh-/- 8 15 23 
CfhloxP/loxP 4 5 9 
Alb-Cre 2 6 8 
 
Two deaths occurred during the 9-month observation period. One was a small 
hepatocyte-Cfh-/- mouse aged 5 weeks. The cause of death is not known although 
renal histology was normal. One Alb-Cre mouse died at 17 weeks with apparent 
bowel perforation. Renal histology was normal. All other animals remained well at 9 
months. 
At the end of the 9-month period I examined renal function and histology in all 
surviving mice. I chose this time period since spontaneous renal disease (MPGN) 
has previously been shown to be fully penetrant histologically at this age (Pickering, 
Cook et al. 2002). 
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3.4.1. Renal function and haematological parameters 
Median urea levels were normal (<20mmol/l) in all mice with the exception of one 
animal in the hepatocyte-Cfh-/- cohort (urea = 26.5mmol/l) and two animals in the 
Cfh-/- cohort (20.5 and 21.7mmol/l, figure 3.6). The median and range of values for 
each cohort were:  hepatocyte-Cfh-/- cohort = 12.0mmol/l (range 7.4-26.5, n=25); Cfh-
/- cohort = 12.4mmol/l (range 6.0-21.7, n=23); CfhloxP/loxP cohort = 7.2mmol/l (range 
3.1-13.7, n=9) and Alb-Cre cohort = 10.9mmol/l (range 6.0-19.7, n=8).  
Albuminuria was only detectable in one of the 25 hepatocyte-Cfh-/- mice at a 
concentration of 2.1mg/ml. Albuminuria was absent from the remaining hepatocyte-
Cfh-/- mice and all other mice in the Cfh-/-, CfhloxP/loxP and Alb-Cre cohorts. 
Since FH dysfunction in mice has been associated with renal thrombotic 
microangiopathy it was important to monitor for haematological abnormalities in the 
cohorts. I measured haematocrit at sacrifice and analysed blood smears for any 
evidence of red cell fragmentation. The haematocrit in hepatocyte-Cfh-/- mice 
(median 35.5%, range 32-44, n=24) was not significantly different from that in Cfh-/- 
(median 37%, range 33-42, n=23), CfhloxP/loxP (median 35%, range 33-41, n=9) and 
Alb-Cre mice (median 39%, range 35-41, n=8, figure 3.7A). Furthermore, there was 
no evidence of red cell fragments on blood smears (figure 3.7B). I concluded that 
there was no haematological evidence of thrombotic microangiopathy in the 
hepatocyte-Cfh-/- mice. 
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Figure 3.6 Plasma urea in 9-month old Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- and Cfh-/- mice. 
Levels were normal (<20 mmol/l) in all mice with the exception of a single hepatocyte-Cfh-/- and two 
Cfh-/- mice. Horizontal bars denote median values.  
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Figure 3.7 Haematocrit (A) and red cell fragments (B) in Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- 
and Cfh-/- mice. Horizontal bars denote median values. Representative images of blood smears in 
Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- and Cfh-/- mice. 
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3.4.2. Renal histology – Light microscopy 
Glomerular hypercellularity was seen in hepatocyte-Cfh-/- mice to a comparable 
extent to Cfh-/- animals (figure 3.8A). Glomerular cellularity was graded as follows: 
grade 0, normal; grade 1, segmental hypercellularity in 10–25% of the glomeruli; 
grade 2, hypercellularity involving >50% of the glomerular tuft in 25–50% of 
glomeruli; grade 3, hypercellularity involving >50% of the glomerular tuft in 50–75% 
of glomeruli; grade 4, glomerular hypercellularity in >75% or crescents in >25% of 
glomeruli.   
There was evidence of capillary wall thickening in only a small number of animals in 
these two groups: 1 out of 25 of the hepatocyte-Cfh-/- cohort and 2 out of 23 Cfh-/- 
animals.  
Consistent with the normal appearance of the peripheral blood film and normal 
haematocrits, there was no evidence of glomerular thrombosis in hepatocyte-Cfh-/- 
mice (figure 3.8B). 
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Figure 3.8 (A) Glomerular cellularity in 9-month old Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- and 
Cfh-/- mice. Horizontal bars denote median values. (B) Representative images of glomerular 
appearances in Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- and Cfh-/- mice. Original magnification x40. 
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3.4.3. Renal histology – Immunofluorescence studies for C3 and IgG 
Spontaneous renal disease in Cfh-/- mice is triggered by the deposition of C3 along 
the GBM producing a characteristic linear C3 staining pattern (Pickering, Cook et al. 
2002). Consistently, in my cohort all Cfh-/- mice had glomerular linear C3 staining 
using a polyclonal anti-mouse C3 antibody (figure 3.9). Abnormal glomerular C3 
deposition was also observed in hepatocyte-Cfh-/- mice (figure 3.9). However, this 
was distinct from that seen in Cfh-/- mice. In hepatocyte-Cfh-/- mice glomerular C3 
was granular in nature and deposited within the mesangium. When I quantified 
mesangial and capillary wall C3 staining in the Cfh-/- and hepatocyte-Cfh-/- mice, 
using a graded score of 0-3 (corresponding to absent, mild, moderate and marked 
staining) in a blinded fashion, this distinction was clear (figure 3.10A and B).  
Tubulointerstitial C3 staining is normally present in wild-type mice. It is dependent on 
an intact AP in plasma (Quigg, Lim et al. 1998, Thurman, Ljubanovic et al. 2003) and 
has been shown to be absent in Cfh-/- mice as these animals have secondary plasma 
C3 depletion (Pickering, Cook et al. 2002). This finding was recapitulated in my Cfh-/- 
cohort. In contrast the hepatocyte-Cfh-/- mice had detectable tubulointerstitial C3 
staining. However, this was reduced compared to the normal staining intensity seen 
in the Alb-cre mice (figure 3.9). I concluded that this was due to the partial rather 
than total AP dysregulation present in the hepatocyte-Cfh-/- mice. 
These data showed that, although the plasma FH levels in the hepatocyte-Cfh-/- mice 
were low, this was sufficient to (i) completely alter the glomerular C3 staining pattern 
seen in complete FH deficiency and (ii) partially maintain tubulointerstitial C3 
staining.  
Notably, renal C3 immunostaining was normal in both the glomerular and 
tubulointerstitial compartments in the CfhloxP/loxP mice (figure 3.9). This is consistent 
with the normal C3 immunostaining seen in heterozygous FH-deficient mice 
(Pickering, Cook et al. 2002). Therefore, although the impaired production of FH 
from the floxed cfh allele resulted in a reduction in plasma C3 levels it did not alter 
spontaneous renal C3 deposition.  
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Mesangial IgG is commonly seen in older mice and I could detect small amounts of 
mesangial IgG in all of the cohorts (figure 3.9). When I performed quantitative 
immunofluorescence scoring in hepatocyte-Cfh-/- and Cfh-/- mice there was 
significantly more IgG in the Cfh-/- group: median fluorescent score 554.1 AFU (range 
284.1-1246, n=12) compared to 354.6 AFU (range 166.1-567, n=12, P=0.0386, 
Mann-Whitney test, figure 3.11).  
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Figure 3.9 Immunostaining for C3 and IgG in 9-month old Alb-Cre, CfhloxP/loxP, hepatocyte-Cfh-/- 
and Cfh-/- mice. The characteristic linear capillary wall C3 deposition seen in Cfh-/- mice is replaced 
by a mesangial staining pattern in hepatocyte-Cfh-/- mice. Furthermore, tubulointerstitial C3 deposition 
typically absent in Cfh-/- mice is present in hepatocyte-Cfh-/- mice, but at a reduced intensity compared 
to CfhloxP/loxP and Alb-Cre animals. 
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Figure 3.10 Glomerular capillary wall (A) and mesangial (B) C3 scores in hepatocyte-Cfh-/- and 
Cfh-/- mice. Horizontal bars denote median values.  
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Figure 3.11 Quantitative immunofluorescence staining for IgG in hepatocyte-Cfh-/- and Cfh-/- 
mice. This group comprised 12 mice from each cohort. Horizontal bars denote median values. AFU – 
arbitrary fluorescence units.   
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3.4.4. Renal histology – Immunofluorescence studies for C3d and mouse FHR 
proteins 
To determine the nature of the glomerular C3 present in the hepatocyte-Cfh-/- mice, I 
performed C3 immunostaining with a polyclonal goat anti-mouse C3d antibody and 
compared this with the reactivity seen with the goat polyclonal anti-mouse C3 
antibody used above. The anti-mouse C3d antibody does not detect C3b deposits in 
the mesangium of mice that are FI-deficient demonstrating that it does not react with 
tissue-bound C3b (Paixao-Cavalcante, Hanson et al. 2009). It does recognise the 
linear C3 glomerular deposits in Cfh-/- mice (Paixao-Cavalcante, Hanson et al. 2009), 
indicating that these contain iC3b and/or C3d. Consistent with this published data, 
when I performed dual staining with the anti-C3 and anti-C3d antibodies in sections 
from Cfh-/- mice, linear glomerular staining was seen with both and this staining co-
localised (figure 3.12).  I next used this approach in the glomerular sections from the 
hepatocyte-Cfh-/- mice (figure 3.12).  This demonstrated very weak reactivity within 
the mesangium when the anti-C3d antibody was used indicating that the mesangial 
C3 in these mice did not contain much iC3b or C3d. When the anti-C3 antibody was 
used there was clear mesangial reactivity that did not co-localise with the anti-C3d 
antibody. The mesangial C3 could be intact C3, C3b or C3c. I considered that C3c 
was the most likely candidate but this would require demonstration with mono-
specific anti-mouse C3 antibodies.  
Previous data showed that the glomerular C3 in Cfh-/- mice reacted with a polyclonal 
goat anti-human FH antibody (Paixao-Cavalcante, Hanson et al. 2009). Since these 
mice completely lack mFH it was concluded that the anti-human FH antibody was 
interacting with mouse FHR proteins that had bound in vivo to the GBM-bound C3. 
When I performed dual staining using this anti-human FH antibody and the anti-C3 
antibody in Cfh-/- mice, I reproduced these observations (figure 3.13). When I 
performed the procedure on hepatocyte-Cfh-/- mice there were areas of C3 reactivity 
that did and did not co-localise with the anti-human FH antibody (figure 3.13). It is 
difficult to draw conclusions from these data since although human FHR proteins 
interact with C3b, iC3b and C3d (Goicoechea de Jorge, Caesar et al. 2013) little is 
known about the interactions of mouse FHR proteins. I speculate that the areas that 
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were reactive with the anti-C3 but not the anti-human FH or anti-C3d antibody are 
most likely to represent C3c.  
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Figure 3.12 Dual staining using anti-mouse C3 (green) and anti-mouse C3d (red) antibodies in 
Cfh-/- and hepatocyte-Cfh-/- mice. Linear C3 deposits that co-localise can be seen in the Cfh-/- mice. 
Mesangial C3 deposits that do and do not co-localise can be seen in hepatocyte-Cfh-/- mice.  
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Figure 3.13 Dual staining using anti-mouse C3 (green) and anti-human FH (red) antibodies in 
Cfh-/- and hepatocyte-Cfh-/- mice. Linear C3 deposits that co-localise can be seen in the Cfh-/- mice. 
Mesangial C3 deposits that do and do not co-localise can be seen in hepatocyte-Cfh-/- mice. 
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3.4.5. Renal histology - Electron microscopy 
I was able to obtain electron microscopy images of renal tissue from 4 of the 9-
month old hepatocyte-Cfh-/- mice. The electron microscopy was performed by Dr. Jill 
Moss, Consultant Histopathologist, Charing Cross Hospital, London. In the 
hepatocyte-Cfh-/- mice examined the appearances were within normal limits. 
Specifically, there was no evidence of electron dense deposits in the GBM and only 
a single electron dense deposit was seen within the mesangium of one of the 
glomeruli examined.   
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Figure 3.14 Electron microscopy images. Subendothelial electron dense GBM deposits are seen in 
9-month old Cfh-/- mice (A) whereas the appearances were normal in age-matched hepatocyte-Cfh-/- 
mice (B). 
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3.5. Discussion 
Mice with hepatocyte-specific FH deficiency (hepatocyte-Cfh-/- mice) were 
established by inter-crossing conditional FH-deficient animals with mice expressing 
Cre recombinase under the control of the murine albumin promoter. Hepatocyte-Cfh-
/- mice had median plasma FH levels of 19% of wild-type levels. This resulted in a 
secondary reduction in plasma C3 levels as a result of impaired regulation of the AP. 
The hepatocyte-Cfh-/- mice did not develop uraemia, albuminuria, anaemia or red cell 
fragmentation at the age of 36 weeks. There was mild glomerular hypercellularity 
comparable to that seen in aged-matched Cfh-/- mice. Notably, the pattern of 
glomerular C3 staining was different in the hepatocyte-Cfh-/- animals compared to 
both control strains (Alb-Cre and CfhloxP/loxP) and the mice with complete FH 
deficiency (Cfh-/- mice). Glomerular C3 in the hepatocyte-Cfh-/- mice was granular in 
pattern and mesangial in distribution. This staining pattern was not seen in the 
control strains and was clearly different to the linear pattern seen in the Cfh-/- mice. In 
addition, hepatocyte-Cfh-/- mice did have tubulointerstitial C3 staining, which is 
absent in Cfh-/- mice. Tubulointerstitial C3 deposition has previously been shown to 
be dependent on intact circulating C3 and the ability to activate the AP (Alexander, 
Wang et al. 2007, Lenderink, Liegel et al. 2007, Paixao-Cavalcante, Hanson et al. 
2009). Therefore, the fact that tubulointerstitial staining was present but reduced 
when compared to wild-type mice was consistent with partial regulation of plasma C3 
activation through the AP. My data, taken together, demonstrate that plasma FH 
levels of approximately 19% of wild-type were sufficient to significantly alter the 
glomerular C3 phenotype described in Cfh-/- mice (Pickering, Cook et al. 2002). 
The mesangial C3 deposition seen in hepatocyte-Cfh-/- mice was similar to that seen 
in Cfh-/- mice following the administration of purified mouse (mFH) or human FH 
(Paixao-Cavalcante, Hanson et al. 2009, Fakhouri, de Jorge et al. 2010). Twenty-
four hours after intra-peritoneal injection of mFH, plasma C3 levels in Cfh-/- mice rose 
in association with the appearance of intact circulating C3 and a reduction in GBM 
C3 deposition. Notably, these changes were accompanied by the appearance of 
both mesangial and tubulointerstitial C3 staining. Administration of human FH to Cfh-
/- mice similarly led to a rise in plasma C3 levels comparable to wild-type levels, 
together with the appearance of mesangial and tubulointerstitial C3 staining in 
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association with a reduction in GBM C3 deposition (Fakhouri, de Jorge et al. 2010). 
Repeated FH injections led to normalisation of glomerular C3 reactivity with barely 
detectable mesangial staining and nothing along capillary walls. 
Using the polyclonal anti-C3 and anti-C3d antibodies used above, mesangial C3 
detected by the anti-C3 antibody following injection of mFH to Cfh-/- mice showed no 
reactivity with the anti-C3d antibody (Paixao-Cavalcante, Hanson et al. 2009). 
Similar observations were made in Cfh-/- mice given a single dose of human FH 
(Fakhouri, de Jorge et al. 2010). This anti-C3d antibody has been shown to react 
with C3dg but not with C3b (Leung, Yun et al. 2009). Based on these observations, it 
was concluded that the mesangial C3 seen in Cfh-/- mice after either mFH or human 
FH could represent C3b, iC3b or C3c but not C3dg. Recently, the mesangial C3 
seen in Cfh-/- mice after administration of FH was shown to not only co-localise with 
properdin but also to be a properdin-dependent phenomenon (Ruseva, Vernon et al. 
2013). This suggests that the mesangial C3 is either a result of properdin-dependent 
surface activation and/or C3 fragments combined with properdin.  
Since my data showed that the mesangial C3 in hepatocyte-Cfh-/- mice did not react 
with the anti-C3d antibody I considered that the mesangial C3 could also represent 
C3b, iC3b or C3c. Depletion of properdin either genetically or by use of an anti-
properdin antibody would enable the properdin-dependent nature of mesangial C3 
deposition in hepatocyte-specific FH deficiency to be determined. In addition, there 
was no clear co-localisation between the anti-C3 and anti-human FH antibodies 
suggesting that the mesangial C3 did not contain either mFH or mouse FHR 
proteins. Clearly, to definitively characterise the nature of the mesangial C3 I would 
need to develop monospecific antibodies to each C3 fragment. 
In mice with FI deficiency spontaneous mesangial C3 deposits are seen that are 
reactive with the anti-C3 but not the anti-C3d antibody (Rose, Paixao-Cavalcante et 
al. 2008). In this situation the absence of FI means that proteolytic conversion of C3b 
to downstream fragments cannot occur. In this situation the mesangial C3 is C3b but 
its nature is very different to the mesangial C3 seen in either the hepatocyte-Cfh-/- 
mice or in Cfh-/- mice reconstituted with FH. In the FI-deficient mice the mesangial 
C3b is much more marked and associated with electron dense deposits within the 
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mesangial matrix and PAS-reactive material within the mesangium on light 
microscopy. Whether or not this mesangial C3b in FI-deficiency is properdin-
dependent is not known.  
What is the relevance of this mesangial C3 to human glomerular disease associated 
with C3 dysregulation? Paramesangial deposits composed solely of C3c have been 
reported in DDD (the original report used the descriptor: MPGN type II) specifically 
during episodes of hypocomplementaemia (West, Witte et al. 2001). It was 
hypothesised that these derived from plasma C3c that had been released following 
the FI-mediated proteolytic cleavage of iC3b to C3dg. Certainly, this mechanism 
could be operating in the hepatocyte-Cfh-/- mice continuously as they have chronic 
AP activation with hypocomplementaemia due to sub-total FH deficiency. 
A critical observation was that both plasma FH and C3 levels were reduced in the 
CfhloxP/loxP mice. This indicated that the targeted locus had impaired expression of 
FH. Impaired expression of targeted genes due to the introduction of loxP sites 
and/or selectable markers has been reported. For example, in a study in which the 
murine glucokinase gene was conditionally targeted with three loxP sites and a 
neomycin resistance gene, expression of the targeted gene was reduced by 28% 
compared to the wild-type gene (Postic, Shiota et al. 1999). The mechanisms 
through which these exogenous genetic elements impair gene expression have been 
established in some cases. For example, the insertion of a neomycin resistance 
gene within an intron of a floxed gene was shown to generate cryptic splice sites 
(Jacks, Shih et al. 1994, Carmeliet, Ferreira et al. 1996, Wassarman, Lewandoski et 
al. 1997) and these may result in the generation of a hypomorphic allele (Meyers, 
Lewandoski et al. 1998). Targeting cassettes containing neomycin resistance genes 
may affect the expression of not only the target gene but also genes in close 
proximity. For example, mice with a targeted deletion within the murine β-globin 
locus control region were found to have up to a 5-fold reduction in expression of all 
genes in the locus (Fiering, Epner et al. 1995). Importantly, after removal of the 
neomycin resistance gene within the targeted locus, expression of all affected genes 
returned to normal. 
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When the construct was designed it was anticipated that the neomycin resistance 
gene could interfere with FH expression. To address this, FRT sites were placed 
either side of the neomycin resistance gene. This would enable the neomycin 
resistance gene to be excised by Flp recombinase. In view of my data showing that 
FH expression is impaired, my supervisor is currently inter-crossing the CfhloxP/loxP 
mice with mice expressing Flp recombinase. The plan will be to examine plasma FH 
and C3 levels after removal of the neomycin resistance gene to determine if the 
neomycin resistance gene was responsible for the impaired FH expression of the 
targeted allele.  Clearly, with the knowledge that there is impaired FH expression 
from the targeted allele, I am unable to derive firm conclusions with respect to the 
contribution of extra-hepatocyte FH to the total FH pool. 
Despite this limitation, the spontaneous phenotype of the hepatocyte-Cfh-/- strain was 
informative in that it demonstrated that sub-total FH deficiency (in this case 
approximately 20% of normal FH levels) was sufficient to completely prevent the 
spontaneous renal phenotype associated with complete FH deficiency. However, the 
hepatocyte-Cfh-/- strain did develop spontaneous mesangial C3 deposition and this 
type of lesion has been reported as a subset of human C3 glomerulopathy (Servais, 
Fremeaux-Bacchi et al. 2007). It is now appreciated that many patients with C3 
glomerulopathy develop renal impairment in association with an environmental 
trigger, such as infection. The hypothesis is that the inability to regulate the AP 
predisposes not only to spontaneous renal disease but also to exaggerated renal 
injury during any intercurrent event that triggers complement activation within the 
kidney. To model this, I next examined the effect of serum nephrotoxic nephritis in 
the hepatocyte-Cfh-/- strain. 
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3.6. Conclusions 
3.6.1. Conditional FH-deficient mice had significantly reduced basal plasma FH and 
C3 levels compared to wild-type control mice indicating that expression of FH by the 
targeted locus was impaired. 
3.6.2. Mice with hepatocyte-specific FH deficiency have been successfully 
established by inter-crossing conditional FH-deficient mice with mice expressing Cre 
recombinase under the control of a hepatocyte-specific promoter. 
3.6.3. Hepatocyte-Cfh-/- mice have low plasma FH and C3 levels and develop 
spontaneous mesangial C3 deposition without any evidence of 
membranoproliferative glomerulonephritis or thrombotic microangiopathy at 36 
weeks of age. 
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4. CHAPTER FOUR: RESPONSE OF 
HEPATOCYTE-SPECIFIC FACTOR 
H-DEFICIENT MICE TO 
EXPERIMENTAL NEPHRITIS 
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4.1. Introduction 
Renal antibody deposition is considered a key event in the aetiology of immune-
mediated glomerulonephritis. Nephrotoxic nephritis (NTN) is a widely used model of 
glomerulonephritis that utilises anti-GBM antibodies (Hammer and Dixon 1963). 
Following injection of the anti-GBM antibody preparation (termed nephrotoxic serum) 
renal injury develops in two phases. The initial phase of renal injury is a 
consequence of inflammation secondary to the binding of the anti-GBM antibody 
along the GBM. Since the anti-GBM antibody is raised in a different species (typically 
rabbit or, as in my experiments, sheep) to the experimental animal (mouse or rat) 
this phase is referred to as the heterologous phase. Subsequently, the experimental 
animal (e.g. mouse) develops an immune response to the anti-GBM antibody. This 
results in the formation of immune complexes along the GBM, which comprise the 
heterologous anti-GBM antibody and the host IgG.  This results in a second phase of 
renal injury, termed the autologous phase. The autologous phase can be triggered 
immediately after injecting anti-GBM antibody by using animals that have been pre-
immunised with immunoglobulin from the species used to generate the anti-GBM 
antibody. In my experiments I used a sheep anti-mouse GBM antibody. To generate 
accelerated NTN I immunised mice with sheep IgG in adjuvant 5 days prior to 
injection of the anti-GBM antibody.  
Recruitment of neutrophils to glomeruli is important in the heterologous stage since 
neutrophil depletion is protective (Cochrane, Unanue et al. 1965). Complement 
activation is pivotal to neutrophil recruitment since these cells do not accumulate in 
glomeruli following either complement depletion or the use of non-complement fixing 
anti-GBM antibody (Cochrane, Unanue et al. 1965). Fc receptors are critical for the 
development of injury in NTN since mice with genetic deletion of the Fc receptor 
gamma chain are completely protected against renal injury (Park, Ueda et al. 1998, 
Suzuki, Shirato et al. 1998). The lack of renal injury in CD40-deficient mice, that are 
unable to produce IgG, IgA or IgE responses due to defective immunoglobulin class 
switching, indicated that antigen-specific IgM is insufficient to trigger disease 
(Wakayama, Hasegawa et al. 2000). Whilst this would suggest a dominant role for 
antibody in the effector phase, other studies have shown antibody-independent renal 
injury. Most notably, µ-chain deficient mice that have intact cell-mediated immunity 
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but no mature B cells, develop crescent formation, proteinuria and renal dysfunction 
comparable to wild-type animals (Li, Holdsworth et al. 1997). The genetic 
background of mice influences the phenotype possibly through differences in T cell 
responses to antigen. C57BL/6 mice (those used in my experiments) develop 
primarily a Th1 response, whilst a Th2 response is characteristic in BALB/c mice. 
Complement depletion (using cobra venom factor) had no effect on disease in 
C57BL/6 mice, but led to a marked attenuation in BALB/c mice where disease is 
characterised by significant glomerular IgG and complement deposition (Huang, 
Holdsworth et al. 1997). 
Consistent with both injurious and protective functions, complement has been shown 
to exacerbate and protect from renal injury in NTN. In C3-deficent mice, disease is 
milder in the heterologous phase but more severe in the autologous phase (Sheerin, 
Springall et al. 2001). The latter may relate to the inability of C3-deficient mice to 
physiologically remove immune complexes. Defective clearance of immune deposits 
and apoptotic cells from glomeruli was proposed as the explanation for the 
observation that C1q-deficient mice developed more severe injury during NTN 
(Robson, Cook et al. 2001).  
The inability to regulate complement activation is associated with increased renal 
injury during NTN. FH-deficient mice are more susceptible to both heterologous 
(Pickering, Warren et al. 2006) and autologous NTN (Pickering, Cook et al. 2002). 
This injurious phenotype was completely abolished when AP activation was 
prevented in this strain by introducing FB deficiency (Pickering, Cook et al. 2002). In 
this chapter, I present data from the study of hepatocyte-Cfh-/- mice during 
accelerated NTN. My hypothesis was: sub-total FH deficiency enhances renal injury 
during experimental NTN because of impaired regulation of complement activation 
within the kidney.  
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4.2. Overview of NTN experiments 
My aim was to compare the response of hepatocyte-Cfh-/- mice to wild-type mice and 
I performed two experiments in which I compared these two groups. In a further two 
experiments I also included CfhloxP/loxP animals and used either wild-type or Alb-Cre 
mice as controls. The experiments are summarised as follows: 
 
NTN experiment Wild-type Alb-Cre hepatocyte-
Cfh-/- 
CfhloxP/loxP 
1  - female mice N=10 - N=7 - 
2  - male mice - N=5 N=6 N=5 
3 - male mice N=7 -  N=3 - 
4 - female mice N=9 - N=14 N=12 
 
The outcome of these experiments was that it was clear that the hepatocyte-Cfh-/- 
mice had an exaggerated response to the NTN compared to the response of wild-
type mice. Furthermore, the CfhloxP/loxP animals also displayed a hypersensitive 
response to NTN. In this chapter, I present all of the experimental data relating to 
NTN experiment 4 since this is representative of the dataset as a whole. In the 
appendix I summarise the data from NTN experiments 1 – 3. The small number of 
hepatocyte-Cfh-/- animals (n=3) in NTN experiment 3 was due to a genotyping error.  
 
 
 
 
 
125 
 
4.3. Survival 
In my initial experiments it was evident that the hepatocyte-Cfh-/- mice became 
unwell within days of administration of the nephrotoxic serum (NTS). This is in 
marked contrast to what is seen in wild-type mice in this model. Wild-type mice are 
typically sacrificed 10-12 days after administration of the NTS and it is uncommon for 
these animals to show any signs of disease other than abnormal urinalysis. The 
rapid adverse reaction of hepatocyte-Cfh-/- mice necessitated culling of the animals 
at day 3 after administration of the NTS. In NTN experiment 4, two out of the 14 
hepatocyte-Cfh-/- mice died 3 days after receiving NTS. There were no deaths 
amongst the 12 CfhloxP/loxP and 9 wild-type animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
4.4. Renal function: urinalysis 
Within 24 hours of receiving NTS, all hepatocyte-Cfh-/- mice had maximal haematuria 
(defined as 3+ using the reagent strips) whereas haematuria was absent in all wild-
type mice and variably present in the CfhloxP/loxP mice (figure 4.1a). On day 3 post 
administration of the NTS the median haematuria in the CfhloxP/loxP mice had risen 
whereas no significant haematuria was present in the wild-type mice (figure 4.1b). In 
contrast, proteinuria did not differ statistically between the groups on either day one 
or day three (figure 4.2). In view of the clinical condition of the hepatocyte-Cfh-/- mice 
(ruffled coat and anasarca), I did not place the animals in metabolic cages to collect 
a timed urine sample.  
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Figure 4.1 Haematuria in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice at day 1 (A) and 3 (B) 
following NTS injection. Haematuria was already maximal by dipstick analysis within 24 hours of 
receiving NTS in hepatocyte-Cfh-/- mice. Haematuria grading: 0 = negative, 1 = trace, 2 = 1+, 3 = 2+ 
and 4 = 3+. P values calculated using Bonferroni multiple comparison test. Horizontal bars denote 
median values.  
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Figure 4.2 Proteinuria in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice at day 1 (A) and 3 (B) 
following NTS injection. Proteinuria was not statistically different between the groups at either time 
point. Proteinuria grading: negative or trace = 0, 1+ (0.3g/l) = 1, 2+ (1g/l) = 2, 3+ (3g/l) = 3 and 4+ 
(≥20g/l) = 4. Horizontal bars denote median values.    
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4.5. Renal function: serum urea 
In keeping with more severe haematuria, hepatocyte-Cfh-/- mice had significantly 
higher urea levels (median 121.9mmol/l, range 86.3-172.0, n=12) than both 
CfhloxP/loxP (median 32.6mmol/l, range 10.8-62.5, n=12, p<0.001, Bonferroni multiple 
comparison test) and wild-type mice (median 22.1mmol/l, range 8.3-30.6, n=9, 
p<0.001, Bonferroni multiple comparison test, figure 4.3). Urea levels in CfhloxP/loxP 
mice were higher than in wild-type mice but this did not reach statistical significance. 
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Figure 4.3 Serum urea in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice at day 3 following NTS 
injection. P values calculated using Bonferroni multiple comparison test. Horizontal bars denote 
median values. 
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4.6. Haematological parameters 
Hepatocyte-Cfh-/- mice had significantly lower haematocrits (median 22.5%, range 
16-26, n=12) than wild-type mice (median 35%, range 30-40, n=9, p<0.001, 
Bonferroni multiple comparison test, figure 4.4a).  
Red cell fragments were also present on peripheral blood film examination in 
hepatocyte-Cfh-/- mice (median 20 per 200 red blood cells (RBCs) counted, range 
10-37, n=12, versus median 3 per 200 RBCs in wild-type mice, range 1-10, n=9, 
p<0.001, Bonferroni multiple comparison test, figure 4.4b).  
Blood film examination in hepatocyte-Cfh-/- mice was also notable for the paucity of 
platelets (figure 4.5).  
The reduced haematocrit, red cell fragmentation and thrombocytopenia were 
consistent with the presence of a microangiopathic haemolytic anaemia in the 
hepatocyte-Cfh-/- mice.  
Consistent with the reduced basal expression of the floxed Cfh allele in CfhloxP/loxP 
mice, induction of NTN in these animals gave rise to a haematological phenotype 
intermediate to that of wild-type and hepatocyte-Cfh-/- mice. Haematocrit in CfhloxP/loxP 
mice (median 24%, range 16-32, n=12) was significantly lower than in wild-type mice 
(median 35%, range 30-40, n=9, p<0.001, Bonferroni multiple comparison test, figure 
4.4a), whilst red cell fragments were significantly greater (median 17.5 per 200 
RBCs, range 6-43, n=12 versus median 3 per 200 RBCs, range 1-10, n=9, p<0.001, 
Bonferroni multiple comparison test, figure 4.4b).   
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Figure 4.4 Haematocrit (A) and red cell fragments (B) in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- 
mice on day 3 following NTS injection. Hepatocyte-Cfh-/- mice developed a microangiopathic 
haemolytic anaemia characterised by a low haematocrit and red cell fragmentation. CfhloxP/loxP animals 
displayed an intermediate phenotype. P values calculated using Bonferroni multiple comparison test. 
Horizontal bars denote median values.  
A 
B 
N
um
be
r o
f r
ed
 c
el
l f
ra
gm
en
ts
 
pe
r 2
00
 R
B
C
s 
H
ae
m
at
oc
rit
 
%
 
P <  0.001 
P <  0.001 
 wild-type          CfhloxP/loxP    hepatocyte-Cfh-/- 
0
10
20
30
40
 wild-type          CfhloxP/loxP    hepatocyte-Cfh-/- 
0
10
20
30
40
50
 wild-type          CfhloxP/loxP    hepatocyte-Cfh-/- 
P <  0.001 
P <  0.001 
133 
 
 
 
Figure 4.5 Peripheral blood film examination in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice 
3 days following NTS injection. Red cell fragments and thrombocytopaenia were typically seen in 
hepatocyte-Cfh-/- and to a lesser extent in CfhloxP/loxP mice. 
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4.7. Renal histology 
I first noted macroscopic evidence of more severe renal injury in the sacrificed 
hepatocyte-Cfh-/- animals. Kidneys from these animals at this time point had 
haemorrhagic areas over their surface. In contrast, kidneys from CfhloxP/loxP and wild-
type animals were macroscopically normal.  
 
4.7.1. Glomerular light microscopy 
Severe glomerular thrombosis was evident in all of the hepatocyte-Cfh-/- animals at 
day 3 following NTS injection (median 3.2, range 2.9-3.8, n=14, figure 4.6 and figure 
4.7). This was in stark contrast to the almost complete absence of these changes in 
wild-type animals at this time point (median 0.1, range 0-1, n=9, p<0.001, Bonferroni 
multiple comparison test).  
Consistent with other haematological and biochemical parameters after induction of 
NTN, CfhloxP/loxP mice exhibited glomerular thrombosis that was intermediate 
between hepatocyte-Cfh-/- and wild-type animals (median 1.9, range 0.6-3.1, n=12, 
p<0.001 vs. either hepatocyte-Cfh-/- or wild-type animals, Bonferroni multiple 
comparison test, figure 4.6 and figure 4.7).  
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Figure 4.6 Glomerular thrombosis in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice at day 3 
following NTS injection. Marked glomerular thrombosis typical of haemolytic uraemic syndrome was 
observed in all hepatocyte-Cfh-/- mice. P values calculated using Bonferroni multiple comparison test. 
Horizontal bars denote median values. 
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Figure 4.7 Representative images of renal sections in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- 
mice at day 3 following NTS injection. Marked glomerular thrombosis typical of haemolytic uraemic 
syndrome was observed in all hepatocyte-Cfh-/- mice. Renal tissue is PAS-stained and original 
magnification x40. 
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4.7.2. Glomerular immunofluorescence for mouse C3 
Hepatocyte-Cfh-/- mice have abnormal spontaneous mesangial C3 accumulation but 
during NTN glomerular C3 deposition altered. At the time of sacrifice C3 staining was 
evident within thrombosed glomerular capillary loops. When I quantified glomerular 
C3 immunofluorescence there were increased scores in hepatocyte-Cfh-/- (median 
score 2.4, range 2-3, n=12) compared to wild-type animals (median score 0, range 0-
0.5, n=9, p<0.001, Bonferroni multiple comparison test, figure 4.8).  
Glomerular C3 deposition in CfhloxP/loxP mice (median 0.6, range 0.1-2.0, n=11) was 
increased compared to wild-type animals (p<0.01, Bonferroni multiple comparison 
test) but less than that seen in the hepatocyte-Cfh-/- mice (p<0.001, Bonferroni 
multiple comparison test, figure 4.8). 
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Figure 4.8 Glomerular C3 immunofluorescence studies in wild-type, CfhloxP/loxP and hepatocyte-
Cfh-/- mice at day 3 following NTS injection. P values calculated using Bonferroni multiple 
comparison test. Horizontal bars denote median values. 
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4.7.3. Glomerular immunofluorescence for mouse IgG 
There were no significant differences in glomerular mouse IgG deposition between 
the hepatocyte-Cfh-/- (median 308.3 AFU, range 143.5-625.4, n=12) and wild-type 
animals (median 418.8 AFU, range 317.7-786.3, n=9, figure 4.9). Hepatocyte-Cfh-/- 
mice had less glomerular mouse IgG detected than CfhloxP/loxP animals (median 
503.8 AFU, range 228.3-1113.0, n=11, p<0.05, Bonferroni multiple comparison test) 
despite having more severe disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Glomerular mouse IgG immunofluorescence studies in wild-type, CfhloxP/loxP and 
hepatocyte-Cfh-/- mice at day 3 following NTS injection. P values calculated using Bonferroni 
multiple comparison test. Horizontal bars denote median values. AFU – arbitrary fluorescence units. 
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4.7.4. Glomerular immunofluorescence for sheep IgG 
To determine whether the sheep anti-mouse GBM antibody had deposited to a 
comparable extent in the three groups, I quantified glomerular sheep IgG 
immunofluorescence staining (figure 4.10).  
Glomerular sheep IgG deposition in hepatocyte-Cfh-/- mice (median 591.7 AFU, 
range 457.8-834.2, n=12) was significantly lower than that seen in wild-type mice 
(median 953.9 AFU, range 722.7-1256.0, n=9, p<0.001, Bonferroni multiple 
comparison test). Interestingly, whilst this might be predicted to give rise to less 
disease (since there was ostensibly less antibody within the glomeruli) the converse 
was found. My interpretation was that the extensive thrombosis and damaged 
glomerular architecture precluded an accurate quantitative assessment of the 
deposited sheep anti-GBM antibody in these animals. In contrast, where the 
glomerular appearance was almost normal by light microscopy in the wild-type 
animals at this time point, this approach was valid (figure 4.11).  
Like wild-type animals, the glomerular sheep IgG deposition in the CfhloxP/loxP animals 
(median 762.3 AFU, range 626.9-954.1, n=12) was significantly greater than that 
seen in the hepatocyte-Cfh-/- mice (p<0.01, Bonferroni multiple comparison test). 
Consistent with my interpretation that severe glomerular thrombosis was a 
confounding factor in this analysis, glomerular sheep IgG deposition in CfhloxP/loxP 
animals was intermediate between hepatocyte-Cfh-/- and wild-type mice.  
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Figure 4.10 Glomerular sheep IgG immunofluorescence studies in wild-type, CfhloxP/loxP and 
hepatocyte-Cfh-/- mice at day 3 following NTS injection. P values calculated using Bonferroni 
multiple comparison test. Horizontal bars denote median values. AFU – arbitrary fluorescence units. 
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Figure 4.11 Representative immunofluorescence staining images for C3, mouse IgG and sheep 
IgG in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice at day 3 following NTS injection. 
Glomerular C3 deposition was significantly greater in hepatocyte-Cfh-/- mice compared to wild-type 
animals. 
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4.8. Immune response in hepatocyte-specific FH-deficient mice 
In studies by my colleague, Dr. Marieta Ruseva, the immune response to sheep IgG 
administered intra-peritoneally in complete Freund’s adjuvant was assessed in 
hepatocyte-Cfh-/-, CfhloxP/loxP and wild-type animals. These data showed that there 
was no significant difference in the immune response between the experimental 
groups (figure 4.12). From her data, I concluded that the hypersensitive response of 
the hepatocyte-Cfh-/- animals was not due to an aberrant immune response to the 
injected sheep IgG. 
 
 
  
145 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Immune response to sheep IgG in complete Freund’s adjuvant in the absence of 
NTN in wild-type, CfhloxP/loxP and hepatocyte-Cfh-/- mice (courtesy of Dr. Marieta Ruseva). Sheep 
IgG in adjuvant was administered intra-peritoneally at day 0 and serum samples collected at days 2, 4 
and 9. No significant differences in the mouse IgG anti-sheep IgG titres were seen between the 
groups at any of the time points.    
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4.9. Discussion 
Since hepatocyte-Cfh-/- mice had sub-total FH deficiency, I hypothesised that these 
animals would be more susceptible to experimental renal injury induced by NTN as a 
consequence of an inability to regulate complement within the kidney. In this chapter 
I have presented data demonstrating that these mice were extremely sensitive to 
renal injury during NTN. Within 24 hours of receiving heterologous sheep anti-mouse 
GBM antibody, all hepatocyte-Cfh-/- mice developed haematuria and at day three had 
glomerular thrombosis, reduced haematocrit, and red cell fragmentation on 
peripheral blood films. My interpretation was that they had developed a phenotype 
consistent with haemolytic uraemic syndrome (HUS) during NTN. 
It is interesting that the spontaneous phenotype and the phenotype observed during 
NTN were so different. These animals developed spontaneous accumulation of C3 
within the mesangium but no evidence of either renal impairment or spontaneous 
thrombotic microangiopathy by the age of 36 weeks. These are features of C3 
glomerulopathy. During NTN, there was rapid development of HUS. In my 
introduction I reviewed the association between FH dysfunction and the renal 
disorders: C3 glomerulopathy and HUS. Hepatocyte-Cfh-/- mice provide some insight 
into these associations since they illustrate how the same genetic defect can 
predispose to both spontaneous C3 glomerulopathy and environmentally triggered 
HUS. It is evident that there is phenotypic variation among individuals with the same 
complement mutation. For example, in CFHR5 nephropathy the spectrum of renal 
disease varies from microscopic haematuria to end-stage renal failure (Athanasiou, 
Voskarides et al. 2011). Similarly in atypical HUS, incomplete penetrance in the 
setting of complement mutations is common (Caprioli, Castelletti et al. 2003). It is 
also established that most episodes of atypical HUS are preceded by a triggering 
event such as infection, drugs and pregnancy (Caprioli, Castelletti et al. 2003). 
Furthermore, environmental events can aggravate established disease. For 
example, upper respiratory tract infection is well recognised as an exacerbating 
factor in IgA nephropathy, where it manifests clinically as synpharyngitic 
macroscopic haematuria. It is now known that this phenomenon is frequently seen in 
patients with C3 glomerulopathy. For example, in CFHR5 nephropathy 
synpharyngitic macroscopic haematuria is reported (Gale, de Jorge et al. 2010, 
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Vernon, Goicoechea de Jorge et al. 2012). It is relevant to note that the hepatocyte-
Cfh-/- mice were housed in specific pathogen-free conditions so this is an artificial 
environment and I do not know how the renal phenotype might change in the setting 
of infection in these mice. 
In mouse models of FH-associated renal injury, renal thrombotic microangiopathy 
(the pathological hallmark of HUS) is dependent on (1) the ability to regulate both C3 
and C5 in plasma and (2) the presence of defective surface regulation by FH. Mice 
with complete FH deficiency clearly have impaired surface regulation since there is a 
complete absence of FH. However, the absence of FH results in complete 
consumption of both C3 and C5 through uncontrolled AP activation. Hence they do 
not develop spontaneous HUS (Pickering, Cook et al. 2002). When FH-deficient 
mice were engineered to transgenically express a FH protein that could regulate C3 
but not mediate surface regulation, spontaneous HUS developed (Pickering, de 
Jorge et al. 2007). The important role of C5 was illustrated by the observation that 
HUS did not develop in these transgenic animals that were additionally rendered C5-
deficient (de Jorge, Macor et al. 2011). These observations demonstrate that, in the 
setting of impaired surface regulation by FH, the development of HUS is influenced 
by the presence of functionally intact C3 and C5, with C5 playing a critical role. I 
have shown that the hepatocyte-Cfh-/- mice have sub-total FH deficiency, which is 
able to maintain plasma C3 levels at approximately 20% of normal. In my thesis I 
have not examined C5 activity but Dr. Marieta Ruseva in my supervisor’s laboratory 
has subsequently developed C5 assays and shown that C5 is present in the 
hepatocyte-Cfh-/- mice (unpublished data). Extrapolating from these data and the 
published observations, hepatocyte-Cfh-/- mice were susceptible during NTN due to a 
combination of (1) the inability of the sub-total FH deficiency to adequately regulate 
complement within the kidney together with (2) the ability of the sub-total FH 
deficiency to preserve sufficient C3 and C5 in plasma. I would predict that C5 
activation is the key effector mechanism during NTN in these mice and this is 
presently being tested in my supervisor’s laboratory.  
It was also important and clear from my data that the response of the CfhloxP/loxP mice 
during NTN was not equivalent to wild-type animals. This strain developed 
glomerular thrombosis that was significantly greater than that seen in wild-type mice 
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but significantly less than that seen in the hepatocyte-Cfh-/- mice.  The finding that 
CfhloxP/loxP mice developed greater injury compared to wild-type mice was not 
completely unexpected since my data had shown that these animals had reduced 
FH levels. Their NTN phenotype indicated to me that this reduction in FH was 
sufficient to impair complement regulation within the kidney during NTN although not 
to the same extent as that seen in hepatocyte-Cfh-/- mice.  
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4.10. Conclusions 
4.10.1. Conditional FH-deficient mice develop greater renal injury during NTN 
compared to wild-type mice consistent with impaired expression of FH by the 
targeted locus. 
4.10.2. Mice with hepatocyte-specific FH deficiency develop greater renal 
injury during NTN compared to both wild-type and conditional FH-deficient mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
150 
 
5. CHAPTER FIVE:  THE ROLE OF 
FACTOR H-RELATED PROTEINS 
IN C3 GLOMERULOPATHY 
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5.1. Introduction 
In this chapter I present data relating to the biological role of the factor H-related 
(FHR) proteins. I will first summarise the key points relating to the disease 
associations of the FHR protein family and the recent data that have revealed that 
some of these proteins antagonise the action of FH, a process termed FH 
deregulation.  
As discussed in my introduction, there are five FHR proteins termed FHR1, FHR2, 
FHR3, FHR4 and FHR5. These are encoded by separate but related genes located 
immediately downstream of the CFH gene. The presence of large genomic repeat 
regions at this locus predisposes to recombination events, which can result in gene 
deletion, exon loss or hybrid genes. Genetic variability within the CFH-CFHR locus is 
increasingly recognised as influencing disease susceptibility. Polymorphic deletion of 
the CFHR3 and CFHR1 genes (ΔCFHR3-1) is associated with a reduction in the risk 
of age-related macular degeneration (Hughes, Orr et al. 2006) and IgA nephropathy 
(Gharavi, Kiryluk et al. 2011) but increased susceptibility to systemic lupus 
erythematosus (Zhao, Wu et al. 2011). The deletion is also associated with the 
development of autoantibodies to FH in atypical HUS (Skerka and Zipfel 2008). 
Abnormal rearrangements within this locus include mutant FHR proteins and hybrid 
genes, which are associated with atypical HUS (Venables, Strain et al. 2006, 
Francis, McNicholas et al. 2012) and C3 glomerulopathy (Gale, de Jorge et al. 2010, 
Malik, Lavin et al. 2012, Tortajada, Yebenes et al. 2013) respectively. These are 
shown schematically in figure 5.1.  
Some in vitro studies claimed that some of the FHR proteins have intrinsic 
complement regulatory activity. FHR1 was reported to inhibit the C5 convertase 
(Heinen, Hartmann et al. 2009), FHR5 inhibited the C3 convertase (McRae, Duthy et 
al. 2005) and FHR3, FHR4 and FHR5 have been reported to have cofactor activity 
for the FI-mediated cleavage of C3b (Hellwage, Jokiranta et al. 1999, McRae, 
Cowan et al. 2001, Fritsche, Lauer et al. 2010, Hebecker, Okemefuna et al. 2010). 
More recently, and since I completed my thesis work, data has emerged that has 
demonstrated that FHR1, FHR2 and FHR5 have no intrinsic complement regulatory 
activity but are able to compete with FH for binding to C3b. Under physiological 
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conditions neither FHR1 nor FHR5 inhibit or interact with C5 or possess FI cofactor 
activity (Goicoechea de Jorge, Caesar et al. 2013, Tortajada, Yebenes et al. 2013). 
FHR1, FHR2 and FHR5 compete with FH for interaction with C3b and, unlike FH, 
when these FHR proteins interact with C3b further C3b amplification can occur. 
FHR4 also promotes complement activation by facilitating C3 convertase formation 
when C3b is bound to ligand (Hebecker and Jozsi 2012). The current paradigm is 
that these proteins prevent the ability of FH to inactivate C3b (Goicoechea de Jorge, 
Caesar et al. 2013, Tortajada, Yebenes et al. 2013). This FH antagonism has 
implications for how we should now view the mechanistic basis of the association of 
abnormal FHR proteins in renal disease. 
The liver is the presumed major site of synthesis of the FHR proteins, although a 
comprehensive description of the cell types responsible for their synthesis is yet to 
be defined. FHR5 was first identified as a component of glomerular complement 
deposits (Murphy, Georgiou et al. 2002). FHR1 has also been detected in the kidney 
in the lining of larger arteries and in afferent and efferent arterioles (Heinen, 
Hartmann et al. 2009). FHR1 is expressed in the retina (although at levels >250,000-
fold lower than in the liver (Hageman, Hancox et al. 2006)), whilst FHR1-5 have all 
been detected in middle ear effusion fluid in children with otitis media (Narkio-
Makela, Hellwage et al. 2001). Defining the ability of tissues like the kidney and 
retina to synthesise FHR proteins is likely to be important in understanding their 
biological role. For example, up-regulation of mRNA expression of a glomerular 
epithelial cell rat factor H-related protein, reportedly similar to human FHR5, has 
been described in a rodent model of complement activation (Ren, Doshi et al. 2002). 
The ability of locally produced complement components to exert functionally 
significant effects is established for C3 (Springall, Sheerin et al. 2001, Pratt, Basheer 
et al. 2002, Farrar, Zhou et al. 2006).  
The data in this chapter is in three parts. The first two parts describe clinical studies I 
performed in two informative patients with C3 glomerulopathy and the third outlines 
work that I performed to determine if there was significant renal synthesis of the FHR 
proteins. The first study demonstrates that renal-derived FHR5 could not prevent the 
recurrence of CFHR5 nephropathy. The second describes the association between 
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C3 glomerulopathy and haploinsufficiency of FHR5. In the third section I sought to 
characterise the expression of the human FHR proteins in liver and kidney tissue. 
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Figure 5.1 Schematic depiction of abnormal FHR proteins associated with C3 glomerulopathy. 
(A) hybrid FHR3-1 protein;  (B) internal duplication in FHR1 and (C) an internal duplication in FHR5. 
The respective normal protein(s) are shown above the abnormal protein. The coloured domains 1 and 
2 depict those that mediate the obligate dimerization amongst FHR1, FHR2 and FHR5.  
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5.2. Recurrence of familial C3 glomerulonephritis in a renal transplant 
In this section I present my work characterising the first known case of recurrence of 
CFHR5 nephropathy in an unrelated deceased donor renal transplant (Vernon, Gale 
et al. 2011). CFHR5 nephropathy was the term used to describe C3 
glomerulonephritis (C3GN) associated with an internal duplication of exons 2 and 3 
of the CFHR5 gene (Gale, de Jorge et al. 2010). It is a familial renal disease 
characterised by persistent microscopic haematuria, synpharyngitic macroscopic 
haematuria and progressive renal failure in individuals of Cypriot origin. The natural 
course of the disease appears more aggressive in males who possess a higher risk 
of progressing to end-stage renal failure (Athanasiou, Voskarides et al. 2011). The 
pathological features of C3GN include membranoproliferative or mesangial 
proliferative changes within affected glomeruli.  
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5.2.1. Outline of the case 
The index case was a 47-year old British male with Cypriot ancestry who reached 
end-stage renal failure after presenting 11 years earlier with persistent microscopic 
haematuria, synpharyngitic macroscopic haematuria and renal dysfunction. 
Retrospective review of two renal biopsies performed during his progression to end-
stage renal disease demonstrated features consistent with C3GN. Capillary wall C3 
accompanied an increase in mesangial cellularity and matrix, along with 
subendothelial, mesangial and more rarely, subepithelial deposits (figure 5.2). The 
second biopsy also revealed capillary wall thickening with double contours and 
mesangial cell interposition. Staining for immunoglobulins including IgA was 
negative. 
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Figure 5.2 Native renal biopsy. (A) Light microscopic appearance showing segmental 
glomerulosclerosis and hyalinosis and increased mesangial matrix (hematoxylin and eosin). (B) 
Immunoperoxidase staining showing granular capillary wall C3 deposition. C3 was detected using a 
polyclonal rabbit anti-human C3c antibody (Dako, Ely, UK). (C) Electron micrograph showing multiple 
subendothelial electron dense deposits (denoted by arrows). 
A 
B 
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5.2.2. Diagnosis of CFHR5 nephropathy 
To establish the diagnosis of CFHR5 nephropathy two approaches are commonly 
adopted: (i) screening of genomic DNA for the presence of the break point within the 
CFHR5 gene and (ii) screening of plasma for the presence of the abnormal FHR5 
protein. 
Detection of the CFHR5 gene break point is readily done by performing PCR on 
genomic DNA using primers that amplify both the wild-type and mutant loci (Gale, de 
Jorge et al. 2010).  The nature of the break point that results in the internal 
duplication of exons 2 and 3 of the CFHR5 gene means that this approach is unable 
to distinguish between individuals carrying the break point in heterozygosis or 
homozygosis.  
However, since both the wild-type and mutant plasma proteins are secreted and 
differ significantly in size, the presence of the mutation and whether or not it is 
present in heterozygosis (both mutant and wild-type protein) or homozygosis (mutant 
protein alone) can be determined by analysing serum FHR5 by western blotting. The 
wild-type protein is comprised of 9 SCR domains and the mutant protein composed 
of 11 SCR domains. Using western blotting of serum from the affected individual, I 
was able to demonstrate the presence of both the mutant and wild-type FHR5 
proteins using a polyclonal anti-FHR5 antibody. This confirmed the diagnosis of 
CFHR5 nephropathy and that the mutation was present in heterozygosis (figure 5.3).  
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Figure 5.3 Western blot of serum for FHR5 from the affected individual. Both the wild-type FHR5 
protein and the higher molecular weight mutant FHR5 protein are seen. The schematic depicts the 
short consensus repeat (SCR) domain structures of the wild-type and mutant proteins. The wild-type 
contains 9 SCR domains and the mutant contains 11 domains since domains 1 and 2 are duplicated. 
SCR – short consensus repeat. 
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5.2.3. Renal transplantation 
At the age of 53, he received an unrelated deceased donor renal transplant (2,1,1 
mismatch), which proceeded without complication. The donor had normal renal 
function and there were no recipient class I or II human leucocyte antigen antibodies 
at the time of transplantation. Immunosuppression comprised Alemtuzumab 
induction and peri-operative corticosteroids with Tacrolimus monotherapy continued 
on discharge. 
Whilst his creatinine initially fell, failure to fall below 186µmol/l in the presence of 
microscopic haematuria and a single episode of macroscopic haematuria, led to the 
decision to perform a renal transplant biopsy (figure 5.4). At the time of biopsy, 
serum C3 was 0.73g/L (normal range 0.7-1.7g/L), FH 320mg/L (207% of normal 
control) and FI 32mg/L (177% of normal control).  
Only 46 days post transplantation, capillary wall C3 and C9 deposition was found 
accompanying an increase in mesangial matrix with mesangial and subendothelial 
deposits. C4d staining was negative.  
A second biopsy, undertaken 3 months later after a further decline in graft function, 
confirmed recurrence of his original disease. In this biopsy sample I had access to 
frozen tissue. This enabled me to determine if there was evidence of TP activation 
since it had been shown that a monoclonal mouse anti-human C5b-9 antibody 
(Dako, Ely, UK) reliably detected C5b-9 in frozen tissue sections. I applied an 
immunofluorescence staining approach using a two-step procedure in which I first 
applied the mouse anti-human C5b-9 antibody and then applied a fluorescein 
isothiocyanate-labelled goat anti-mouse IgG (Sigma, Dorset, UK). Using this 
approach I was able to detect C5b-9 staining in the second transplant kidney biopsy 
(figure 5.5). 
 
 
 
161 
 
 
 
Figure 5.4 Renal transplant biopsy. (A) Light microscopy showing a normal glomerulus (periodic 
acid-Schiff). (B) Immunoperoxidase staining showing granular capillary wall and mesangial C3 
deposition. C3 was detected using a polyclonal rabbit anti-human C3c antibody (Dako, Ely, UK). (C) 
Electron micrograph showing subendothelial deposits (denoted by arrows) with new basement 
membrane beneath. 
A 
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Figure 5.5 Renal transplant biopsy staining for C5b-9. C5b-9 was detected using a monoclonal 
mouse anti-human C5b-9 antibody and a FITC-labelled goat anti-mouse IgG. Diffuse glomerular 
staining for C5b-9 is evident. 
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5.2.4. Summary 
In summary this was the first characterised case of recurrence of CFHR5 
nephropathy in a renal transplant. The points that this study revealed were (i) the 
recurrence of abnormal complement deposition along the GBM was rapid i.e. 46 
days post transplantation and (ii) if there is any biologically relevant synthesis of 
FHR5 within the kidney, this renal-derived FHR5 could not prevent the recurrence of 
CFHR5 nephropathy. 
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5.3. Persistent glomerulonephritis following streptococcal infection in 
an individual with heterozygous FHR5 deficiency 
In this section I present my work characterising the complement profile of a patient 
who developed persistent glomerulonephritis following a streptococcal infection 
(Vernon, Goicoechea de Jorge et al. 2012). The patient was a 12-year old female 
with persistent kidney disease and hypocomplementaemia 5 years after 
streptococcal infection and I identified a heterozygous mutation in the CFHR5 gene. 
This single nucleotide insertion in exon 4 of CFHR5 resulted in a premature stop 
codon and was associated with reduced serum FHR5 levels and C3 glomerulopathy 
on renal biopsy. 
5.3.1. Outline of the case 
A 7-year old Caucasian female presented with a 10-day history of sore throat, cough, 
fever and lethargy accompanied by abdominal pain, vomiting and dark-coloured 
urine. Previously fit and well, clinical examination and investigation revealed 
periorbital oedema, abnormal urinalysis (blood [3+] and protein [3+]; 
protein/creatinine ratio 590mg/mmol) and renal impairment (serum urea 17.9mmol/l 
and creatinine 87µmol/l). Whilst serum C4 was normal (0.29g/L [reference range 
0.11-0.43g/L]), C3 was low (0.36g/L [reference range 0.75-1.65g/L]), and anti-
streptolysin O (>200U/mL) and anti-DNase antibody (360U/mL) titres were both 
elevated. Renal ultrasound showed loss of corticomedullary differentiation. 
Treatment with phenoxymethylpenicillin led to clinical improvement but microscopic 
haematuria and proteinuria persisted. 
Following a further episode of macroscopic haematuria coinciding with an upper 
respiratory tract infection, she underwent a renal biopsy nine months after the initial 
presentation on account of persistent haematuria, proteinuria and low C3 levels 
(figure 5.6). Mesangial hypercellularity, segmental endocapillary hypercellularity and 
capillary wall double contours were accompanied by marked granular capillary wall 
and mesangial C3, C9 and FHR5 deposition. Immunoglobulins and C1q were 
absent. Electron microscopy revealed a thickened GBM with segmental duplication 
and mesangial cell interposition. Intramembranous electron dense deposits (EDD) 
were seen with occasional subendothelial and hump-like subepithelial deposits. 
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These findings are consistent with C3 glomerulopathy with a membranoproliferative 
pattern of glomerulonephritis and were also seen on a second biopsy performed 20 
months after the original illness. Persistent membranoproliferative glomerulonephritis 
and tubulointerstitial scarring affecting 40% of the cortex were observed with both 
intramembranous and mesangial deposits (figure 5.6). 
Angiotensin receptor blockade and glucocorticoid therapy led to a reduction in 
proteinuria, but serum C3 levels remained low throughout. Her clinical course is 
summarised in figure 5.7. She has not developed ocular drusen or lipodystrophy. 
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Figure 5.6 Kidney biopsies performed at 9 and 20 months post presentation. Light microscopy 
(first row) shows mesangial hypercellularity, segmental endocapillary hypercellularity, and capillary 
wall double contours with marked capillary wall C3, C9, and FHR5 seen on immunoperoxidase 
staining (second [C3] and fourth [C9, FHR5] rows). On electron microscopy (third row), there were 
intramembranous and occasional subendothelial electron dense deposits. Rare hump-like 
subepithelial deposits were seen in the first biopsy specimen. 
  
9 months 20 months 
C9 FHR5 
First renal biopsy 
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Figure 5.7 Serum complement C3 and creatinine levels versus time. Serum C3 levels remained 
profoundly depressed throughout the illness.  
 
 
 
0 10 20 30 40 50 
0.0 
0.5 
1.0 
1.5 
2.0 
months after presentation 
angiotensin)receptor)blockade)
prednisolone)
Synpharyngitic macroscopic 
haematuria 
C3)normal)range)0.771.7g/l)
co
m
pl
em
en
t C
3 
g/
l 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
cr
ea
tin
in
e 
m
g/
dl
 
168 
 
5.3.2. Assessment of serum factor triggering C3 activation 
It was clear that this individual had chronic low levels of C3 so it was important to 
exclude the presence of C3 nephritic factor and autoantibodies to FH. Both these 
were excluded by assays used in clinical practice and performed by our clinical 
immunology department. 
 
So my next approach was to exclude any other serum factor that might be causing 
complement C3 consumption. To achieve this I tested whether or not exogenous C3 
was consumed when added to the serum of the index case, as would occur in sera 
that contained C3 nephritic factor.  In my assay I added 0.5% purified C3 (Merck 
Sharpe and Dohme, Hertfordshire, UK) to serum from the index case and compared 
its haemolytic activity at 2 and 4 hours with that of C3-deficient human serum 
reconstituted with purified C3 in an identical fashion. Haemolytic activity at 2 (60% vs 
57%) and 4 hours (43% vs 47%) did not differ between the test and control sera, 
indicating that there was no evidence of accelerated serum C3 conversion in serum 
of the index case. 
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5.3.3. Complement genetic investigations 
In parallel my supervisor’s laboratory organized genetic screening of complement 
genes to exclude mutations that have been associated with C3 glomerulopathy. 
There were no mutations in the exons and splice sites of the genes encoding FH, FI, 
CD46, FB and C3. In view of the characterization of CFHR5 nephropathy the 
laboratory performed sequence analysis of the CFHR5 gene. This was done by Mrs. 
Kirsten Rose and revealed a single heterozygous nucleotide duplication in exon 4 
(c.485dupA) which generates a reading frame shift at amino acid 163 and a 
premature stop codon at amino acid position 197 (p.Glu163Argfs*34, figure 5.8). 
This variant was not detected by sequencing of 198 ethnically matched DNA 
samples (obtained from the UK Blood Services Collection of Common Controls) and 
was not present in the databases. 
 
The healthy mother (I-2) and sister (II-1), but not the 2 other siblings examined (II-2 
and II-4), were heterozygous for this sequence variant (figure 5.9). 
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Figure 5.8 Sequence chromatogram from the index case. Sequence depicts CFHR5 exon 4 
sequence demonstrating duplicated sequence from the nucleotide c485. This results in a reading 
frame shift altering the amino acids (denoted in red) and generating a stop codon at amino acid 
position 197. Nucleotides: G – guanine, A – adenine, T – thymine, C – cytosine. Amino acids: P – 
phenylalanine, K – lysine, E – glutamic acid, S – serine, Y – tyrosine, N – asparagine, R – arginine, L 
– leucine, T - threonine. Numbering – A of ATG = 1, Methionine = 1. 
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Figure 5.9 Family pedigree. II-3 (filled blue circle) denotes the index patient. A central dot within the 
symbol (circle and square denoting female and male individuals, respectively) indicates the sequence 
variant is present, empty symbols denote absence of the sequence variant, and symbols with a 
question mark indicate genetic status unknown. 
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5.3.4. Assessment of FHR5 
To further assess FHR5 in this pedigree I first performed serum western blotting for 
FHR5 to determine if there was any evidence of internal duplication that would result 
in abnormally large protein. This was important, as Sanger sequencing does not 
detect exon duplications such as that seen in CFHR5 nephropathy. In this pedigree 
there was no evidence of an aberrant FHR5 protein on western blotting of sera 
(figure 5.10).  
I next measured serum FHR5 levels using an ELISA (see methods) and this 
demonstrated that, as was suspected from the FHR5 western blotting, serum FHR5 
was reduced in the index case but not in the two other members of the family with 
the CFHR5 mutation. These values and the complement parameters performed by 
the clinical immunology laboratory are summarized in table 5.1.  
To determine the normal range for serum FHR5 I performed the ELISA using sera 
from 13 healthy individuals (figure 5.11). This showed a median level of 5.5µg/ml, 
range 3.4 - 10.1 (n=13). This range clearly needs to be confirmed in a much larger 
cohort but is close to the range reported in a previous publication which quoted a 
range of 4-6µg/ml but did not provide details of the assay used or numbers analysed 
(McRae, Duthy et al. 2005).  
Based on my data it was clear that the mutation alone could not account for the low 
serum FHR5 level in the index case (since levels were not similarly reduced in 
unaffected relatives with the mutation). I hypothesised that this could be explained by 
the fact that serum FHR5 was sequestered by complement present in the kidney of 
the index case. Consistent with this was the observation that FHR5 could be 
detected within glomeruli on renal biopsy (figure 5.6). Additionally, I was able to 
measure FHR5 levels in 23 patients with biopsy-proven C3 glomerulonephritis in 
whom CFHR5 mutations had been excluded. These were provided by Dr. Fremeaux-
Bacchi (Paris, France).  The median level in these patients, 4.3µg/ml (range 1.2 – 
7.4, n=23), was significantly lower than that of my control cohort (P=0.02, Mann-
Whitney test, figure 5.11).  
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Figure 5.10 Western blot for FHR5 using sera from pedigree members. No evidence of an 
aberrant FHR5 protein was seen. Lane 6 contains a positive serum control for aberrant protein which 
is the FHR512123-9 protein associated with CFHR5 nephropathy. Equal amounts of sera were loaded 
per lane and it was evident that the levels of FHR5 in the index case were low. 
 
 
 
 
 
 1     2      3       4      5      6    LANES: 
 
1 – normal human sera 
2 – index case (II-3) 
3 – II-1 
4 – I-2 
5 – II-2 
6 – Patient with CFHR5 nephropathy 
FHR512123(9*
FHR5123(9*
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Table 5.1 Complement profile in the index case and other pedigree members where available. 
 
 
Pedigree number 
 
I-2 
 
II-1 
 
II-2 
 
II-4 
 
II-3 
 
CFHR5 mutation 
 
YES* 
 
YES* 
 
NO 
 
NO 
 
YES* 
 
C3 g/l (0.7-1.7) 
 
1.43 
 
1.03 
 
1.08 
 
1.14 
 
0.07 
 
C4 g/l (0.16-0.54) 
 
0.24 
 
0.17 
 
0.21 
 
0.16 
 
0.22 
 
Factor H %NHP** 
 
181 
 
132 
 
132 
 
147 
 
148 
 
Factor I %NHP** 
 
174 
 
132 
 
157 
 
186 
 
154 
 
CH100 (50-150%NHP) 
 
108 
 
47 
 
99 
 
95 
 
absent 
 
AP100 (50-150%NHP) 
 
92 
 
53 
 
102 
 
95 
 
absent 
 
Serum FHR5  
 
µg/ml 
 
% of controls 
 
 
 
5.3  
 
96.2 
 
 
3.8 
 
69.9 
 
 
4.0 
 
72.5 
ND 
 
 
2.1 
 
37.3 
 
*c.485dupA (p.E163Rfs*34) – numbering and nomenclature follows human genome variation 
society recommendations (methionine = 1, A in ATG = 1, www.hgvs.org).  
 
**no validated reference range exists for FH and FI so results are expressed as % of NHP.  
 
FHR5 levels are expressed as both absolute values in µg/ml and as a % of the median value 
(5.5µg/ml) of 13 healthy controls.  
 
Abbreviations: FHR5 – factor H-related protein 5, NHP – normal human sera pool, CH100 – 
total complement haemolytic activity, AP100 – alternative pathway haemolytic activity, ND – 
not done due to insufficient sample 
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Figure 5.11 Serum FHR5 levels in individuals with biopsy-proven C3 glomerulonephritis and no 
CFHR5 mutation. The median FHR5 level in the C3GN group (4.3µg/ml, range 1.2-7.4, n=23), was 
significantly lower than the median in the healthy controls (5.5µg/ml, range 3.4-10.1, n=13, p=0.02, 
Mann-Whitney test). 
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5.3.5. Summary 
In summary, this was a young girl who developed persistent glomerulonephritis and 
hypocomplementaemia following a streptococcal throat infection. I demonstrated that 
she had reduced serum FHR5 levels most likely a consequence of both 
haploinsufficiency of FHR5 and sequestering of serum FHR5 by complement within 
the inflamed glomeruli.  
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5.4. Synthesis of FH and FHR proteins by the kidney 
In view of the association between abnormalities in FHR5 and C3 glomerulopathy, I 
wanted to determine if there was evidence of local production of FHR5 and the other 
FHR proteins within the kidney. To do this I obtained normal human liver and kidney 
frozen tissue from the Hospital tissue bank.  
I extracted RNA from liver and kidney tissue and then generated cDNA using 
random primers. This cDNA was then used as a template to determine (i) if I could 
amplify FH and the FHR proteins and (ii) to compare the relative expression of any of 
these genes within the kidney to that seen within the liver. 
5.4.1. Absolute expression of CFH and CFHR genes in liver and kidney tissue 
Liver and kidney expression was investigated by PCR using liver and kidney cDNA 
and gene-specific primers. In this analysis I had liver tissue (and therefore cDNA) 
from 10 samples (L1-10) and kidney tissue from 8 samples (K1-8). 
The expected amplicon for FH and all of the FHR proteins was seen in 8 out of 10 of 
the liver samples (figure 5.12). In the remaining 2 out of 10 liver samples, all had 
expression of FH, FHR2, FHR4 and FHR5.  In one of these samples there was no 
amplicon for either FHR3 or FHR1 and I speculate that this could be explained by 
the fact that this sample came from a donor who was homozygous for the ΔCFHR3-
1 deletion. In the other sample there was no amplicon for FHR1. 
In the 8 kidney samples only FH and FHR5 were detected in each sample (figure 
5.12). 
All amplicons were confirmed as gene-specific by sequencing.  
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Figure 5.12 Expression of CFH and CFHR1-5 in human liver and kidney tissue. Gene-specific 
primers were used to amplify target sequence from cDNA. L1-3 = liver tissue, K1-2 = kidney tissue, C 
– water control.   
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5.4.2. Relative expression of CFH and CFHR5 genes in liver and kidney tissue 
I next tried to determine the relative expression of kidney FH and FHR5 both with 
their respective liver expression by quantitative PCR using cDNA from liver and 
kidney. In these reactions I amplified two housekeeping genes: beta-actin and 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase). I then used the comparative 
Ct (cycle threshold) method to determine relative expression. These calculations 
showed that (i) liver expression of CFHR5 was 8-fold less than that of CFH and (ii) 
that kidney expression of CFHR5 was extremely low with Ct values of greater than 
30 (table 5.2).  
 
Table 5.2 Relative expression of CFH and CFHR5 in liver and kidney tissue 
      
ΔCT 
  
ΔΔCt 
CFHR5-CFH 
fold-change* 
CFHR5 vs. CFH 
Tissue Gene Ct actin GAPDH actin GAPDH actin GAPDH 
Liver CFH 19.6 1.5 1.2 
    Liver CFHR5 22.6 4.5 4.2 3 3 8x less 8x less 
Liver actin 18.1 
      Liver GAPDH 18.4 
   
 
  Kidney CFH 26.3 11 11.3 
    Kidney CFHR5 33.4 18.1 18.4 7.1 7.1 137x less 137x less 
Kidney actin 15.3 
      Kidney GAPDH 15 
   
 
  Ct – cycle threshold, *calculated by 2^-ΔΔCt  
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5.5. Discussion  
In this chapter I have presented evidence that CFHR5 nephropathy recurs in the 
transplant kidney. This was the first reported case. Disease recurrence post 
transplantation is common in patients with DDD, accounting for 70% of allograft 
failure within five years of transplantation (Lu, Moon et al. 2012). It is not surprising 
perhaps that transplant recurrence of DDD occurs in the presence of circulating C3 
nephritic factors. My report illustrates that renal-derived wild-type FHR5 could not 
prevent the development of C3 glomerulonephritis. Whilst long-term outcome data 
are not yet available for CFHR5 nephropathy, it may be that its slow natural history 
does not preclude transplantation. Even with recurrence, patients may maintain 
meaningful renal function for a significant number of years without progression to 
end-stage renal failure.  In my published report (Vernon, Gale et al. 2011), I 
discussed how two other incompletely characterized cases with the CFHR5 mutation 
and renal disease, had good allograft function one decade after deceased donor 
renal transplantation. Firstly, a Cypriot male with a renal biopsy demonstrating C3 
glomerulonephritis reached end-stage renal failure at the age of 46. A deceased 
donor renal transplant was performed at the age of 48 and he died 12 years later 
from a myocardial infarction. The serum creatinine 3 months before his death was 
89µmol/l and the graft was never biopsied. Secondly, a 40 year old Cypriot individual 
with end-stage renal failure and small kidneys, who presented with macroscopic 
haematuria at the age of ten but had been lost to follow up, received a deceased 
donor renal transplant at the age of 43. The transplant functioned well for 10 years 
until it was lost following atheroembolic complications of diagnostic coronary 
angiography. He returned to haemodialysis and died 6 years later. These cases, 
together with the observations that the original disease takes many decades to 
cause end-stage renal failure, suggest that graft loss due to recurrence of CFHR5 
nephropathy is not inevitable.  
Acute post-streptococcal glomerulonephritis is a common cause of acute nephritis in 
childhood. Serum complement C3, C5 and properdin are reduced acutely in contrast 
to C4 levels which are usually normal, demonstrating selective AP activation. C3 
nephritic factor has been identified transiently in some individuals (Fremeaux-Bacchi, 
Weiss et al. 1994) and streptococcal components may also activate the pathway 
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(Bellon, Kuhn et al. 1979, Hummell, Swift et al. 1985, Rodriguez-Iturbe and Batsford 
2007). Complement levels characteristically return to normal within 12 weeks but a 
minority of individuals develop chronic disease associated with prolonged 
hypocomplementaemia (Popovic-Rolovic 1973, Payne, Houtman et al. 2008). In this 
chapter I have described an association between heterozygous FHR5 deficiency and 
persistent glomerulonephritis following a streptococcal throat infection.  Previously 
published evidence that FHR5 interacts with glomerular complement (Murphy, 
Georgiou et al. 2002) suggested to me that this was the reason for the fall in serum 
FHR5 in the index case. Consistent with this hypothesis was our observation that 
glomerular FHR5 was detectable in kidney biopsy specimens from the index case, 
median serum FHR5 levels were low in individuals with C3 glomerulonephritis, and 
serum FHR5 level in the index patient was lower than levels in other family members 
with the sequence variant, but no kidney disease. An interesting additional insight 
based on these data is that serum FHR5 levels may be a useful biomarker of 
glomerular C3 deposition. My report was the first description of the association of 
kidney disease with a heterozygous sequence variant causing frameshift and 
premature truncation of FHR5. Interestingly, the same variant was reported in an 
individual serving as a control in a study investigating the role of FHR5 in atypical 
haemolytic uremic syndrome (Monteferrante, Brioschi et al. 2007). No clinical details 
for this individual were reported. The presence of the CFHR5 sequence variant in the 
mother and sister of the index patient (neither of whom had overt evidence of kidney 
disease) indicated that heterozygosity for this CFHR5 sequence variant was not 
sufficient to cause kidney disease. My view was that both the heterozygous CFHR5 
sequence variant and streptococcal infection precipitated chronic kidney disease in 
the index patient. Interestingly, individuals with other genetic defects within the CFH 
gene family are susceptible to exacerbation of kidney disease during throat 
infections. Synpharyngitic macroscopic haematuria is characteristic of CFHR5 
nephropathy (Gale, de Jorge et al. 2010) and common in FH deficiency states (Levy, 
Halbwachs-Mecarelli et al. 1986, Pichette, Querin et al. 1994). Furthermore, 
exacerbation of urinary abnormalities in dense deposit disease has been associated 
with streptococcal infection (Sibley and Kim 1984). Rarely, kidney biopsies following 
acute post-streptococcal glomerulonephritis have shown changes consistent with 
dense deposit disease (Clark, White et al. 1988, Sawanobori, Umino et al. 2009, 
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Suga, Kondo et al. 2010). I considered the question: is dense deposit disease 
triggered by streptococcal infection or is it a pre-existing lesion that becomes 
clinically overt during streptococcal infection. I found one report describing apparent 
progression from biopsy-proven acute post-streptococcal glomerulonephritis to 
dense deposit disease (Shahidi-Asl, Ananth et al. 2000). However, in others, it 
seems that dense deposit disease may have predated the episode of acute post-
streptococcal glomerulonephritis (Sibley and Kim 1984, Sawanobori, Umino et al. 
2009). In my report the index case had no previous evidence of kidney disease, 
although it is possible that sub-clinical disease was present before the episode of 
streptococcal infection. Further studies will be required to determine if 
haploinsufficiency of FHR5 represents a risk factor for the development of chronic 
glomerulonephritis following streptococcal infection.  
The presence of low serum C3 levels in this case cannot be explained by the 
heterozygous sequence variant in CFHR5 alone because serum C3 levels were 
normal in the index patient’s mother and sister, who also carried the sequence 
variant. Notably, in CFHR5 nephropathy, serum C3 levels typically are normal whilst 
in DDD a low serum C3 level is typical and commonly associated with the presence 
of C3 nephritic factor. However, rarer causes such as anti-FB antibodies have 
recently been reported (Strobel, Zimmering et al. 2010). C3 nephritic factor was 
consistently undetectable in our case and I could not detect any other factor within 
the serum of the index case that was causing accelerated C3 consumption. I 
concluded that the serum C3 depletion was a result of excessive C3 activation within 
the kidney. 
 
Following recent work demonstrating that FHR proteins mediate deregulation of FH 
in vitro (Goicoechea de Jorge, Caesar et al. 2013, Tortajada, Yebenes et al. 2013), I 
would have predicted that FHR5 deficiency would not be deleterious in C3 
glomerulopathy since this would reduce FHR5-mediated deregulation of FH. It may 
be that reduction of FHR5 increases the ability of FHR1 to deregulate by altering the 
composition of FHR homo- and heterodimers. Alternatively, the sequestration and 
relative abundance of FHR5 in the kidney may act to increase complement 
deregulation locally, leading to increased complement activation and damage within 
183 
 
the glomerulus. Indeed, the alteration of FHR concentrations locally has been 
proposed as a mechanism by which complement activation may be modulated 
through the effect on FH deregulation (Fritsche, Lauer et al. 2010, Goicoechea de 
Jorge, Caesar et al. 2013). By increasing competition for binding to C3b and thereby 
the deregulation of FH, higher concentrations of FHR proteins could facilitate 
complement activation. In circumstances where complement activation is not 
desirable, lower FHR protein levels would enable FH-mediated inactivation of C3b. A 
previous study of middle ear effusion fluid from children with otitis media found 
evidence to suggest AP dysregulation and a relative abundance of the FHR proteins 
compared to serum (Narkio-Makela, Hellwage et al. 2001). Further investigation of 
larger patient cohorts with post-streptococcal glomerulonephritis and C3 
glomerulopathy is now required in order to clarify the role, if any, of FHR5 deficiency 
in these settings. 
Little is known about the synthesis and expression of the FHR proteins within the 
kidney. I could only amplify FHR5 cDNA from whole human kidney tissue but when I 
performed quantitative analysis the relative expression was minimal. This, together 
with the observation that CFHR5 nephropathy recurs in the transplant kidney 
suggested to me that the biological contribution of renal-derived FHR5 is minimal. 
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5.6. Conclusions 
5.6.1. Renal-derived FHR5 did not prevent recurrence of CFHR5 nephropathy in the 
transplant kidney 
5.6.2. Haploinsufficiency of FHR5 may influence susceptibility to glomerulonephritis 
following streptococcal throat infection 
5.6.3. Serum FHR5 levels may be a useful biomarker of C3 deposition within the 
kidney 
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6. CHAPTER SIX:  DISCUSSION 
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Complement plays a pivotal role in a variety of processes including the defence 
against invading pathogens and the clearance of apoptotic cells whilst also forming a 
link between innate and adaptive immunity. Effective regulation of the complement 
system is critical in preventing unwanted damage to host tissues and complement 
dysregulation is increasingly associated with disease. 
 
Fundamental to control of the AP pathway of complement is FH, a 150-kDa plasma 
protein synthesised predominantly in the liver. Encoded by the CFH gene within the 
regulators of complement activation gene cluster on chromosome 1, it forms the FH 
protein family with the splice variant FHL-1 and the five FHR proteins (FHR1-5). 
Complete deficiency of FH leads to uncontrolled complement activation with 
secondary depletion of AP complement components such as complement C3, and is 
associated with the development of renal disease typified by isolated glomerular C3 
deposition. Spontaneous and experimental animal models of total FH deficiency are 
characterised by the development of MPGN, whilst in humans FH deficiency is 
typically associated with DDD (now recognised as a form of C3 glomerulopathy) and 
more rarely, aHUS. aHUS is more frequently associated with mutations affecting the 
carboxyl terminal of FH responsible for surface binding, and complement regulatory 
activity mediated by the four amino terminal SCRs typically remains intact. 
 
The ability to regulate complement activation within the circulation has proved critical 
to the renal pathology observed. A membranoproliferative pattern of disease is seen 
in the presence of complement dysregulation in complete FH deficiency, whilst mice 
expressing a FH protein lacking only the five C-terminal SCRs (FHΔ16-20) develop 
thrombotic microangiopathy and aHUS. Notably, animals with lower circulating levels 
of this mutant FH protein (Cfh-/-.FHΔ16-20low) were protected from aHUS, indicating 
that effective plasma C3 regulation is required in addition to dysfunctional surface 
recognition in order for disease to occur. Furthermore, Cfh-/-.FHΔ16-20low mice with 
higher circulating C3 levels than Cfh-/- animals had reduced mesangial expansion, 
capillary wall C3 deposition and subendothelial electron dense deposits.  
Synthesised by a variety of cell types, the majority of FH originates from the liver. 
The contribution of extra-hepatic FH to the total circulating pool and plasma C3 
regulation has not been defined. To determine the ability of extra-hepatic FH to 
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prevent the GBM C3 deposition and MPGN seen in Cfh-/- mice, I generated a mouse 
line with hepatocyte-specific FH deficiency (hepatocyte-Cfh-/-). 
What does this model tell us about plasma C3 regulation and its relationship to 
complement deposition within the kidney? 
Median plasma FH levels in hepatocyte-Cfh-/- mice were 19% of those observed in 
wild-type animals and were accompanied by a secondary reduction in circulating C3 
levels to 20% of wild-type levels. FH and C3 levels were significantly lower in 
hepatocyte-Cfh-/- mice compared to CfhloxP/loxP animals, whilst C3 levels in 
hepatocyte-Cfh-/- mice were higher than in Cfh-/- animals indicating that extra-hepatic 
FH contributes in part to plasma C3 regulation. At 36 weeks of age, there was no 
evidence of uraemia, albuminuria or thrombotic microangiopathy in hepatocyte-Cfh-/- 
mice. However, whilst there was mild glomerular hypercellularity comparable to Cfh-/- 
animals, the glomerular C3 staining was completely different. In contrast to the linear 
capillary wall deposition seen in Cfh-/- mice, glomerular C3 in hepatocyte-Cfh-/- 
animals was granular and mesangial in distribution. Furthermore, tubulointerstitial C3 
reactivity in hepatocyte-Cfh-/- mice indicated the presence of intact circulating C3 not 
present in Cfh-/- animals. Reduced staining relative to the tubulointerstitium in wild-
type mice, however, demonstrated that extra-hepatic FH could only partially regulate 
C3 within plasma.  
 
The administration of murine or human FH to Cfh-/- mice also results in a change in 
the distribution of glomerular C3 from the GBM to the mesangium and is associated 
with the reappearance of tubulointerstitial C3 staining (Paixao-Cavalcante, Hanson 
et al. 2009, Fakhouri, de Jorge et al. 2010). This clearance of GBM iC3b/C3d in Cfh-/- 
mice has recently been shown to be properdin-dependent (Ruseva, Vernon et al. 
2013). Lack of reactivity of mesangial C3 in hepatocyte-Cfh-/- mice with an anti-C3d 
antibody mirrors that in FH-treated Cfh-/- mice, and together with the absence of co-
localisation with FH/FHR proteins, appears to support the possibility that mesangial 
C3 in hepatocyte-Cfh-/- mice may also contain C3c. The role of properdin in the C3 
deposition seen in hepatocyte-Cfh-/- animals remains to be defined. 
Lower FH and C3 levels in CfhloxP/loxP mice compared to Alb-Cre animals indicated 
impaired expression of the targeted Cfh locus, likely secondary to the insertion of 
either the loxP sites or the neomycin resistance gene. This precluded a definitive 
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conclusion regarding the contribution of extra-hepatic FH to the total circulating pool. 
To circumvent this technical issue, FH and C3 levels need to be measured following 
removal of the Neo cassette using a transgenic mouse expressing the Flp 
recombinase. 
 
The spontaneous phenotype in hepatocyte-Cfh-/- mice can be considered a new 
model of C3 glomerulopathy characterised by mesangial C3 deposition in the 
absence of significant immunoglobulin. Furthermore, it illustrates that relatively low 
levels of FH are sufficient to prevent the renal disease associated with complete FH 
deficiency. 
 
The presence of C3 deposition along the GBM appears deleterious even in the 
absence of C5 activation and is associated with exaggerated renal injury in 
experimentally-triggered nephritis in Cfh-/- mice (Pickering, Cook et al. 2002). 
Additional environmental triggers such as infection are known to exacerbate renal 
injury in C3 glomerulopathy. To investigate this, I induced NTN in hepatocyte-Cfh-/- 
mice. In the presence of spontaneous mesangial C3, NTN led not only to 
accelerated and more severe disease, but also to a different phenotype not seen in 
wild-type animals. Microangiopathic haemolytic anaemia, thrombocytopaenia and 
renal failure were accompanied by marked glomerular thrombosis on light 
microscopy in hepatocyte-Cfh-/- mice. Immunofluorescence microscopy revealed 
further C3 deposition in the distribution of thrombosed capillary loops. Although the 
higher circulating levels of FH resulting from extra-hepatic production in hepatocyte-
Cfh-/- mice are sufficient to prevent the GBM C3 deposition and MGPN observed in 
Cfh-/- animals, they are not able to adequately control C3 activation in the presence 
of additional complement activation. With greater circulating C3 and C5 than Cfh-/- 
animals, failure to control surface complement activation on the renal endothelium in 
the context of NTN culminates in thrombotic microangiopathy.  
 
The induction of NTN in CfhloxP/loxP mice was also associated with more severe 
disease than wild-type animals consistent with reduced FH levels and underlying 
complement dysregulation, but this was significantly less than that observed in  
hepatocyte-Cfh-/- mice. 
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The same genetic mutation in hepatocyte-Cfh-/- mice can therefore be associated 
with two distinct phenotypes depending on the accompanying environment. The 
spontaneous phenotype in hepatocyte-Cfh-/- animals represents a form of C3 
glomerulopathy, whilst in the presence of an additional insult such as NTN, is 
consistent with atypical HUS. The induction of NTN in hepatocyte-Cfh-/- mice 
provides a novel model of atypical HUS which can be used to further delineate the 
pathophysiological mechanisms involved and enable new therapies to be examined. 
This model of atypical HUS is not only reproducible and predictable with a rapid 
onset of disease, it also has the benefit of being able to clearly identify the onset of 
disease as animals do not have thrombotic microangiopathy prior to the induction of 
NTN. The other murine model of atypical HUS whereby mice lack the 5 C-terminal 
SCRs of FH (Cfh-/-.FHΔ16-20) is associated with the development of spontaneous 
disease at variable time points. The development of FH-associated or atypical HUS 
in hepatocyte-Cfh-/- mice exposed to experimental nephritis mirrors the pathogenesis 
of atypical HUS in humans. The requirement for an additional insult in addition to 
underlying complement dysregulation is now widely acknowledged. 
 
Exacerbation of underlying renal disease in the presence of infection is also well 
recognised. In addition to IgA nephropathy, synpharyngitic macroscopic haematuria 
is also a feature of CFHR5 nephropathy and renal disease associated with FH 
deficiency (Levy, Halbwachs-Mecarelli et al. 1986, Pichette, Querin et al. 1994). The 
role of infection in the aetiology of DDD remains unclear with some case reports 
suggesting possible progression from acute post-streptococcal glomerulonephritis to 
DDD (Shahidi-Asl, Ananth et al. 2000). Here, I have reported a case of persistent 
hypocomplementaemia and C3 glomerulopathy following streptococcal infection in a 
patient with heterozygous FHR5 deficiency. Notably, serum FHR5 and C3 levels in 
the index case were significantly lower than in the mother and sister with the same 
mutation who did not have renal disease. Marked glomerular C3 deposition 
accompanied by FHR5 reactivity suggested consumption of C3 within the kidney and 
sequestration of FHR5 from the circulation. This appears consistent with the finding 
that serum FHR5 levels in patients with biopsy-proven C3GN are significantly lower 
than in healthy controls. Serum FHR5 levels may therefore act as a marker of 
concurrent complement activation within the kidney. Whilst the role of FHR5 in the 
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development of chronic glomerulonephritis following streptococcal infection remains 
to be determined, abnormalities in the FHRs are increasingly being associated with 
the development of other complement-mediated renal diseases including atypical 
HUS and C3 glomerulopathy. 
 
Similarly encoded within the RCA gene cluster on chromosome 1, the high degree of 
sequence identity between FHR1-5 and FH has long suggested a role for the FHR 
proteins in complement regulation. Interestingly, FHR1, 2 and 5 have recently been 
shown to form homo- and heterodimers through a shared dimerization motif in the 
two amino terminal SCR domains. By competing with FH for binding to C3b, FHR1, 2 
and 5 act to deregulate complement inhibition by FH. Duplication of the dimerization 
domains in mutant proteins leads to even greater complement deregulation 
(Goicoechea de Jorge, Caesar et al. 2013, Tortajada, xEd et al. 2013) and a 
reduction in this competition afforded by the ∆CFHR3-1 has been proposed as a 
mechanism by which the deletion is protective in AMD (Fritsche, Lauer et al. 2010). 
The FHR proteins may therefore play a complement modulatory role locally through 
the degree of competitive antagonism of FH function.  
 
However, as is the case for atypical HUS associated with FH mutations, renal-
derived wild-type FHR5 was unable to prevent the recurrence of CFHR5 
nephropathy in an unrelated renal transplant (Vernon, Gale et al. 2011). I have 
described the first known case of disease recurrence in a graft, identified on a renal 
transplant biopsy only 46 days after transplantation. Similar to FH, hepatic 
expression of FHR5 is markedly greater than in the kidney. The relatively higher 
concentration of circulating mutant FHR5 from the liver may therefore predominate in 
any deposits within the kidney leading to increased complement deregulation and 
activation of complement C3 locally. Sequestration thereafter of further abnormal 
FHR5 from the circulation by glomerular C3 may then exacerbate complement 
deregulation with uncontrolled C3 activation resulting in C3 glomerulopathy. 
Glomerular C5b-9 reactivity in the transplant biopsy also provided evidence of TP 
activation. 
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Graft failure has been reported in up to 60-90% of atypical HUS patients within a 
year of transplantation and combined liver-kidney transplantation has been used 
successfully in patients with complement abnormalities affecting circulating 
components derived from the liver such as FH (Wong, Goodship et al. 2013). 
Combined liver-kidney transplantation, however, is not without significant risk. 
Eculizumab has also been used to prevent and treat recurrent aHUS following renal 
transplantation (Wong, Goodship et al. 2013). A humanized monoclonal antibody 
directed against complement C5 (Eculizumab) blocks the generation of C5a and 
C5b-9. Originally approved for the treatment of paroxysmal nocturnal 
haemoglobinuria, it has recently been evaluated in two clinical trials in patients with 
atypical HUS with either progressive thrombotic microangiopathy despite plasma 
therapy, or those with chronic disease requiring ongoing plasma therapy (Legendre, 
Licht et al. 2013). Treatment with Eculizumab resulted in inhibition of thrombotic 
microangiopathy and a time-dependent improvement in renal function. The relative 
contribution of C5a and the MAC in mediating renal injury in atypical HUS is still to 
be ascertained, and the new model of atypical HUS described here will enable these 
to be interrogated in more detail. Furthermore, it will also provide a means by which 
the efficacy of other therapies for atypical HUS can be investigated. It is notable that 
Eculizumab is currently the only drug licensed for the treatment of atypical HUS, and 
a recommendation regarding commissioning in the UK is still awaited from the 
National Institute for Care and Health Excellence.  
 
The success of Eculizumab in atypical HUS has led to consideration of its use in the 
treatment of other complement-mediated renal diseases. However, whilst the 
success of C5 blockade in atypical HUS is clear, its efficacy in complement-mediated 
renal diseases dependent on C3, but not C5 activation, remains to be determined. 
The GBM C3 deposition and MPGN characteristic of Cfh-/- mice and dependent on 
C3 activation, still occurs in the absence of C5 in Cfh-/-.C5-/- animals. Whilst inhibition 
of C5 activation in Cfh-/- mice did ameliorate spontaneous and experimentally-
induced disease (Pickering, Warren et al. 2006), the continuing accumulation of 
glomerular C3 appears to mediate proteinuria. Inhibition at the level of complement 
C3 may therefore be preferable in C3 glomerulopathy where glomerular pathology is 
typified by C3 deposition.  
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The use of Eculizumab in patients with C3 glomerulopathy has been associated with 
varying success (Bomback, Smith et al. 2012, Daina, Noris et al. 2012, Herlitz, 
Bomback et al. 2012, Vivarelli, Pasini et al. 2012, Gurkan, Fyfe et al. 2013). 
Individuals with either DDD or C3GN (with or without C3 nephritic factor) have been 
reported to show improvements in serum albumin, renal function and proteinuria 
following Eculizumab (Bomback, Smith et al. 2012, Daina, Noris et al. 2012, Vivarelli, 
Pasini et al. 2012). Typically, these have occurred in patients with high levels of 
soluble C5b-9 (sC5b-9) prior to the initiation of therapy, which subsequently 
normalised during treatment. Those individuals with normal levels of sC5b-9 prior to 
Eculizumab showed no improvement or even deteriorated (Bomback, Smith et al. 
2012). Of note, whilst a reduction in histological disease activity has been reported 
with Eculizumab, progression of glomerulosclerosis has also been observed 
(Bomback, Smith et al. 2012, Herlitz, Bomback et al. 2012, Vivarelli, Pasini et al. 
2012). More recently, normalisation of sC5b-9 levels and improving proteinuria in a 
patient treated with Eculizumab for transplant recurrence of C3 glomerulopathy was 
followed by a rise in proteinuria and progression of disease on biopsy (Gurkan, Fyfe 
et al. 2013). C3 glomerulopathy represents a spectrum of pathology and Eculizumab 
may benefit a subgroup of patients, although these remain to be defined. Elevated 
sC5b-9 levels may be useful in predicting response. The longer-term implications of 
Eculizumab binding to C5 within the kidney, mirroring monoclonal immunoglobulin 
deposition disease, are unknown (Herlitz, Bomback et al. 2012). Inhibition of the TP 
also increases the risk of infection with encapsulated organisms and meningococcal 
vaccination is recommended prior to the initiation of Eculizumab. 
 
Recognition of isolated glomerular C3 deposition as a pathological entity has led to 
interest in the therapeutic inhibition of complement at the level of C3. Successful 
inhibition of complement C3 has been reported in a number of models by inhibitors 
including recombinant proteins and Compstatin, a cyclic peptide identified from 
phage-display libraries. Binding C3b and C4b, complement receptor 1 (CR1/CD35) 
blocks both the AP and CP, exhibiting decay accelerating and FI cofactor activities. 
Soluble recombinant human complement receptor 1 (sCR1) reduces inflammation in 
a variety of models including three models of acute glomerulonephritis in the rat 
(Couser, Johnson et al. 1995). To avoid immunogenicity, a soluble recombinant form 
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of Crry fused with non-complement activating mouse IgG1 (Crry-Ig) has been used 
in rodent models and this agent significantly reduced renal injury in both antibody-
mediated glomerulonephritis and in MRL/lpr lupus mice (Quigg, Kozono et al. 1998, 
Bao, Haas et al. 2003).  
In addition to systemic inhibition by Crry-Ig, targeted inhibition to sites of complement 
activation has also been achieved. An iC3b/C3dg-binding fragment of mouse 
complement receptor 2 (CR2) linked to Crry (CR2-Crry) targeted local and remote 
sites of complement activation following intestinal ischaemia reperfusion injury (IRI), 
and required a 10-fold lower dose than Crry-Ig to provide the same protection 
(Atkinson, Song et al. 2005). Furthermore, susceptibility to infection after CR2-Crry 
was no different from PBS control in contrast to significantly enhanced susceptibility 
with Crry-Ig. 
 
More recently, targeted inhibition of the AP has been investigated as a means of 
avoiding blockade of all pathways either at the level of C3 or C5. With its roles in 
host defence and immune homeostasis, systemic inhibition of complement is not 
without potential adverse effects. A fragment of CR2 linked to N-terminal domains of 
FH (CR2-FH) was protective against intestinal IRI, almost totally abolishing intestinal 
C3 deposition (Huang, Qiao et al. 2008) and with a therapeutic dose much lower 
than untargeted Crry-Ig.  
 
Compstatin is a cyclic tridecapeptide and selective C3 inhibitor which through direct 
binding to native C3, inhibits the convertase-mediated cleavage of C3 to C3a and 
C3b (Ricklin and Lambris 2008). The single binding site of Compstatin resides within 
the C3c portion of C3 away from other C3 binding sites and does not appear to 
interfere with convertase formation or complement regulatory proteins. It was the first 
complement-specific agent to enter clinical trials for the treatment of AMD (Ricklin 
and Lambris 2008). The AP is known to be the major contributor to biomaterial-
induced complement activation seen during extracorporeal blood circulation such as 
in haemodialysis (Andersson, Ekdahl et al. 2005) and C3a generation, C3b 
deposition and MAC formation were all reduced when Compstatin was added to 
circulating blood in PVC tubes (Nilsson, Larsson et al. 1998). Studies of C3 inhibition 
in C3 glomerulopathy are awaited. 
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In summary, how has the data presented here contributed to the literature on 
complement dysregulation and renal disease? Hepatocyte-Cfh-/- mice have 
demonstrated that relatively low levels of circulating FH are able to prevent the GBM 
C3 deposition and MPGN typical of complete FH deficiency. The subtotal deficiency 
of FH in hepatocyte-Cfh-/- animals is instead associated with a spontaneous 
phenotype consistent with C3 glomerulopathy. The induction of NTN in these mice 
leads to atypical HUS consistent with the paradigm in humans where a further trigger 
is required in addition to underlying complement dysregulation in order for disease to 
occur. Hepatocyte-Cfh-/- mice therefore illustrate that the same genetic mutation can 
be associated with a different phenotype depending on the accompanying 
environment and confirm the ability to regulate complement activation within the 
circulation is critical to the renal pathology observed.  
 
Hepatocyte-Cfh-/- mice notably provide a novel model of both C3 glomerulopathy and 
atypical HUS. These can be used not only to further define pathophysiological 
mechanisms, but also facilitate the identification of therapeutic targets and enable 
such therapies to be tested. Notably, the mesangial C3 deposition characteristic of 
the spontaneous phenotype in hepatocyte-Cfh-/- mice provides an alternative model 
of C3 glomerulopathy compared to the GBM C3 and MPGN typical of Cfh-/- mice, 
and may therefore enable the efficacy of treatments to be assessed across a wider 
spectrum of pathology comprising C3 glomerulopathy. Whilst the induction of NTN in 
hepatocyte-Cfh-/- mice is associated with a severe phenotype and may not entirely 
match disease triggers in human disease, it also adds to the only other animal model 
of atypical HUS in existence, and has the advantages of predictability and a short 
interval to disease onset, which is also clearly definable. 
 
During characterisation of the hepatocyte-Cfh-/- phenotype, it became evident that 
insertion of loxP sites and/or the neomycin cassette in CfhloxP/loxP animals affected 
expression at the Cfh locus. Removal of the Neo cassette using Frt-mediated 
recombination is currently underway in my supervisor’s laboratory. Confirmation of 
an effect on gene expression will enable a more accurate conclusion to be drawn 
regarding the contribution of extra-hepatic FH to the total circulating pool through the 
investigation of hepatocyte-Cfh-/- mice in which the Neo cassette has been removed. 
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What has the work presented here added to the literature on the FHRs in renal 
disease? The recurrence of CFHR5 nephropathy in an unrelated renal transplant 
illustrates that locally derived normal FHR5 is unable to prevent disease. This may 
not be surprising in light of the expression studies demonstrating minimal renal 
expression of FHR5. 
The role of FHR5 in chronic GN remains to be determined, but my study of FHR5 
haploinsufficiency has shown that this is not sufficient in itself to cause C3 
glomerulopathy. Glomerular sequestration of FHR5 may lead to reduced serum 
levels and represent a marker of concomitant C3 deposition within the kidney. 
Further work is required to characterise the exact role of the FHRs in renal disease, 
but this may involve the local modulation of FH deregulation mediated by varying 
FHR dimer composition and/or concentrations.  
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8.1. Appendix 1: Demonstration of hepatocyte-specific Cre-mediated 
recombination (see Chapter 3, page 91) 
 
 
 
 
 
 
PCR was performed to confirm hepatocyte-specific Cre-mediated recombination. The 527-bp floxed 
Cfh locus amplified in tail genomic DNA from hepatocyte-Cfh-/- mice (lane 3, panel I) was not present 
in hepatic genomic DNA from the same animals (lane 2, panel I) indicating hepatocyte-specific 
recombination. This was confirmed by the presence of a 546-bp amplicon only seen following excision 
of exons 2 and 3, in hepatic genomic DNA from hepatocyte-Cfh-/- mice (lane 7, panel II). The 450-bp 
wild-type amplicon was seen at the Cfh locus in both hepatic and tail genomic DNA from Alb-Cre mice 
(lanes 4 and 5, panel I). 
 
 
 
 
  
Lane 1 – Size marker 
Lane 2 and 7 – hepatocyte-Cfh-/- hepatic DNA  
Lane 3 and 8 – hepatocyte-Cfh-/- tail DNA 
Lane 4 and 9 – Alb-Cre hepatic DNA 
Lane 5 and 10 – Alb-Cre tail DNA 
Lane 6 and 11 – H2O 
600bp 
400bp 
200bp 
1 2 3 4 5 6 7 8 9 10 11 
I II 
recombinant allele = 527bp 
wild-type allele = 450bp 
recombinant allele post Cre 
recombinase-mediated excision 
of exons 2 and 3 = 546bp 
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8.2. Appendix 2: Summary of NTN experiments 1-3 (see Chapter 4, 
page 124) 
 
NTN experiment Wild-type Hepatocyte-Cfh-/- CfhloxP/loxP Alb-Cre 
n Median (range) n Median (range) n Median (range) n Median (range) 
Experimental numbers 
NTN1 10  7      
NTN2   6  5  5  
NTN3 7  3      
Haematuria at cull (day 4) 
NTN1 8 0 (0-0) 2 4 (4-4)     
NTN2   4 4 (4-4)a 5 0 (0-2) 5 0 (0-2) 
NTN3 7 0 (0-3) 3 4 (4-4)     
Proteinuria at cull (day 4) 
NTN1 8 1.5 (0-2) 2 4 (4-4)     
NTN2   4 4 (4-4) 5 3 (2-4) 5 3 (2-4) 
NTN3 7 1 (1-3) 3 3 (3-3)     
Urea at cull (day 4) - mmol/l 
NTN1 10 12.0 
(7.0-25.2) 
7 138.0b 
(77.0-160.8) 
    
NTN2   5 156.6c 
(12.4-163.3) 
5 30.4 
(25.5-34.6) 
5 20.5 
(13.0-50.1) 
NTN3 7 17.2 
(9.5-50.3) 
3 155.6d 
(138.2-163.5) 
    
Red cell fragments (day 4) - number of red cell fragments per 200 red blood cells counted 
NTN1 10 2 (2-3) 7 37 (16-64)e     
NTN2   5 13 (7-18)f 5 7 (1-19) 5 2 (0-4) 
NTN3 7 2 (0-3) 3 19 (8-25)g     
Glomerular thrombosis (day 4) - amount of PAS-positive material per glomerular cross-section 
NTN1 10 0.40 
(0.15-0.55) 
7 3.50h 
(1.9-3.65) 
    
NTN2   5 2.10 
(1.25-2.60) 
5 1.2 
(0.50-2.40) 
5 1.0 
(0.80-2.60) 
NTN3 7 1.2 (0.80-2.80) 3 2.80i 
(2.30-3.30) 
    
n = number of mice examined 
There was one death in the NTN2 experiment in the hepatocyte-Cfh-/-  experimental group 
aP<0.001 versus CfhloxP/loxP and Alb-Cre male mice, Bonferroni multiple comparison test 
bP=0.0001 versus wild-type female mice, Mann-Whitney test 
cP<0.01 versus CfhloxP/loxP and Alb-Cre male mice, Bonferroni multiple comparison test 
dP=0.0167 versus wild-type male mice, Mann-Whitney test 
eP=0.0001 versus wild-type female mice, Mann-Whitney test 
fP<0.01 versus Alb-Cre male mice, Bonferroni multiple comparison test 
gP=0.0167 versus wild-type male mice, Mann-Whitney test 
hP=0.0001 versus wild-type female mice, Mann-Whitney test 
iP=0.0333 versus wild-type male mice, Mann-Whitney test. 
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Summary of NTN experiments 1-3 (continued) 
 
NTN experiment Wild-type Hepatocyte-Cfh-/- CfhloxP/loxP Alb-Cre 
n Median (range) n Median (range) n Median (range) n Median (range) 
Glomerular C3 immunofluorescence (day 4) – arbitrary fluorescence units 
NTN1 9 421.6 
(199.5-623.1) 
7 1325.0j 
(782.1-1644.0) 
    
NTN2   5 527.0k 
(370.0-780.9) 
5 249.0 
(179.0-314.5) 
5 232.5 
(113.7-419.9) 
NTN3 7 292.3 
(167.3-1110.0) 
3 1122.0l 
(979.8-1326.0) 
    
Glomerular mouse IgG immunofluorescence (day 4) – arbitrary fluorescence units 
NTN1 9 18.5 
(8.2-40.5) 
7 39.4m 
(18.0-73.3) 
    
NTN2   5 320.0 
(195.9-339.1) 
5 280.6 
(154.2-519.6) 
5 347.0 
(209.2-812.9) 
NTN3 7 697.7 
(394.3-1293.0) 
3 736.1 
(715.0-779.3) 
    
Glomerular sheep IgG immunofluorescence (day 4) – arbitrary fluorescence units 
NTN1 10 1722.0 
(1318.0-3019.0) 
7 1071.0n 
(920.1-1719.0) 
    
NTN2   5 1345.0 
(945.6-1726.0) 
5 1485.0 
(1339.0-1734.0) 
5 1649.0 
(1502.0-1815.0) 
NTN3 7 1625.0 
(1405.0-2379.0) 
3 1337.0 
(842.8-1460.0) 
    
n = number of mice examined 
jP=0.0002 versus wild-type female mice, Mann-Whitney test 
kP<0.05 versus CfhloxP/loxP and Alb-Cre male mice, Bonferroni multiple comparison test 
lP=0.0333 versus wild-type male mice, Mann-Whitney test 
mP=0.0164 versus wild-type female mice, Mann-Whitney test 
nP=0.0031 versus wild-type female mice, Mann-Whitney test 
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Complement factor H-related protein 5 (CFHR5)
nephropathy is a familial renal disease endemic in
Cyprus. It is characterized by persistent microscopic
hematuria, synpharyngitic macroscopic hematuria and
progressive renal impairment. Isolated glomerular ac-
cumulation of complement component 3 (C3) is typi-
cal with variable degrees of glomerular inflammation.
Affected individuals have a heterozygous internal du-
plication in the CFHR5 gene, although the mechanism
through which this mutation results in renal disease is
not understood. Notably, the risk of progressive renal
failure in this condition is higher inmales than females.
We report the first documented case of recurrence of
CFHR5 nephropathy in a renal transplant in a 53-year-
old Cypriot male. Strikingly, histological changes of
CFHR5 nephropathy were evident in the donor kidney
46 days post-transplantation. This unique case demon-
strates that renal-derived CFHR5 protein cannot pre-
vent the development of CFHR5 nephropathy.
Key words: CFHR5 nephropathy, complement, recur-
rence, renal transplant
Abbreviations: C3, complement component 3; C3c,
complement component 3c; C4d, complement com-
ponent 4d; C5b, complement component 5b; C9, com-
plement component 9; CD46, cluster of differentiation
46 (membrane cofactor protein); CFH, complement fac-
tor H; CFHL-1, CFH-like protein; CFHR5, complement
factor H-related protein 5; C3GN, C3 glomerulonephri-
tis; EM, electron microscopy; ESRF, end-stage renal
failure; lmol, micromole (s); mg, milligram (s); mmol,
millimole (s); PCR, polymerase chain reaction; RCA,
regulator of complement activation; SCR, short con-
sensus repeat.
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Introduction
Complement dysregulation is associated with several
distinct patterns of glomerular pathology. Common to
glomerular abnormalities associated with defective con-
trol of the alternative pathway is deposition of C3 in the
absence of significant immunoglobulin (1,2). This patho-
logical appearance typifies a number of conditions associ-
ated with genetic or acquired complement dysregulation,
including dense deposit disease, C3 glomerulonephritis
(C3GN) and CFHR5 nephropathy. ‘C3 glomerulopathy’ has
recently been proposed as a new term under which this
heterogeneous group of disorders can be classified (1).
C3GN is a feature of CFHR5 nephropathy, a familial re-
nal disease characterized by persistent microscopic hema-
turia, synpharyngitic macroscopic hematuria and progres-
sive renal failure (3). C3GN may be associated with
membranoproliferative or mesangial proliferative features.
Endemic in Cyprus, affected individuals have a heterozy-
gous internal duplication in the CFHR5 gene. Previously,
mutations in complement factor H, CD46 (membrane co-
factor protein) and factor I were identified among patients
with biopsy-proven C3GN (2), but CFHR5 nephropathy is
the first description of C3GN associated with a mutation in
the CFHR5 gene. CFHR5 is a member of the complement
factor H (CFH) family, a group of highly related proteins
encoded by genes located within the regulator of com-
plement activation (RCA) gene cluster on chromosome 1.
Comprising CFH, CFH-like protein (CFHL-1) and comple-
ment factor H-related proteins 1–5, the proteins are com-
posed of individual domains termed short consensus re-
peats (SCRs), which display varying degrees of amino acid
sequence similarity to each other. CFHR5 is a 65 kDa pro-
tein composed of nine SCRs, and the internal duplication
in exons 2 and 3 characteristic of CFHR5 nephropathy re-
sults in an expressed protein with duplicated SCRs 1 and
2 respectively. Although the role of CFHR5 is not yet fully
understood, its complement regulatory activity in vitro (4)
and co-localization with renal complement deposits in vivo
(5) suggest that it may play a role in complement regula-
tion within the kidney. Furthermore, themutant protein has
been shown to have reduced affinity for glomerular-bound
complement, raising the possibility of impaired targeting to
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complement within the kidney (3). We report the case of a
53-year-old gentleman with end-stage renal failure (ESRF)
secondary to CFHR5 nephropathy, who underwent renal
transplantation from a deceased donor and was found to
have evidence of disease recurrence in a transplant biopsy
46 days later.
Case Presentation
A previously healthy British male with Cypriot ancestry
was referred at the age of 36 with persistent microscopic
hematuria, episodes of macroscopic hematuria coinciding
with upper respiratory tract symptoms, and renal impair-
ment (serum creatinine 178 lmol/L). He was not aware
of any family history of renal disease at that time al-
though relatives with CFHR5 nephropathy have subse-
quently been identified. Physical examination and blood
pressure were normal. However urinalysis demonstrated
1+ blood and 1+ protein, and a renal biopsy was per-
formed. Light microscopy revealed 30% glomerular obso-
lescence with a fibrous crescent in one glomerulus, and
a few tubular red cell casts. Immunoperoxidase staining
showed capillary wall C3 but notably was negative for IgA.
Subendothelial electron dense deposits and rare subep-
ithelial ‘humps’ were seen on electron microscopy (EM),
as were mesangial deposits associated with an increase in
mesangial cells and matrix. A further decline in renal func-
tion 6 years later led to a second biopsy (Figure 1). This
demonstrated large segmental scars, capillary wall thicken-
ing with double contours and mesangial cell interposition.
Granular capillary wall C3 was again evident in the absence
of immunoglobulin staining. On EM there were suben-
dothelial and mesangial deposits, and rare subepithelial
deposits. These histological features are consistent with
C3 glomerulonephritis.
Over the following 4 years he suffered progressive renal
impairment and required renal replacement therapy at the
age of 47. Six years after commencing hemodialysis, dur-
ing which he had further episodes of macroscopic hema-
turia, he received a deceased donor renal transplant. The
donor was a 65-year-old female with no significant past
medical history, who had a creatinine of 82 lmol/L. HLA
matching demonstrated a 2,1,1 mismatch, but there were
no recipient class I or II HLA antibodies at the time of
transplantation, and this proceeded with no complications.
Immunosuppression included alemtuzumab and corticos-
teroids peri-operatively, with tacrolimus monotherapy con-
tinued at discharge. Although his renal function initially
improved, his creatinine stabilized at 186 lmol/L, and in
the presence of persistent microscopic hematuria and fol-
lowing a single episode of macroscopic hematuria (with
a urine protein: creatinine ratio of 56 mg/mmol), he under-
went a renal transplant biopsy, 46 days after transplantation
(Figure 2).
Light microscopy showed occasional neutrophils in the
capillary loops of one glomerulus and a small area of tubu-
lointerstitial fibrosis. Immunoperoxidase staining showed
capillary wall granular C3 and complement component 9
(C9),whilst electronmicroscopy showed increasedmesan-
gial matrix associated with scatteredmesangial and suben-
dothelial deposits (with new basement membrane be-
neath in two areas; Figure 2C). Complement component
4d (C4d) staining was negative. The findings in the renal
transplant were therefore consistent with a recurrence of
his original disease. Serum C3 was 0.73 g/L (normal range
0.7–1.7 g/L) at the time of biopsy, whilst CFH and fac-
tor I levels were 320 mg/L (207% of normal control) and
32 mg/L (177% of normal control), respectively.
A second transplant biopsy performed 3 months later
on account of a rise in the serum creatinine to 250
lmol/L, showed granular (mainly mesangial) C3 staining
associated with subendothelial, mesangial and subepithe-
lial deposits. Indirect immunofluorescence also showed
the presence of glomerular complement components 5b
(C5b)-9 (Figure 2D). Polymerase chain reaction (PCR) using
genomic DNA isolated from peripheral blood monocytes
Figure 1: Native renal biopsy. (A) Light microscopic appearance showing segmental glomerulosclerosis and hyalinosis and increased
mesangial matrix (hematoxylin and eosin). (B) Immunoperoxidase staining showing granular capillary wall C3 deposition. C3 was de-
tected using a polyclonal rabbit anti-human C3c antibody (Dako Ltd., Ely, United Kingdom). (C) Electron micrograph showing multiple
subendothelial electron dense deposits (denoted by arrows).
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Figure 2: Renal transplant biopsy. (A)
Light microscopy showing a normal
glomerulus (periodic acid-Schiff). (B) Im-
munoperoxidase staining showing granu-
lar capillary wall and mesangial C3 depo-
sition. C3 was detected using a polyclonal
rabbit anti-humanC3c antibody (Dako Ltd.,
Ely, United Kingdom). (C) Electron micro-
graph showing subendothelial deposits
(denoted by arrows) with new basement
membrane beneath. (D) Glomerular C5b-
9 by indirect immunofluorescence. C5b-9
was detected using a monoclonal mouse
anti-human C5b-9 antibody (DakoCytoma-
tion Ltd., Ely, United Kingdom) and a flu-
orescein isothiocyanate-labeled goat anti-
mouse IgG (Sigma-Aldrich Company Ltd.,
Dorset, United Kingdom).
and serumCFHR5western blot analysis (Figure 3) revealed
the presence of the heterozygous internal duplication in
the CFHR5 gene, confirming the diagnosis of CFHR5
nephropathy.
Discussion
To our knowledge this is the first description of recurrence
of CFHR5 nephropathy in a transplant. The recurrence of
CFHR5 nephropathy in an unrelated kidney demonstrates
that local synthesis of normal CFHR5 by the kidney is
not sufficient to prevent disease. However, we are aware
of two other incompletely characterized cases with the
CFHR5 mutation and renal disease, in which good allograft
function was evident one decade after deceased donor
renal transplantation. Firstly, a Cypriot male with a renal
biopsy demonstrating C3GN reached ESRF at the age of
46. A deceased donor renal transplant was performed at
the age of 48 and he died 12 years later from a myocardial
Figure 3: Internal duplication of CFHR5. Western blot of serum for CFHR5 and schematic depicting normal and mutant CFHR5
proteins (denoted CFHR5123–9 and CFHR512123–9 respectively). A polyclonal anti-CFHR5 antibody was used to detect the wild-type and
mutant CFHR5 proteins in sera from the patient (P) and control (C). The wild-type CFHR5 protein consists of nine protein subunits termed
short consensus repeat (SCR) domains. The internal duplication of exons 2 and 3 in the mutant CFHR5 gene results in a mutant protein
that contains two additional SCR domains (duplicated protein domains depicted in orange in the schematic). The mutant CFHR5 protein
therefore has a higher molecular weight than the wild-type protein. The mutant protein was readily detectable in the patient but not in
the control sample. The presence of the wild-type protein in the patient sample confirmed that the mutation is present in heterozygosity
in this individual.
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infarction. The serum creatinine 3 months before his death
was 89 lmol/L and the graft was never biopsied. He was a
member of a family described previously and genotyping of
his daughter and the offspring of his cousin demonstrated
that he was an obligate carrier of the CFHR5 mutation (in-
dividual III-1 from family 1 in reference (3)). Secondly, a
40-year-old Cypriot individual with ESRF and small kidneys,
who presented with macroscopic hematuria at the age of
ten but had been lost to follow up, received a deceased
donor renal transplant at the age of 43. The transplant func-
tionedwell for 10 years until it was lost following atheroem-
bolic complications of diagnostic coronary angiography. He
returned to hemodialysis and died 6 years later. Subse-
quent molecular testing on stored genomic DNA demon-
strated the presence of the CFHR5 mutation. There was
no record of either native or allograft renal biopsy. These
cases, together with the observations that the original dis-
ease takes many decades to cause ESRF, suggest that
graft loss due to recurrence of CFHR5 nephropathy is not
inevitable. Clearly larger studies will be required to estab-
lish the clinical course of CFHR5 nephropathy in renal trans-
plantation. In summary, we describe the first reported case
of recurrence of CFHR5 nephropathy in an unrelated renal
transplant. Notably histological recurrencewas demonstra-
ble only 46 days after transplantation.
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Case Report
Acute Presentation and Persistent Glomerulonephritis Following
Streptococcal Infection in a Patient With Heterozygous
Complement Factor H–Related Protein 5 Deficiency
Katherine A. Vernon, MB, BS,1 Elena Goicoechea de Jorge, PhD,1
Angela E. Hall, FIBMS,2 Veronique Fremeaux-Bacchi, PhD,3
Timothy J. Aitman, FMedSci,4 H. Terence Cook, FMedSci,1
Robert Hangartner, FRCPath,5 Ania Koziell, PhD,6,7 and Matthew C. Pickering, PhD1
Acute poststreptococcal glomerulonephritis is a common cause of acute nephritis in children. Transient
hypocomplementemia and complete recovery are typical, with only a minority developing chronic disease. We
describe a young girl who developed persistent kidney disease and hypocomplementemia after a streptococcal
throat infection. Kidney biopsy 1 year after presentation showed isolated glomerular complement C3 deposi-
tion, membranoproliferative changes, and subendothelial, intramembranous and occasional subepithelial
electron-dense deposits consistent with C3 glomerulopathy. Complement gene screening revealed a heterozy-
gous single nucleotide insertion in exon 4 of the complement factor H–related protein 5 gene (CFHR5),
resulting in a premature stop codon. This variant was not detected in 198 controls. Serum CFHR5 levels were
reduced. The mother and sister of the index patient were heterozygous for the sequence variant, with no overt
evidence of kidney disease. We speculate that this heterozygous CFHR5 sequence variant is a risk factor for
the development of chronic kidney disease after streptococcal infection.
Am J Kidney Dis. 60(1):121-125. © 2012 by the National Kidney Foundation, Inc.
INDEX WORDS: Complement; kidney; streptococcus; C3 glomerulopathy.
Acute poststreptococcal glomerulonephritis(APSGN) is a common cause of childhood
acute nephritis. Serum complement C3, C5, and pro-
perdin levels typically are reduced acutely, whereas
C4 levels are normal.1,2 This pattern of hypocomple-
mentemia reflects selective activation of the comple-
ment alternative pathway. Streptococcal components
have been shown to activate this pathway,3-5 and
transient C3 nephritic factor (C3NeF) has been shown
in some cases.6 C3NeF potentiates activation of the
alternative pathway and typically is seen in dense
deposit disease, a condition strongly associated with
alternative pathway dysregulation. In APSGN, most
children recover completely and complement levels
return to normal within 12 weeks. For reasons that are
unknown, a minority develop chronic kidney disease
associated with continuing hypocomplementemia.7,8
We report a case of persistent kidney disease after
streptococcal infection in association with a heterozy-
gous mutation in the gene encoding complement
factor H–related protein 5 (CFHR5).
CASE REPORT
A previously healthy 7-year-old Caucasian female presented
with a 10-day history of lethargy, fever, sore throat, and cough
associated with abdominal pain, vomiting, and dark colored urine.
Mild periorbital edema was accompanied by abnormal urinalysis
results (protein [3!], blood [3!]). Results of investigations in-
cluded the following values: serum urea nitrogen, 50.1 mg/dL
(17.9 mmol/L); creatinine, 0.98 mg/dL (87 !mol/L); hemoglobin,
10.9 g/dL (109 g/L); C-reactive protein, 77 mg/L; C3, 0.36 mg/mL
(0.36 g/L; reference range, 0.75-1.65); C4, 0.29 mg/mL (0.29 g/L;
reference range, 0.11-0.43); and urine protein-creatinine ratio,
5,221 mg/g. Both serum anti-streptolysin O ("200 U/mL) and
anti-DNase antibody titers (360 U/mL) were elevated. Kidney
ultrasound showed 8.3-cm kidneys with loss of corticomedullary
differentiation.
The patient improved after treatment with phenoxymethylpeni-
cillin, although proteinuria and microscopic hematuria persisted.
Four months later, she developed macroscopic hematuria after an
upper respiratory tract infection.
Nine months after presentation, kidney biopsy showed mesan-
gial hypercellularity, segmental endocapillary hypercellularity, and
segmental capillary wall double contours on light microscopy.
Immunoperoxidase staining showed marked granular capillary
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wall and mesangial C3, C9, and CFHR5 deposition (Fig 1A).
Glomerular C1q and immunoglobulins were absent. On electron
microscopy, glomerular basement membranes appeared thickened,
with segmental duplication of the basement membrane and mesan-
gial cell interposition. There were intramembranous electron-
dense deposits with occasional subendothelial deposits, as well as
scattered hump-like subepithelial deposits. Mesangial deposits
were absent. Angiotensin receptor blockade reduced urinary pro-
tein loss and kidney function remained normal.
Twenty months after presentation, a second kidney biopsy (Fig
1A) showed persistent membranoproliferative glomerulonephritis
with tubulointerstitial scarring involving !40% of the cortex.
Electron microscopy showed intramembranous electron-dense de-
posits and some mesangial deposits. The findings in both biopsies
are consistent with C3 glomerulopathy with a membranoprolifera-
tive pattern of glomerulonephritis.9 Proteinuria improved with
glucocorticoid therapy. Since the onset of disease, circulating C3
levels have remained low (Fig 1B). She has not developed ocular
drusen or lipodystrophy. C3NeF has been consistently undetect-
able and anti-factor H autoantibodies have not been detected.
To determine whether there was any other serum factor enhanc-
ing C3 activation, we added purified C3 (0.5% solution; Merck,
www.merck.com/index.html) to serum from the index case and
compared its hemolytic activity at 2 and 4 hours with that of
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Figure 1. (A) Kidney biopsies performed at 9 and 20 months postpresentation. Light microscopy (first row) shows mesangial
hypercellularity, segmental endocapillary hypercellularity, and capillary wall double contours with marked capillary wall C3, C9, and
CFHR5 seen on immunoperoxidase staining (second [C3] and fourth [C9, CFHR5] rows). On electron microscopy (third row), there
were intramembranous and occasional subendothelial electron-dense deposits. Rare hump-like subepithelial deposits were seen in the
first biopsy specimen. Rabbit anti-human C3 (Dako, www.dako.com), mouse anti-human C9 (Leica, www.leica.com), and mouse
anti-human monoclonal CFHR5 antibodies (a gift from Dr J. McRae) were used for immunoperoxidase staining. (B) Serum complement
C3 and creatinine levels versus time. Serum C3 levels remained profoundly depressed throughout the illness. Conversion factor for
serum creatinine in mg/dL to !mol/L, "88.4. (C) Family pedigree. II-3 (filled circle) denotes the index patient. A central dot within the
symbol (circle and square denoting female and male individuals, respectively) indicates the sequence variant is present, empty
symbols denote absence of the sequence variant, and symbols with a question mark indicate genetic status unknown. (D) Serum
CFHR5 levels in individuals with biopsy-proven C3 glomerulonephritis and absence of the CFHR5 sequence variant. Median CFHR5
level in the C3 glomerulonephritis group (4.3; range 1.2-7.4 !g/mL; n # 23) was significantly lower (P # 0.02, Mann-Whitney test)
than the median in healthy controls (5.5; range 3.4-10.1 !g/mL; n# 13). CFHR5 was measured by enzyme-linked immunosorbent
assay using rabbit anti-human CFHR5 and mouse anti-human CFHR5 antibodies (both from Abcam, www.abcam.com) as
capture and primary antibodies, respectively. The standard curve was generated using recombinant CFHR5 (R&D Systems,
www.rndsystems.com).
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C3-deficient human serum reconstituted with purified C3 in an
identical fashion. Hemolytic activity at 2 (60% vs 57%) and 4
hours (43% vs 47%) did not differ between the test and control
sera, indicating that there was no evidence of accelerated serum C3
conversion in serum of the index case.
We performed screening for the known genetic causes of alterna-
tive pathway dysregulation. No coding mutations were detected in
the complement genes CD46, complement factor H (CFH), factor
B, factor I, and C3. No copy number variation within the CFH-
CFHR gene locus was seen using a multiplex ligation-dependent
probe amplification assay. CFHR5 gene sequencing revealed a
single heterozygous nucleotide duplication in exon 4 (c.485dupA)
which generates a reading frameshift at amino acid 163 and a
premature stop codon at amino acid position 197 (p.Glu163Argfs*34).
This variant was not detected by sequencing of 198 ethnically matched
DNA samples (obtained from the UK Blood Services Collection of
Common Controls) and was not present in dbSNP (www.ncbi.nlm.ni-
h.gov/snp, accessed October 2011). The healthy mother (I-2) and
sister (II-1), but not the 2 other siblings examined (II-2 and II-4), were
heterozygous for this sequence variant (Fig 1C). The complement
profile of the kindred is shown in Table 1. Serum CFHR5 levels in
unaffected members with the gene variant were within the range seen
in healthy controls (3.4-10.1 !g/mL). However, serum CFHR5 level
was decreased in the index case (2.1!g/mL). Notably, serum CFHR5
levels also were found to be decreased in individuals with biopsy-
proven C3 glomerulonephritis (Fig 1D).
DISCUSSION
CFHR5 is a member of the CFH family of proteins
encoded within the regulators of complement activation
gene cluster on chromosome 1.10 CFHR5 has been
shown to have complement-regulatory function in vitro11
and to colocalize with complement deposits within the
kidney in a variety of glomerular pathologic states.12
The biological role of CFHR5 is unclear, but it is
postulated to have a physiologic role in the processing of
complement within the kidney.13 This hypothesis has
derived from reports of genetic variation in CFHR5 and
susceptibility to kidney disease. A heterozygous CFHR5
mutation has been shown to be associated with the
development of familial C3 glomerulonephritis in indi-
viduals of Cypriot ancestry,13 and allelic variants of
CFHR5 have been associated with dense deposit dis-
ease.14 Previously published evidence that CFHR5 inter-
acts with glomerular complement12,13 suggests that this
phenomenon contributed to the decrease in serum CFHR5
levels in the index case. Consistent with this hypothesis
was our observation that glomerular CFHR5 was easily
detectable in kidney biopsy specimens from the index
case, median serum CFHR5 levels were low in individu-
als with C3 glomerulonephritis, and serum CFHR5 level
in the index patient was lower than levels in other family
members with the sequence variant, but no kidney dis-
ease. An interesting additional insight based on these
data is that serum CFHR5 levels may be a useful
biomarker of glomerular C3 deposition.
Our report is to our knowledge the first description
of the association of kidney disease with a heterozy-
gous sequence variant causing frameshift and prema-
ture truncation of CFHR5. Interestingly, the same
variant that we describe was reported in an individual
serving as a control in a study investigating the role of
CFHR5 in atypical hemolytic uremic syndrome.15 No
clinical details for this individual were reported. The
presence of the CFHR5 sequence variant in the mother
and sister of the index patient (neither of whom had
Table 1. Complement Profile
Pedigree No.
Reference
RangeI-2 II-1 II-2 II-4 II-3a
CFHR5 sequence variant Yesb Yesb No No Yesb
C3 (g/L) 1.43 1.03 1.08 1.14 0.07 0.7-1.7
C4 (g/L) 0.24 0.17 0.21 0.16 0.22 0.16-0.54
CFH (%)c 181 132 132 147 148
CFI (%)c 174 132 157 186 154
Total complement hemolytic activity (%)d 108 47 99 95 ND 50-150
Alternative pathway hemolytic activity (%)d 92 53 102 95 ND 50-150
Serum CFHR5
Absolute amount (!g/mL) 5.3 3.8 4.0 NA 2.1 3.4-10.1
Relative amount (%)e 96.2 69.9 72.5 NA 37.3
Abbreviations: CFH, complement factor H; CFHR5, complement factor H-related protein 5; CFI, complement factor I; NA, not
available (insufficient sample); ND, not detectable.
aIndex patient.
bc.485dupA (p.Glu163Argfs*34); numbering and nomenclature follows Human Genome Variation Society recommendations (for
cDNA, A in ATG start codon is position 1; for protein, the methionine encoded by the start codon is position 1).
cNo validated reference range exists for CFH and CFI, so results are expressed as percentage of the level in pooled serum from
apparently healthy controls.
dPercentage of the activity in pooled serum from apparently healthy controls.
eCompared with the median value in 13 apparently healthy controls, which was 5.5 !g/mL (Fig 1D).
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overt evidence of kidney disease) indicates that
heterozygosity for this CFHR5 sequence variant is not
sufficient to cause kidney disease. We speculate that it
was the presence of both the heterozygous CFHR5
sequence variant and streptococcal infection that pre-
cipitated chronic kidney disease in our index patient.
Interestingly, individuals with other genetic defects
within the CFH gene family are susceptible to exacer-
bation of kidney disease during throat infections.
Synpharyngitic macroscopic hematuria is characteris-
tic of CFHR5 nephropathy13 and common in factor H
deficiency states.16,17 Furthermore, exacerbation of
urinary abnormalities in dense deposit disease has
been associated with streptococcal infection.18 Rarely,
kidney biopsies following APSGN have shown
changes consistent with dense deposit disease.19-21
This raises the difficult question of whether dense
deposit disease is triggered by streptococcal infection
or is a pre-existing lesion that becomes clinically
overt during streptococcal infection. We found one
report describing apparent progression from biopsy-
proven APSGN to dense deposit disease.22 However,
in others, it seems that dense deposit disease may
have predated the episode of APSGN.18,20 Our patient
had no previous evidence of kidney disease, although
it is possible that subclinical disease was present
before the episode of streptococcal infection.
The presence of low serum C3 levels in this case
cannot be explained by the heterozygous sequence
variant in CFHR5 alone because serum C3 levels
were normal in the index patient’s mother and sister,
who also carried the sequence variant. Notably, in
CFHR5 nephropathy, serum C3 levels typically are
normal.13 In contrast, in dense deposit disease, low
serum C3 level is typical and commonly associated
with the presence of C3NeF. However, rarer causes
such as anti–factor B antibodies recently have been
reported.23 C3NeF was repeatedly undetectable in our
case and we could not detect any other factor within
the serum of the index case that was causing acceler-
ated C3 consumption. The serum C3 depletion in our
case most likely results from excessive C3 activation
within the kidney.
In summary, we have identified a heterozygous
sequence variant causing frameshift and premature
truncation of CFHR5 in an individual with chronic
kidney disease after streptococcal infection. We specu-
late that CFHR5 mutations may be a risk factor for the
development of chronic glomerulonephritis after strep-
tococcal infection.
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